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ABSTRACT
This research work has investigated the molecular characterization of oral 
Candida of individuals (with no signs of candidosis) from different dental clinical 
settings in the United Kingdom and patients from diverse geographical regions of the 
world (UK, Greece, Italy and Brazil) who have undergone bone marrow 
transplantation (BMT). Subjects from the different dental settings were classified into 
healthy (subjects from a Private Dental Clinic, Prosthodontic Clinic and Orthodontic 
Clinic) or diseased subjects (patients from The Oral Medicine Clinic with mucosal 
diseases and Special Needs Clinic). The oral carriage of Candida and the presence of 
C. dubliniensis from the diseased subjects were significantly greater than that of the 
healthy subjects (p = 0.025 and p  = 0.008 respectively). The healthy subjects had 
more non-albicans Candida (other than C. dubliniensis) than the diseased subjects (p 
= 0.024). Recipients of bone marrow transplantation (UK) had more non-albicans 
Candida (p = 0.024) than the healthy subjects. There was no difference in Candida 
diversity between isolates from BMT recipients from diverse geographic locales, 
although genotypic diversity among BMT recipients was observed from the Italian 
isolates (p = 0.041). PCR finger-printing with subsequent phylogenetic analysis 
revealed that there were significant differences between C. albicans strains from the 
UK BMT recipients with time and the strains from the UK BMT recipients were 
significantly more diverse than strains from the control subjects and the recipients of 
BMT from other geographical locales (p = 0.0001). Virulence attributes of Candida 
species were studied in-vitro utilizing adherence and proteinase assays. Candida 
isolates from BMT recipients in the UK had a trend of less in-vitro adherence (p = 
0.076) than those from the healthy subjects, but there was no difference in adhesion
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between isolates from BMT recipients from different geographic regions. There was 
no difference in proteolytic activity of isolates from BMT recipients and control 
subjects, but there were significant differences in proteolytic activity between isolates 
from BMT recipients from different geographic regions (p = 0.001). Candida species 
from the Brazilian BMT recipients had very low extracellular proteinase activity. In- 
vitro fluconazole susceptibility test utilizing the National Committee for Clinical 
Laboratory Standards (NCCLS) M27-A showed that the isolates from BMT recipients 
from the UK were significantly more resistance to fluconazole than those from the 
control subjects (p = 0.027) or isolates from BMT recipients from other geographical 
regions (p = 0.009). There were no associations of Candida carriage, isolation of 
more non-albicans Candida, virulence attributes and developing of fluconazole 
resistance from subsequent sampling from the UK and Greek BMT recipients. 
Finally, the expression of secreted aspartyl proteinase (SAP) genes and agglutinin-like 
sequence (ALS) genes by strains o f C. albicans utilizing RT-PCR was found to be 
influenced by the growth medium. It is concluded that bone marrow transplantation 
can have a significant impact upon the carriage of non-albicans Candida, virulence 
attributes and in-vitro fluconazole resistance of the oral Candida.
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The aims and hypothesis of the research
1: The aims of the present study
1) To assess candidal presence, quantity, Candida species, genotypes of C. 
albicans and molecular characterization of oral Candida isolates from healthy 
subjects, patients with mucosal abnormalities, patients with special needs in the UK 
and from BMT recipients resident in the UK, Italy, Greece and Brazil.
2) To determine the geographic variability of oral C. albicans strains, in BMT 
recipients using DNA fingerprinting.
3) To assess the virulence attributes (extracellular proteinase activity and in-vitro 
adhesion) of oral Candida in BMT recipients (from the UK, Italy, Greece and Brazil) 
and healthy subjects.
4) To determine the in-vitro fluconazole resistance of oral Candida isolates in 
BMT recipients (from the UK, Italy, Greece and Brazil) and healthy subjects.
5) To investigate the differential expression of agglutinin-like sequence (ALS) 
genes and secreted aspartyl proteinase (SAP) genes by C. albicans in different media 
utilizing a semi-quantitative RT-PCR method.
2: The hypotheses
1) That the oral Candida carriage, load (ctu/ml), diversity of oral Candida and
C. albicans genotypes (A, B or C) are different in individuals from healthy 
individuals, patients with mucosal abnormalities, patients with special needs and 
BMT recipients.
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2) C. albicans strains are genetically similar in non-BMT recipients and in BMT 
recipients in diverse geographical regions (UK, Greece, Italy and Brazil).
3) That the virulence attributes (extracellular proteinase activity and the in-vitro 
adherence) and susceptibility to fluconazole of oral Candida have variations in BMT 
recipients (from diverse regions) and healthy subjects.
4) That the agglutinin like sequence (ALS) genes and the secreted aspartyl 
proteinase {SAP) genes are up-regulated during the in-vitro assays o f virulence 
associated phenotypes.
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CHAPTER 1 
Literature review
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1.1. Important trends in candidal infections
Candida albicans is a dimorphic, imperfect yeast having no sexual cycle and 
is believed to be associated with warm-blooded animals. However, because o f the 
ability of C. albicans to adapt itself to a range of morphology, it has been re-classified 
as polymorphic yeast (Chaffin et al., 1998, Pitarch et al., 2003). Detailed review of 
the microbiological aspects of Candida albicans and non-albicans species are 
available elsewhere (Campbell et al., 1996; Williams and Lewis, 2000). The present 
review will focus upon aspects of candidal infection relevant to the present work.
Candida species are present harmlessly in the mouth of healthy individuals 
(Abu-Elteen and Abu-Alteen, 1998). However, when there is any alteration in the 
host, Candida can become an aggressive pathogen causing superficial, mucosal, or 
even life-threatening infections, particularly in an immunocompromised host (Fetter 
et al., 1993; Lupetti et al., 1995; Lockhart et al., 1999; Kretschmar et al., 1999; 
Muller et al., 1999; Farah et al., 2000; Sturtevant 2000; Hube and Naglik, 2001; 
Bektic et al., 2001). Similarly, systemic mycoses such as Aspergillus fumigatus, a 
normally endogenous organism, may cause serious or even fatal infections in 
immunocompromised individuals such as bone marrow transplant (BMT) recipients 
(Sturtevant, 2000).
Factors that influence the oral carriage of yeast include infancy and old age 
individuals (Lockhart et al., 1999), local ulcerative and non-ulcerative mucosal 
disease (Lipperheide et al., 1996; Al-Karaawi et al., 2002), the presence of 
xerostomia (e.g. in Sjogren’s Syndrome) (Wahlin, 1991; Abraham et al., 1998; Al- 
Karaawi et al., 2002), tobacco smoking (Arendorf and walker, 1980; Akpan and
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Morgan., 2002), pregnancy, wearing oral prostheses (Ellepola and Samaranayake, 
2000a), severity and type of systemic illness (and associated therapy) and duration o f 
hospitalization (Fidel et al., 1999). However, there is little evidence of the incidence 
of Candida carriage and the type of Candida species present in the oral cavity of 
patients with other oral mucosal diseases or in patients who wear orthodontic 
appliances or have special dental needs due to physical or mental disabilities (Al- 
Karaawi et al., 2002).
The gastrointestinal tract is believed to be the major habitat of the commensal 
Candida species and thought to be the ultimate source of most forms of candidal 
infections (Odds, 1987). The significance of the increased incidence of fungal 
infections in the past two decades (Beck-Sague and Jarvis 1993; McCullough et al., 
1996; McCullough et al., 1999a; Sturtevant, 2000) has principally arisen as a 
consequence of the increased use of immunosuppressive therapies, the increased 
number o f individuals with HIV disease and, perhaps to a lesser extent the increased 
use of a widening range o f antibiotics (Espinel-Ingroff et al., 1995; Stutevant 2000; 
Velasco et al., 2000). In addition, the late detection of candidal infection (Verfaillie et 
al., 1991; Marrison and McGlave, 1993) and the increased survival rate of patients 
with malignancy, and the widening resistance of fungal infection to antifungal therapy 
have contributed to the increasing frequency, and clinical importance of fungal 
infections. The majority of infections occur during the neutropenic phase early 
following bone marrow transplantation (BMT) (Tollemar et al., 1999). However, the 
incidence of serious candidal infection following BMT can be reduced with 
appropriate prophylaxis (Marr et al., 2000) but may increase colonization by non- 
albicans species such as C. glabrata, C. tropicalis and C. krusei (Marr et al., 2000).
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Fortuitously, understanding of species identification, communalism and 
pathogenicity, person to person spread, and development of anti-fungal resistance 
within specific strains has been greatly enhanced by the availability and utilization of 
molecular epidemiological methodologies (Pujol et al., 1997a; Reiss et al., 1998; Al- 
Karaawi et al., 2002).
Epidemiological studies indicate that the endogenous commensal Candida 
population is the major source of infection in susceptible individuals. However, the 
precise mechanisms of Candida communalism are not fully known (Gaur and Klotz,
2000). Although, C. albicans is the most commonly isolated pathogen from the oral 
cavity (Seto et al., 1985; Epstein, 1990; Moran et al., 1997; Muller et al., 1999; 
Sullivan et al., 2004), other Candida species have been isolated and encountered in 
human infections including C. tropicalis, C. glabrata, C. parapsilosis and C. krusei 
particularly in immunocompromised patients (McCullough et al., 1996; Moran et al. 
1997; Muller et al., 1999; Sullivan et al., 2004). These species are distinguishable 
from C. albicans both phenotypically and genotypically. However, C. stellatoidea, 
because of its relatively high DNA homology to C. albicans, it has been reclassified 
as a sucrose-negative variant o f C. albicans (McCullough et al., 1999b). Recently, 
there has been an increased awareness of the isolation of the newly described species 
C. dubliniensis, particularly from immunocompromised patients (McCullough et al., 
1995; Sullivan et al., 1995; Sullivan and Coleman 1997; McCullough et al., 1999b; 
Jabra-Rizk et al., 2000). O f clinical relevance C. dubliniensis exhibits the two major 
phenotypic characteristics used to identify C. albicans chlamydospore and true hypha 
formation (Joly et al., 1999; Sullivan et al., 2004) and thus its identification usually 
necessitates the use of molecular techniques.
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Furthermore, several recent investigations have demonstrated distinct genotypic 
sub-groups of C. albicans (Forche et al., 1999; McCullough et al., 1999b; Xu et al., 
1999a) and shown that these distinct sub-groups may be important in anti-fungal 
susceptibility or virulence attributes (McCullough et al., 1999b; Xu et al., 2000).
1.1.1. Changing epidemiology of oral candidal carriage
As a result of increasing frequency of candidal infections of the mouth and 
other body sites, the most striking epidemiological changes are the increasing 
emergence of non-albicans strains (often more pathogenic than C. albicans) and the 
emergence of antifungal strains.
It has been suggested that most people usually carry a single strain of Candida 
at different body sites (Odds, 1987). However, a small proportion of hospitalised and 
immunocompromised patients may harbour more than one strain or species of 
Candida at the same time (Odds, 1987). For example, in one study, Candida was 
isolated from the mouth of 44% of the patients undergoing bone marrow transplant 
and 19% of those who were colonized with Candida had more than one species 
isolated from their mouth (Marr et al., 2000).
Candida albicans accounted for 70%-80% of isolates in the severely ill 
patients while other non-albicans species such as C. glabrata and C. tropicalis 
account for about 5 to 8% of oral isolates (reviewed by Fidel et al., 1999). The 
increase frequency of C. glabrata and the reduced susceptibility to antifungal agents, 
particularly azole antifungal agents (especially fluconazole) have increased the
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clinical significance of this species in recent years (Vazquez et al., 1998; Fidel et al., 
1999), particularly as infection with C. glabrata can lead to high rates o f mortality in 
some groups of immunocompromised patients (Fidel et al., 1999). A study by 
Schoofs and colleagues (1998) on HIV patients found that 30.7 % of oral Candida 
isolates were non-albicans as compared with 15.9 % of isolates from healthy persons 
(Schoofs et al., 1998). Furthermore, C. tropicalis used to be susceptible to fluconazole 
but in recent years there have been increasing reports of this yeast becoming resistant 
to fluconazole (Warn et al., 2000). As with C. glabrata, C. tropicalis can be 
associated with a higher rate o f mortality (33 to 90%) than C. albicans and some other 
non-albicans species (Warn et al., 2000). Table 1.1 represents the prevalence of 
Candida species in the mouth of healthy individuals as reported by Cannon and 
colleagues (1995) while Table 1.2 represents the prevalence of Candida species in 
bone marrow transplant (BMT) recipients and patients who received radiation therapy 
to the head and neck regions in different regions of the world.
Table 1.1 Percentage of oral Candida from healthy individuals
(Cannon et al., 1995)
C. albicans 47-75
C. glabrata 7
C. krusei <5
C. tropicalis 7
C. parapsilosis <5
C. guilliermondii <5
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Table 1.2 Percentage of Candida carriage in BMT recipients and in patients who 
received irradiation to the head and neck regions
Candida
species
Verfaillie 
et al 
(1991)
Jobbins
etal
(1992)
Leung 
et al 
(2000)
Marr
etal
(2000)
Salonen et al 
(2000)
Safdar and 
Armstrong 
(2002)
Study
country
USA UK
Hong
Kong
USA Finland USA
Diagnosis 
and / or 
treatment
BMT 
(Shortly post 
BMT)
radiotherapy, 
chemotherapy 
for advanced 
cancer 
(Hospitalized)
Average 
of 5years 
post head 
& neck 
radiation
BMT
(Shortly
post
BMT)
BMT & 
Haematological 
malignancies 
(Hospitalized)
BMT 
haematological 
malignancies, 
solid tumours 
(Hospitalized)
Site of 
isolates
Oropharynx, 
nasopharynx 
throat, urine, 
stool culture
oral rinse & 
imprint culture
Oral rinse
Oral
rinse
throat, urine, 
stool culture
sputum, 
vagina, stool, 
urine culture
Candida
carriage
49
(Single site)
83
(Single site)
75
(Single
site)
44
(Single
site)
69
(Multiple sites)
88.6 
(Multiple sites)
C. albicans 57 56.8 76 50 53 69.4
C. glabrata 17 13 0 31 0 15.3
C. krusei 0 3.6 0 6 4 3
C. tropicalis 5.4 1.2 20 2 3 3.2
C.
parapsilosis
0 8.3 8 3 1 3.7
C.
dubliniensis
0 0 0 0 0 0
Other
species
20.6 17.1 4 8 39 5.4
Current data indicates that the profile of Candida infection in bone marrow 
graft recipients may change while C. albicans is the most common colonizing species 
prior transplantation (Tollemar et al., 1999; Marr et al., 2000), shifts from C. albicans 
to non-albicans Candida species (such as C. glabrata, C. tropicalis, C. parapsilosis 
and C. krusei) may have increased following transplantation (reviewed by Fidel et al.,
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1999; Marr, et a l , 2000; Salonen et al., 2000). However, most patients remain 
colonized by one species (Marr, et al., 2000; Salonen et al., 2000). It has been 
reported that, although Candida carriage was not different at the follow up period in 
BMT recipients, the incidence of non -albicans species may have increased (Salonen 
e ta l ,  2000) (Table 1.3).
Table 1.3 Percentage o f Candida carriage at admission and at follow up period in
BMT recipients (Salonen et al., 2000)
Candida
species
Percentage of Candida 
carriage (admission)
Percentage of Candida 
carriage (follow up)
C. albicans 53 42
C. krusei 4 5
C. tropicalis 3 1
C. glabrata - 2
C. parapsolosis 1 1
1.1.2. Aspects of the pathogenicity of Candida
As a consequence of the realization that fungal infections can pose a 
significant clinical problem, there has been an increased interest in many aspects of 
candidal infection (McCullough et al., 1996). C. albicans was previously considered 
to be the most pathogenic of the Candida species (Gilfillan, et al., 1998; Korting et 
al., 1999). However, it is now evident that infection with C. glabrata, C. tropicalis 
and C. dubliniensis, among others, can give rise to widespread systemic illness, by 
virtue of their increased carriage in immunocompromised persons (Sullivan et al., 
1996; Marr et al., 2000; MacMillan et al., 2002), production of virulence factors 
(Haynes, 2001) and ease of development of antifungal strategies by the organism.
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a) Oral influences
Candida species can be isolated from up to 31%-55% of the mouths of healthy 
individuals (Reviewed by Fidel et al., 1999). The presence of dental prostheses, 
xerostomia and tobacco smoking are common factors associated with the increased 
oral carriage of Candida and can lead to clinically manifest disease (Wahlin, 1991, 
Crockett et al., 1992; Abraham et al., 1998; Abu-Elteen and Abu-Alteen, 1998). 
Furthermore, low salivary pH may increase the oral carriage of Candida (Bercier et 
al., 1999). Candida albicans is the most common dominant species in full denture 
wearers (Crockett et al., 1992; Abu-Elteen and Abu-Alteen, 1998). Budtz-Jorgensen 
and colleagues (1996) carried a study on geriatric hospitalized patients, and found that 
72% of the patients had denture stomatitis, and high yeast counts, furthermore oral 
candidosis seem to be associated with poor oral hygiene (Budtz-Jorgensen et al., 
1996). However, it has been reported recently that the actual denture is not the prime 
site of candidal infection. Instead Candida growth occurs between the denture surface 
and the palate, where natural salivary flow is restricted (Nikawa et al., 1998).
Oral mucosal disease such as leukoplakia and lichen planus can also increase 
the oral carriage of yeasts (Krogh et al., 1987; Lipperheide et al., 1996). It has been 
reported that 43.7% of the patients with leukoplakia or oral lichen planus (LP), had 
oral yeasts isolated from their mouth (Lipperheide et al., 1996). C. albicans was the 
dominating species in this population, constituting 82% of all yeast (Krogh et al., 
1987; Lipperheide et al., 1996). Other Candida species such as C. tropicalis, C. 
pintolopesii, C. glabrata and Saccharomyces cerevisiae were also isolated. The 
frequency, load of yeast carriage and fungal infection may be increased in the mouths
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of patients with moderate or severe epithelial dysplasia, median rhomboid glossitis 
and squamous papillomas (Barrett et al., 1998).
Candida albicans genotype A is the most common genotype isolated from 
healthy individuals (McCullough et al., 1999a). Recently, there has been an increase 
in the incidence of C. albicans genotype B and C in healthy and immunocompromised 
individuals (McCullough et al., 1999a, b). Furthermore, C. albicans serotype A was 
the serotype most isolated from individuals with leukoplakia and lichen planus 
(Lipperheide et al., 1996).
It has also been demonstrated that Candida may be frequently isolated in the 
mouths of children wearing orthodontic appliances, and C. albicans is the 
predominant species (Bialasiewicz et al., 1993). Patients with decayed teeth may 
harbour more oral yeasts than those with healthy teeth. A direct correlation between 
dental decay and the incidence of Candida colonization was observed in children by 
Sziegoleit and co-workers (1999). This study found that Candida species were 
isolated from the mouths of 66.7 % of subjects with carious teeth compared with 2% 
of children with sound teeth (Sziegoleit et al., 1999).
b) Systemic influences
Immunosuppressive disease (e.g. HIV infection), iatrogenic 
immunosuppression (e.g. in allograft bone marrow transplantation), diabetes mellitus, 
solid and non-solid haematological malignancy and broad spectrum antibiotic therapy 
predispose to increase Candida colonization and infection (Epstein, 1990; Lockhart et
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al., 1999; Sturtevant, 2000). Furthermore, congenital defects such as Down syndrome 
may contribute to the increased oral carriage of C. albicans presumably as a 
consequence of both local factors and any attendant immunosuppression (Carlstedt et 
al., 1996).
Bone marrow graft recipients are at particular risk of fungal infection. The majority of 
yeast infection in these patients occurs during the neutropenic phase early after bone 
marrow transplantation (BMT) (Tollemar et al., 1999). Candida can enter the blood 
stream from a colonized mucosal surface or through the Hickman line (intravenous 
line for the administration of chemotherapy and other medications) causing infection 
of different organs (Tollemar et al., 1999). Indeed Candida is believed to be now the 
fourth most common organism recovered from blood cultures of the hospitalized 
patients (reviewed by Fidel et al., 1999). It is thus evident that the oral carriage of 
Candida species is influenced by both local and systemic factors. Nevertheless, 
immunosuppression, particularly affecting phagocytic activities (e.g. neutropenia) or 
cell-mediated immunity (e.g. HIV disease or immunosuppressive regimens such as 
ciclosporin) may enhance liability to oral candidal infection and increase the risk of 
systemic candidal infection (Table 1.4).
Table 1.4 Risk factors for oropharyngeal candidosis (Farah et al., 2000; Akpan and
Morgan, 2002)
Host factors (local or systemic)
Local factors include wearing dentures, impaired salivary gland function, inhaled
steroids and oral mucosal disease 
Systemic factors such as age, tobacco smoking, diabetes mellitus, malignancies, 
immunosuppression, nutritional deficiencies and broad spectrum antibiotics
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1.1.3. Candidosis
1.1.3.1. Oral candidosis
The oral carriage of Candida species rarely manifests as clinical disease. 
However, oral candidosis can give rise to a variety of different clinical features. 
Different classifications of oral candidosis have been described over the years. 
Samaranayake and MacFarlane (1990) and Akpan and Morgan, (2002) classified oral 
candidosis into various oral conditions as summarized in Table 1.5 and Table 1.6.
Table 1.5 Clinical types of oral candidosis (Samaranayake and MacFarlane, 1990)
Oral pseudomembranous candidosis (thrush)
Acute atrophic candidosis 
Chronic atrophic candidosis (denture associated stomatitis)
Chronic erythematous candidosis (including median 
rhomboid glossitis)
Chronic hyperplastic candidosis 
Angular cheilitis (singular stomatitis)
Chronic mucocutaneous candidosis
Table 1.6 Classification of oral candidosis (Akpan and Morgan, 2002)
Acute candidosis 
Acute atrophic (erythematous) candidosis 
Acute pseudomembranous candidosis (thrush)
Chronic candidosis 
Chronic hyperplastic candidosis (candidal leukoplakia) 
Denture induced candidosis (chronic atrophic 
(erythematous) candidosis)
Median rhomboid glossitis 
Angular cheilitis (stomatitis)
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A recent accepted classification of oral candidosis is based upon two 
categories primary and secondary oral candidosis (Ellepola and Samaranayake, 
2000a; Farah et al., 2000; Sitheeque and Samaranayake, 2003). In the primary oral 
candidosis, oral candidal infection is confined to the oral and perioral tissues while 
oral lesions of systemic or mucocutaneous candidal infection is classified as 
secondary oral candidosis (Ellepola and Samaranayake, 2000a) (Tables 1.7).
Table 1.7 Classification of oral candidosis (Ellepola and Samaranayake, 2000a; Farah 
et al., 2000; Sitheeque and Samaranayake, 2003)
Primary oral candidosis Secondary oral candidosis
Acute
Pseudomembranous candidosis
Erythematous candidosis
Chronic
Pseudomembranous candidosis
Erythematous candidosis Oral manifestation of
Hyperplastic candidosis systemic or mucocutaneous
Plaque-like candidosis candidosis
Nodular candidosis
Candida-associated lesions
Denture stomatitis
Angular cheilitis
Median rhomboid glossitis
1.1.3.2. Mucocutaneous and systemic candidosis
Chronic mucocutaneous candidosis is an immunodeficiency disorder mainly 
as a result o f T cell dysfunction that is characterized by persistent candidal infection 
of mucous membranes, skin, scalp and nails (Kirkpatrick, 1994; Chiu et al., 2004).
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Depending on the underlying host defect, C. albicans can cause a variety of 
infections, ranging from superficial mucocutaneous candidosis to life-threatening 
disseminated infections (Gozalbo et al., 2004).
Chronic mucocutaneous candidosis (CMC) syndromes are rare disorders 
(Scully and Cawson, 1993). CMC can be classified into familial CMC, diffuse CMC, 
candidosis-endocrinopathy syndrome and candidosis thymoma syndrome (Scully and 
Cawson, 1993; Scully et al., 1994). Table 1.8 summarises the main types of CMC 
syndromes and their salient features o f each type.
Table 1.8 Types of CMC syndromes (Scully and Cawson, 1993;
Scully et al., 1994)
Familial CMC 
Persistent oral candidosis (thrush)
Iron deficiency 
Diffuse CMC (Candida granuloma)
Chronic oral and skin candidal infections 
Iron and vitamin deficiencies 
Susceptibility to bacterial and viral infections 
Candidosis-endocrinopathy syndrome 
Associated with hypoparathyroidism 
Hypoadrenocorticism 
Rare syndrome 
Candidosis-thymoma syndrome 
Late onset chronic candidosis in the middle age individuals 
Associated with bone marrow abnormalities 
Haematological disorders 
Hypogammaglobulinemia 
Myasthenia gravis
44
Fungal infections in patients with chronic mucocutaneous candidosis usually 
respond to treatment with conventional antifungal agents. However; treatment often 
relapses shortly after treatment is discontinued unless the defects in the cell-mediated 
immune system have been corrected (Kirkpatrick, 1989). The incidence of 
candidaemia seems not to be associated with resistant strains, but with the 
compromised immune status of the host (Nucci and Colombo, 2002). Patients at risk 
o f systemic candidosis are summarized in Table 1.9.
Table 1.9 Risk factors of systemic candidosis (Maertens et al., 2001)
Abdominal surgery and bums 
Intensive care and neonatology 
Gastroenterology and pulmonology 
Haematology, oncology, radiotherapy and transplantation 
Presence of intravenous catheters 
AIDS
Autoimmune diseases and prolonged steroid treatment
1.1.4. Microbial host interactions relevant to candidal infection
There are various outcomes of interactions determined by host, microbial and 
environmental factors. The host factors include physical barriers (skin and mucous 
membranes), natural (inflammation, phagocytosis and interferon) and acquired 
immune responses (cell mediated and humoral immunity). Any change to physical 
barriers may facilitate the entry of microorganisms into the host and therefore increase 
the likelihood to infection (Uthaisangsook et al., 2002). However, there is little
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information available regarding molecular events that occur when Candida interacts 
with the host tissues (Sturtevant, 2000).
The present review will focus upon the microbial factors of Candida that may 
affect its pathogenecity and ultimate clinical disease. The microbial factors that 
influence the outcome of the host microbial interaction are termed virulence factors. 
Once the organism colonizes, it will grow and adhere to the epithelial surfaces 
(Beachey, 1981). Usually, there is a balance between the host and Candida such that 
severe infection never occurs as normal host defenses are usually sufficient to prevent 
almost all infection by Candida. However, if  there is a failure of cell-mediated 
immunity (as occurs in iatrogenic immunosuppression and HIV disease) there is an 
increased likelihood of potential infection and attendant morbidity and mortality. An 
example of the host-microbial interactions is that of C. albicans and oral mucosa. 
Many studies have demonstrated that deficiencies in both phagocytic cell function and 
classical cell-mediated or humoral immune responses are linked to the increased 
susceptibility to C. albicans infection (Lupetti et al., 1995). In addition, due to the 
complex nature of the fungus-host interaction (Calderone, 1993; Sturtevant, 2000), 
local host changes such as temperature and local pH and systemic factors such as 
nutrition may alter gene regulation within the yeast to influence any local and 
systemic infection (Sturtevant, 2000).
1.1.5. Virulence factors of Candida species
Several virulence factors for C. albicans that promote successful colonization 
or invasion of host tissues have been described (MacDonald and Odds, 1980;
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Calderone and Braun, 1991). Candida is able to infect a susceptible host by adhering 
to host cells and release a variety of virulence factors that encourage successful 
colonization or invasion of host tissues (MacDonald and Odds, 1980). The three most 
investigated virulence factors are those related to adhesion, extracellular proteinase 
activity and production of germ tubes (Kretschmar et al., 1999; Hazan et al., 2002). 
Other factors contributing to Candida virulence are phospholipases, lipases, 
phenotypic switching, the cell wall, yeast morphogenesis and immune evasion 
(Calderone and Braun, 1991; Calderone and Fonzi 2001). The exact contribution of 
these factors seems to depend upon the model employed (Kretschmar et al., 1999). 
The virulence factors of Candida that cause clinical infection may vary depending 
upon the type of infection, the stage and the site of infection and the nature of the host 
response (Hube and Najlik, 2001; Naglik et al., 2003).
1.1.5.1. Germ tubes and adherence
Candida albicans can grow as a spherical yeast form or germinate and 
produce filaments, which may appear as pseudohyphae or hyphae (Kretschmar et al., 
1999). The ability of Candida to switch between yeast and hyphal growth forms 
(termed morphogenesis) directly influences its virulence (Fidel et al., 1999; Hazan et 
al., 2002) and this would explain why C. albicans adheres to a greater extent to the 
host epithelium than other species that cannot produce germ tubes. For example, the 
germ tube stage of C. albicans has been shown to penetrate the epithelial cell 
membrane and be associated with virulence as demonstrated in several animal models 
(Kretschmar et al., 1999; Naglik et al., 2003) and tissue culture models. It was 
reported that long germ tubes invaded to the deeper tissues while the short ones did 
not invade tissues in animal models (Kretschmar et al., 1999; Naglik et al., 2003). It
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has been demonstrated that the ability of C. albicans to invade in a model of 
esophageal candidiasis was dependent upon the capacity to convert to a hyphal form 
(Bernhardt et al., 2001). This difference in pathogenicity probably reflects differences 
in surface characteristics, antigenicity and altered expression of genes important in the 
later aspect of the pathogenic process (Bouchara et al., 1990).
Successful colonization and infection of host tissues by pathogenic Candida 
species depends upon the ability to adhere to mucosal surfaces. The adherence of 
Candida to epithelial and endothelial cells is a crucial step in the initiation of 
mucocutaneous and systemic infections (Rotrosen et al., 1986). Candida adherence to 
the host tissues is achieved by a combination of specific (ligand-receptor interactions) 
and non-specific (electrostatic charge, aggregation and cell surface hydrophobicity) 
mechanisms which allow the yeast to attach to a wide range of tissue types and 
inanimate surfaces (Cotter and Kavanagh, 2000).
In a study of strains of C. albicans with a reduced ability to adhere in-vitro it 
was shown that they have impaired abilities to cause infection in animal models 
(Calderone and Braun, 1991). In contrast, in a mouse model, strains which had an 
increased ability to adhere to buccal epithelial cells and produced increased amounts 
of extracellular proteinase activity were shown to have an increased lethality 
(Ghannoum and Abu-Elteen, 1986). It has also been observed that C. albicans isolates 
which adhere most strongly to buccal epithelial cells can have the highest relative 
proteinase activities and be the most pathogenic (Ghannoum and Abu-Elteen, 1986; 
Calderone and Braun, 1991). The observation of differences in adherent capacities of
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yeasts and germ tubes suggests that antigens present on germ tubes enhance the 
adhesive properties of C. albicans (Sundstrom, 1999). The ability of different 
Candida species to adhere is variable. For example C. albicans and C. tropicalis 
adhere more to cell walls than C. krusei or C. guilliermondii (Rotrosen et al., 1986; 
McCullough et al., 1996). In one study, the adherence of C. albicans to buccal 
epithelial cells (BEC) from healthy individuals was significantly greater than that of 
C. krusei (Samaranayake et al., 1994). In animal model studies, the adherence of 
some strains of C. dubliniensis to human buccal epithelial cells when grown in 
glucose-rich media can be greater than that of C. albicans, but the virulence of the 
latter may be greater (Gilfillan, et al., 1998).
Agglutinin-like sequences (ALS) genes are known to be associated with 
adherence probably controlled by Candida derived proteins and carbohydrates. C. 
albicans adhesion genes ALAI (for Agglutinin-Like Adhesion) have been identified 
(Gaur and Klotz, 1997; Sundstrom, 1999). ALAI belongs to the C. albicans ALS 
(Agglutinin-Like Sequence) gene family. ALS genes were first described by Hoyer 
and co-workers (1995). These genes (at least 9) play a major role in candidal adhesion 
and pathogenicity (Hoyer, 2001). The ALS gene family can be also divided into 
subfamilies depending on the sequence o f the central tandem repeat domain (Hoyer, 
2001; Hoyer, et al., 2001). However, each ALS gene has a similar three-domain 
structure, including a 5' domain of 1299-1308 bp that is 55-90% identical across the 
family; a central domain of variable numbers of tandemly repeated copies of a 108-bp 
motif; and a 3' domain that is relatively variable in length and sequence across the 
family (Figure 1.1).
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Figure 1.1 Schematic of ALS gene structure. The three-domain structure of a typical ALS 
gene is shown. The length of the 5' domain is nearly constant across the ALS gene family 
while the length of the tandem repeat and 3' domains is highly
variable (Hoyer, 2001)
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Hoyer (2001) demonstrated the sequence similarities between different ALS gene 
families as illustrated in Figure 1.2.
Figure 1.2 The ALS gene family portrait. Human figures correspond to individual ALS 
genes. Heads represent the 5' domain, trunks are the tandem repeat domain, and legs are 
the 3' domain. ALS3 and ALS8 are almost identical, ALS 1-4 cross-hybridize with the 
ALS\ tandem repeats, ALS5-7 cross-hybridize with the ALS5 tandem repeats and ALS9 
with a unique tandem repeat sequence apparently links the other two subfamilies. ALS7 is
largely unique (Hoyer, 2001)
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ALS genes are also found in other Candida species such as C. dubliniensis, C. 
tropicalis and C. parapsilosis (Hoyer, 2001). However, cross-hybridization analysis 
indicated that the ALS genes in Candida species (other than C. albicans) may have 
unique 3' domains unrelated to those present in C. albicans (Hoyer, 2001). Of interest 
expression of ALS genes in C. albicans and C. dubliniensis may be very similar 
(Hoyer, 2001).
Changes in the expression of these genes are important during infection. For 
example, resistance to fluconazole may appear to be responsible for decreased drug 
susceptibility during progression of infection (Lopez-Ribot et al., 1999).
The expression of ALS genes is influenced by a variety of factors that include 
morphological form, growth medium composition, growth phase and the strain of C. 
albicans (Hoyer et al., 2001). In the present research, the expressions of ALS gene 
family will be examined in different media to determine the virulence attributes of 
these genes in C. albicans.
1.1.5.2. Extracellular enzymes
Candida species possess a range of extracellular enzymes that facilitate 
adherence and / or tissue invasion and penetration. The three most investigated 
hydrolytic enzymes produced by Candida species, and most notably by C. albicans, 
are the secreted aspartyl proteinase (SAP), phospholipases (hydrolyze phospholipids) 
and lipases (hydrolyze ester bonds of tryglycerides) (Hube and Naglik 2001).
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However, extracellular proteolytic activity has been reported to be the most 
commonly investigated virulence factor over the past two decades.
1.1.5.2.1. The secreted aspartyl proteinase
The secreted aspartyl proteinase (SAP) genes are expressed by the more 
pathogenic Candida species such as C. albicans, C. dubliniensis, C. tropicalis and C. 
parapsilosis and not by non-pathogenic yeasts such as S. cerevisiae (Hube and 
Naglik, 2001; Naglik et al., 2003) thus supporting the notion that SAP genes are 
directly contributing to the virulence of the pathogenic Candida (Hube and Naglik, 
2001; Naglik et al., 2003).
Candida albicans SAP genes encode similar amino acid sequences (Hube and 
Naglik, 2001; Naglik et al., 2003) and constitute a family of isoenzymes encoded by 
at least ten genes (Schaller et al., 1999; Bektic et al., 2001; Hube and Naglik, 2001; 
Monod and Borg-von Zepelin, 2002; Naglik et al., 2003) while C. tropicalis and C. 
parapsilosis encode 4 and 3 genes respectively (Monod and Borg-von Zepelin, 2002) 
that are differentially expressed in-vitro and in-vivo. Not all of these proteinases are 
required at the same time or stage of the infection process and not all contribute to the 
same types of infection (Hube and Naglik, 2001; Naglik et al., 2003). However, the 
pathogenetic role of each proteinase in oral mucosal infection is not established 
(Schaller et al., 1999; Naglik et al., 2003). The in-vitro expression pattern of these 
isoenzymes suggests that the production of the SAP gene family may target a variety 
of host cells and tissues during Candida infection at different sites of the body 
(Kretschmar et al., 1999; Hube and Naglik, 2001; Naglik et al., 2003). The main
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reasons for the extensive nature of the SAP gene family are probably the provision of 
multiple copies of a gene to achieve a higher level of expression of the gene product, 
a range of enzymes with slightly different specificities and enzymes that can be 
regulated under different environmental conditions (Farley and Sullivan, 1998).
The amino acid sequences of C. albicans SAP cluster into three separate 
families. C. albicans SAP1, SAP2, SAP3, SAP4, SAP5 and SAP6 are closely related 
enzymes while SAP7 and SAP8 are from diverse branches in the tree. However, the 
amino acid sequences of SAP9 and SAP 10 are at the C-terminus of the translation 
products (Hube and Naglik 2001; reviewed by Monod and Borg-von Zepelin 2002; 
Naglik et al., 2003). The percentage of similarity between Sap isoenzymes (based on 
amino acid sequences) is shown in figure 1.3.
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Figure 1.3 Dendrogram of the C. albicans Sap isoenzyme family based upon amino 
acid sequence. The three distinct groups are clustered within the family. The proteins 
of Sap 1-3 are up to 67% identical; Sap4-6 are up to 89% identical while Sap7 is only 
20-27% identical with the other Sap isoenzymes. Sap9 and Sap 10 isoenzymes have 
C-terminal harmony sequences (Hube and Naglik 2001; Naglik et al., 2003).
Sap7 isoenzyme appeared to be the most divergent of the family
I Sap4
------------- -------- Sap6
Sap5
-------------  Sapl
Sap2
  ----------------  Sap3
___________________  Sap8
Sap9
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The secretory aspartyl proteinase (SAP) genes correlate with other virulence 
properties of C. albicans such as adherence and they are of particular relevance in 
studies of the pathogenic action of Candida because of their molecular 
characterization and proven role in the development of experimental and clinical 
candidosis (Schaller et al., 1999; Hoyer et al., 2001). Most of the Sap proteins 
enhance yeast attachment to mucosal surfaces (Schaller et al., 1999; Bektic et al., 
2001). In addition, because SAP genes are able to degrade several host defensive 
factors (De Bemardis et al., 1999) such as immunoglobulin (Staib et al., 2000), they 
can provide nutrients to Candida. However, disruption or inhibition of these SAP 
genes may reduce pathogenicity of C. albicans (Schaller et al., 1999; Hoyer et al.,
54
2001). Addition of the aspartyl proteinase inhibitor (pepstatin A) reduces Candida 
adherence to the epithelial cells (Kretschmar et al., 1999; Schaller et al., 1999; Hube 
and Naglik, 2001; Naglik et al., 2003) but not the dissemination of fungus that has 
already reached the systemic circulation (Hube and Naglik, 2001; Naglik et al., 2003) 
indicating that the production of SAP genes contributed to the early virulence of 
Candida (Schaller et al., 1999). A further study demonstrated that treatment of 
candidosis in a mouse model with proteinase inhibitor pepstatin A was significantly 
reduced tissue damage (Kretschmar et al., 1999) However as pepstatin A is likely to 
inhibit all Sap enzymes, it is not possible to determine which of the proteinase 
enzymes might be contributing to the virulence of the studied yeasts (Kretschmar et 
al., 1999). The SAP gene family is expressed under a variety of laboratory growth 
conditions (Hube and Naglik 2001). The expression of these genes depends upon 
different conditions that include morphological form, composition of the growth 
medium, growth phase and strain of C. albicans (Schaller et al., 1999; Hoyer et al., 
2001; Naglik et al., 2003).
The expression of SAP genes does not always correlate with the in-vitro 
experiments. For example while SAP2 is the dominant SAP in-vitro, it may not be in- 
vivo (Hube and Naglik, 2001; Naglik et al., 2003) probably affecting a wide spectrum 
of local conditions that can occur in-vivo (Hube and Naglik, 2001).
SAP2 is the major proteinase gene expressed in C. albicans yeast forms. The 
expression of SAP2 enables C. albicans to grow rapidly and efficiently in media 
containing serum albumin or other proteins particularly by providing source of
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nitrogen (Hube and Naglik, 2001; Naglik et al., 2003). SAP2 may play a major role in 
the virulence of Candida by enabling effective degradation of host structure proteins 
such as keratin, collagen, laminin, fibronectin and mucin (Hube and Naglik, 2001) as 
well as host defense proteins such as salivary lactoferrin, a- macroglobulin, enzymes 
of the respiratory burst of macrophages and immunoglobulins (Hube and Naglik, 
2001; Naglik et al., 2003). Furthermore, SAP1-3 are most active at lower pH while 
SAP4-6 are most active at higher pH (range from 2.0 to 7.0) (Naglik et al., 2003).
SAP1 and SAP3 may be expressed during phenotypic switching. The 
expression of SAP8 is temperature dependent while SAP9 and SAP 10 are expressed in 
most environmental conditions (Hube and Naglik 2001; Naglik et al., 2003). 
Interestingly, SAP7 is the most diverse gene of the SAP family (showing only 20.4% 
similarity to SAP1) and has never been expressed in-vitro (Hube et al., 1994; Naglik 
et al., 1999; Naglik et al., 2003). In addition SAP 1-3 may be expressed during 
superficial infections while SAP4-6 are expressed during systemic infections (Watts et 
al., 1998; Schaller et al., 1999; Hube and Naglik 2001; Naglik et al., 2003) and SAP2 
is expressed in the late stages of systemic infection (Hube and Naglik 2001). 
Interestingly, disruption of the expression of SAP1 and SAP3 by proteinase inhibitors 
may lead to the expression of SAPS and SAP8, in an attempt to compensate for the 
down-regulating of SAP1 and SAP3 (Hube and Naglik, 2001). It has been also 
reported that SAP4-6 are produced during the transition of yeast to hyphae and 
therefore, these SAP genes may be expressed with germ tube formation (Kretschmar 
et al., 1999). In addition, the production of SAP4-6 may increase adherence of 
Candida to epithelium (Watts et al., 1998) and thus do have a significant contribution 
to the in-vivo virulence (Kretschmar et al., 1999). In the present study, a selection of
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SAP genes (SAP 1-3, SAP6 and SAP8) will be examined in-vitro (according to their 
cluster in SAP gene family) to determine the virulence attributes of these genes and 
the contribution of the protein presence in the growing medium.
I.I.5.2.2. Lipolytic enzymes (phospholipases and lipases)
Phospholipases (PLs) are thought to contribute significantly to C. albicans 
pathogenicity particularly during invasion into the host tissue via hydrolysis of lipids 
in the host cell membranes (Mayser et al., 1996). It has been reported that high 
phospholipase production is correlated with an increased yeast adherence to the host 
tissues and high mortality rate in animal models (Ibrahim et al., 1995; Mayser et al., 
1996). Of the four PLs identified, only PLB1 has been shown to be associated with 
candidal infection in an animal model (Calderone and Fonzi, 2001). The exact 
pathogenic role of this enzyme is not clear (Ibrahim et al., 1995), although in one 
study, isolates with low phospholipase activity had little ability to invade host tissues 
while isolates with high activity o f phospholipase were associated with high mortality 
in a murine model (Ibrahim et al., 1995).
Lipases are not well characterized as the apartyl proteinases and 
phospholipases. Lipases of C. albicans are able to hydrolyze ester bonds of 
tryglycerides (Cygler and Schrag, 1999). The specific role of lipases in the 
pathogenesis of candidal infections is unclear (Fu et al., 1997) but it has been reported 
that the more pathogenic Candida species produce higher lipases than the less 
pathogenic ones (Fu et al., 1997). Lipases of non-pathogenic Candida species are 
commonly used in biotechnology (Cygler and Schrag, 1999).
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1.1.5.3. The cell wall
The cell wall of C. albicans is a multilayered structure located external to the 
plasma membrane. The major components of the cell wall of C. albicans are 
carbohydrates; however proteins and lipids are present as minor wall constituents 
(Chaffin et al., 1998; Martinez et al., 1998; Lopez-Ribot et al., 2004) as shown in 
Table 1.10.
Table 1.10 Summary of the main components of C. albicans cell wall 
Carbohydrates (80 to 90%)
1) Mannan associated with proteins to form mannoproteins 
2) (3-glucans (P - l ,3 and P-l, 6 linkages) (47 to 60%)
3) Chitin (homopolymer of TV-acetyl-D-glucosamine) (0.6 to 9%)
Proteins (6 to 25%)
Lipids (1 to 7%)
Most of the biological functions related to pathogenicity and virulence reside 
in the fungal cell wall (Lopez-Ribot et al., 2004). The cell wall is essential to almost 
every aspect of the biology and pathogenicity of C. albicans (Chaffin et al., 1998) by 
acting as a permeability barrier, maintaining the characteristic shape of the fungus 
(Chaffin et al., 1998; Martinez et al., 1998) and aiding the adhesion of the organism 
to the host tissue (McCullough et al., 1996, Chaffin et al., 1998; Lopez-Ribot et al., 
2004). Furthermore, the cell wall of the yeast mediates the initial physical interaction 
between the fungus and the environment (Chaffin et al., 1998; Martinez et al., 1998; 
Lopez-Ribot et al., 2004), protects the organism against osmotic insult and promotes
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colonization and growth of the cells (MacDdonald and Odds, 1980; Calderone and 
Braun, 1991; McCullough et al., 1996).
Proteins and glycoproteins are present within the most external layers of the 
cell wall (Martinez, et al., 1998; Lopez-Ribot et al., 2004) while other 
polysaccharides (glucan and chitin) appear to be more concentrated in the inner cell 
wall layer, adjacent to the plasma membrane (Martinez, et al., 1998). Mannoproteins 
of the cell wall are required for the adherence of the organism to the epithelial and 
endothelial cells (Calderone and Braun, 1991). Furthermore, the enzymes thought to 
be involved in cell wall biosynthesis are important for candidal growth and cell 
division (Chaffin et al., 1998). However, the expression and behaviour observed in 
the biological properties of C. albicans cell wall proteins and glycoproteins appear to 
be dependent upon multiple factors such as growth conditions, morphology of the 
cells, strain and serotype and phenotypic switching (Martinez, et al., 1998).
1.1.5.4. Phenotypic switching
Phenotypic switching manifests as differences in colony morphology 
(Calderone and Fonzi, 2001). Phenotypic switching is reversible and can occur 
rapidly (Calderone and Fonzi, 2001). It is regulated by a number of specific genes 
which may influence a variety of virulence traits such as adhesion (Odds, 1997), 
secretion of aspartyl proteinases and germination (Odds, 1997; Calderone and Fonzi,
2001). Switching in C. albicans may help the yeast rapidly adapt to the environment 
(Soli, 2002). Phenotypic switching in C. albicans from a white smooth colony to a 
grey flat smooth colony (opaque) is called white-opaque phase (WO-1) and is 
reported to be associated with SAP genes production (White and Agabian, 1995).
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Other forms of switching can have different morphology such as original-smooth (O- 
smooth), irregular-wrinkle, star and revertant-smooth (as demonstrated in Figure 1.4) 
(Vargas et al., 1994). It has been demonstrated that adhesion to buccal epithelium was 
highest in O-smooth cells and least in star cells (Vargas et al., 1994). However, 
phenotypic switching was reported to be higher in active infection than in the 
communalism stage (Odds, 1997).
Figure 1.4 Examples of colony morphologies in the switching repertoire of C. 
albicans 3153A. (A) O-smooth colony, (B) irregular-wrinkle, (C) star colonies, (D) 
switch from star to irregular-wrinkle (iwr) (Vargas et al., 1994)
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1.1.5.5. Morphogenesis
Transition from yeast form to hyphal form in C. albicans is termed 
morphogenesis. This morphogenetic variability of C. albicans is linked to its 
pathogenicity. However, the relationship between cellular morphogenesis and 
pathogenesis in C. albicans is complex (Whiteway and Oberholzer; 2004). Various 
forms of C. albicans interact with the host in different ways to allow the survival of 
the fungus as a commensal, and to facilitate its dissemination as an opportunistic 
pathogen (Whiteway and Oberholzer; 2004). A study by Bernhardt and colleagues 
(2001) found that the ability of C. albicans to invade a model of oesophageal 
candidosis depended upon the ability o f a particular strain to convert from yeast form 
to hyphal form (Bernhardt et al., 2001).
1.1.5.6. Immune evasion
Candida albicans can evade host immune defenses by a variety of 
mechanisms including phenotypic switching as previously described. In addition, 
phagocytes may not be able to ingest large hyphae, and the hyphal form of C. 
albicans may be more resistant to macrophage killing than the yeast form (Vazquez- 
Torres and Balish, 1997).
To date there has been no detailed study of the virulence of oral Candida 
isolates from the recipients of bone marrow transplantation and thus it is unclear if 
Candida isolates from the mouths of BMT recipients may have enhanced virulence. 
From all of the virulence factors of Candida species, only in-vitro adhesion and
61
proteinase activity will be examined in the present study as they were reported to be 
the most common virulence factors in Candida (McCullough et al., 1996).
1.1.6. Analysis of virulence attributes of Candida species
1.1.6.1. Phenotypic methods
1.1.6.1.1. Adhesion assay
Different methods have been employed to examine yeast cells adherence to 
the host cells, immobilized protein ligands and plastic surfaces. Adherence of 
Candida has been quantitated by radiolabel and visual assays (Rotrosen et al., 1996). 
Separation of the attached host cells and yeast can be accomplished by using filters of 
10 to 12 pm pore size after washing several times to remove non-adherent cells. The 
adhered cells can then be quantitated visually or by radiolabeling (Rotrosen et al., 
1996). However, these assays can be tedious and are not well suited for the large scale 
screening required for molecular genetic techniques (Gaur and Klotz, 2000). Gaur and 
Klotz (1997) examined the adherence o f yeast cells to magnetic beads coated with 
extracellular matrix protein fibronectin, type IV collagen or laminin. The key feature 
of C. albicans adherence to protein (e.g. fibronectin) coated magnetic beads is the 
aggregation of yeast cells upon attachment to the beads (Gaur and Klotz, 2000). This 
assay was reported to be efficient in differentiating adherent C. albicans yeast cells 
from non-adherent Saccharomyces cerevisiae yeast cells (Gaur and Klotz, 1997; 
2000). Other reported methods of Candida cells attachment to the oral epithelium 
were observed in a transmission electron microscope using ultra-histochemical 
staining with ruthenium red for glycocalyx visualization (Vitkov et al., 2002).
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1.1.6.1.2. Proteinase assay
Assessment of proteinase activity can be undertaken using an assay employed 
by McDonald and Odds (1980) in which C. albicans is grown in a medium containing 
synthetic vitamins with bovine serum albumin (BSA) to induce proteinase secretion. 
Undigested BSA is removed by precipitation while the digested protein is measured 
spectrophotometrically at 280nm. The change in the absorbance per number of yeast 
cells is considered as the proteinase activity of the examined strain (McDonald and 
Odds, 1980).
1.1.6.1.3. Phospholipase
Phospholipase activity can be measured by growing the yeast on a solid 
medium containing egg yolk (Ghannoum, 2000). When Candida cells grow in an egg 
yolk medium, phospholipase-positive candidal isolates produce a distinct, well- 
defined, dense white zone of precipitation around the colony due to the formation of 
calcium complex with the fatty acids released by the action of phospholipase on the 
phospholipids present in the egg yolk (Ghannoum, 2000). The ratio of colony 
diameter to the diameter of the dense white zone of precipitation around colonies is 
considered as a marker of phospholipase activity (Ghannoum, 2000). This assay is not 
however, suitable for the screening isolates that produce low levels of phospholipase 
and therefore estimation of phospholipase activity necessitates the use of specific 
radiometric or colorimetric assays (Ghannoum, 2000).
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1.1.6.1.4. Animal models
The development o f animal models for specific diseases such as oral or 
systemic candidosis that mimic their human equivalent is the gold standard of animal 
research (Naglic et al., 2003). Animal models such as murine and rat models have 
been employed to investigate microbial-host interactions and yeast virulence. For 
example, a study by Macdonald and Odds (1983) using a mice model indicated that 
proteinase secretion by C. albicans can predict the virulence of that particular strain 
(Macdonald and Odds, 1983).
1.1.6.1.5. Immune response
During the host-fungus interaction, the cell wall triggers and modulates the 
immune response. Multiple arms of the host immune response can eliminate infecting 
organisms, in particular phagocytosis and inflammatory mediators (Lopez-Ribot et 
a l, 2004).
1.1.6.2. Genetic methods
The identification of gene expression aids the understanding of molecular 
mechanisms of pathogenesis. The RT-PCR (reverse transcription polymerase chain 
reaction) method has been shown to be a very sensitive method able to detect even 
only moderately expressed transcripts from a single cell. The RT-PCR consists of 
reverse transcription (RT) of RNAs isolated from different cell populations with 
oligonucleotide primers to generate cDNA (complementary DNA) pools, followed by 
PCR amplification of random partial sequences from cDNA pools with the original 
anchored primer and arbitrary primer (Sturtevant, 2000). However, the major
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limitation of RT-PCR is the large percentage of false positive results as a consequence 
of low stringency annealing, contamination of PCR products and amplification by 
only the arbitrary primers.
RT-PCR is one of the methods that were developed in recent years to identify 
the differential expression of C. albicans genes (such as SAP genes) (Sturtevant, 
2000). However, an alternate method to examine SAP genes expression in-vivo is the 
recombination method based upon in-vivo expression techniques (RIVET) (Naglik et 
al., 2003). RIVET has been employed to assess SAP gene activation in a murine 
gastrointestinal model and in an intravenous model of disseminated candidosis 
(Naglik et al., 2003).
1.1.7. Candida isolation from the oral cavity
A variety of methods are available for the isolation of Candida from the 
mouth include smear, swab, imprint culture, whole saliva, salivary culture, oral rinse, 
impression culture and biopsy as detailed in Table 1.11.
1.1.7.1. Smear
This method is based upon a smear being taken from the lesion, fixed and 
stained with Grams-stain. This method is widely used, and can determine hyphae but 
has a low sensitivity (William and Lewis, 2000).
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1.1.7.2. Swab
In this technique a sample is obtained by rubbing sterile cotton-tipped swabs 
over a lesion and then inoculating the specimen onto Sabouraud’s dextrose agar. This 
method is simple and widely used, but may be limited by the ability to select a sample 
site and the high rate of oral carriage of Candida in well persons (Sitheeque and 
Samaranayake, 2003).
1.1.7.3. Imprint culture
This method utilizes the application of sterile plastic foam pads to a lesion for 
1 min. The pad is then pressed on Sabouraud’s agar for incubation for one to two 
days at 37°C. This is generally a reliable method that can distinguish between infected 
and carrier states although the selection of a sample site can be difficult if clinical 
signs are absent (Sitheeque and Samaranayake, 2003).
1.1.7.4. Salivary culture
In this method subjects expectorate approximately 2 ml of saliva into a sterile 
container. The sample is then cultured on Sabouraud’s agar. This method is similar to 
the imprint culture technique but it is not suitable for patients with xerostomia, or 
when a site of infection cannot be identified (Sitheeque and Samaranayake, 2003).
1.1.7.5. Oral rinse
This method is simple and requires the subject to rinse the mouth with 10 ml 
of sterile phosphate-buffered saline (PBS) or distilled water for 1 min and then 
expectorate the rinse into a sterile container. The solution is then vortexed and
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cultured for 24 to 48 hours at 37°C. The colony forming unit of the growth Candida 
can then be counted. This technique allows the accurate detection of oral yeasts but 
cannot identify possible sites of candidal disease (Williams and Lewis 2000; 
Sitheeque and Samaranayake, 2003). This method is easy and suitable for measuring 
candidal carriage among large population and therefore it will be employed in the 
present research.
Table 1.11 Clinical methods of Candida isolation and quantification
(Sitheeque and Samaranayake, 2003)
Method Advantage Disadvantage
Smear Simple and quick Low sensitivity
Swab Simple Selecting sample site may be critical
Imprint
culture
Sensitive and reliable, 
able to distinguish 
between infected and 
carrier states
Reading above 50 cfu / ml count can 
be inaccurate, selection of the site can 
be difficult if no clinical signs present
Useful to determine
Impression
culture
relative distributions of 
the yeasts on oral 
surfaces
Useful mostly as a research tool
Salivary
culture
Relatively chair-side time consuming,
Similar to imprint culture not suitable for xerostomia, cannot 
identify site of infection
More sensitive than Recommended for surveillance culture
Oral rinse imprint method if the cfu in the absence of focal lesions cannot
/ ml count > 50, simple identify site of infection
Biopsy
Diagnosis of chronic Invasive, inappropriate for majority of
hyperplastic candidosis infections
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1.1.7.6. Impression culture
In this method, maxillary and mandibular alginate impressions are taken and 
then cast in agar prepared with Sabouraud’s broth and incubated. This technique 
allows the distribution of the yeasts on oral surfaces to be determined (Sitheeque and 
Samaranayake, 2003).
1.1.7.7. Biopsy
This is an invasive method and inappropriate for regular use. However, it is 
helpful to confirm diagnosis of oral lesion such as chronic hyperplastic candidosis 
(Williams and Lewis 2000).
1.1.8. Methods used for strain differentiation
Infection by Candida may be as a result of re-colonization of the same species, 
colonization with a new strain or failure to eliminate the original strain. Therefore, 
discrimination between Candida strains to facilitate identification of Candida species 
is important when investigating aspects of epidemiology of candidal infection. 
Previously, phenotypic methods were employed to differentiate between Candida 
species; but such methods do not reveal true strain differences (Fidel et al., 1999). 
The ideal method should be highly reproducible, allow rapid examination of a large 
number of isolates and require minimal time and cost. However, such a method does 
not exist, although a variety of phenotypic and genetic methods are currently used to 
discriminate Candida species such as C. tropicalis, C. glabrata, C. parapsilosis and 
C. krusei from C. albicans (Joly et al., 1999).
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1.1.8.1. Phenotypic methods to differentiate Candida species
The results of studies to differentiate Candida strains for epidemiological 
purposes using a variety of phenotypic markers have been variable. The most 
common methods have been studied and used for epidemiological purposes to 
describe and discriminate Candida species and C. albicans strains are CHROMagar 
test, carbohydrate assimilation tests (API system), germ tube test (to isolate C. 
albicans or C. dubliniensis), clamydospore formation, serotyping, resistogram typing, 
susceptibility to killer toxins, morphotyping and biotyping (Lupetti et al., 1995).
1.1.8.1.1. CHROMagar
CHROMagar Candida is a medium with chromogenic substances allowing 
presumptive identification of Candida species (Tintelnot et al., 2000). Candida grown 
on CHROMagar gives rise to different colours. For example C. glabrata appears pink, 
C. albicans appears green to blue-green (Fidel et al., 1999) while C. dubliniensis 
appears as dark green (Tintelnot et al., 2000). Although this method is convenient, it 
can be unreliable particularly if it is performed on a secondary culture (Tintelnot et 
al., 2000) (Table 1.12).
Table 1.12 Identification of the medically important Candida species
utilizing CHROMagar method
Candida species Colony colour
C. albicans Green
C. dubliniensis Dark green
C. tropicalis Metallic blue/grey
C. krusei Rose-pink fuzzy
C. glabrata pink
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1.1.8.1.2. Carbohydrate assimilation test (API system)
This is a commercial method widely used to identify clinical isolates of oral 
Candida (Pincus et al., 1999; Schorling et al., 2000). This colorimetric test 
(carbohydrate acidification and enzymatic tests) depends upon the activation of the 
reaction on a strip according to the instructions provided by the manufacturer 
(bioMerieux, France). A profile number is generated for each strip and then referred 
to the Analytical Profile Index (API) for each isolate to be transformed into a 
numerical code, which can be compared to a database to identify Candida species. 
The accuracy of the API system in species differentiation ranges from 92.4% to 
97.6% (Ellepola et al., 2003). However, the interpretation of the results can be 
difficult and unclear (Schorling et al., 2000). For example, it has been reported that 
the carbohydrate assimilation system can misidentify C. dubliniensis isolates as 
C. albicans isolates (Ellepola et al., 2003).
1.1.8.1.3. Germ tube test
Candida albicans can grow as a spherical yeast form or germinate and 
produce filaments, which may appear as pseudohyphae or hyphae (Kretschmar et al., 
1999). A simple and quick method of identifying C. albicans (and C. dubliniensis) 
from other Candida species is by cell morphology and a germ tube test (GTT) 
(Ferretti et al., 1988). The germ tube test allows a rapid identification of C. albicans 
and recently C. dubliniensis by placing inoculums of cultures in 0.5 ml of sterile horse 
serum. The presence or absence of germ tubes is investigated under the light 
microscope after 2 h incubation at 37°C (McCullough et al., 1999b). This method, 
however is unreliable.
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1.1.8.1.4. Clamydospore formation
Clamydospore formation is indicative of C. albicans and C. dubliniensis and 
occasionally in C. tropicalis (Campbell et al., 1996 ; Williams et al., 2000). Unlike 
germ tubes, clamydospores may take up to four days to develop on commeal agar 
(Campbell et al., 1996). However, Tween 80 medium quickens the stimulation of 
clamydospores formation within 24 h (Campbell et al., 1996).
1.1.8.1.5. Serotypes of Candida albicans
Serotyping is a phenotypic method of strain differentiation depending upon 
agglutination of C. albicans cells with antisera (Hasenclever and Mitchell, 1961). 
Isolates of C. albicans can be then divided into two serotypes, A and B. However, this 
method has low discriminatory power and problems can arise with auto-agglutinating 
strains (Williams et al., 2000; Soli, 2000).
1.1.8.1.6. Morphotyping
Morphotyping of C. albicans is based upon the type and degree of fringe 
morphology observed in colony suspensions streaked onto malt agar and incubated 
for 10 days (Phongpaichit et al., 1987). Although this method is relatively cost 
effective and easy, limitations arise with its reproducibility and discriminatory power.
1.1.8.1.7. Yeast “killer toxin” typing
Killer toxins are extracellular toxins produced by certain yeast species which 
kill sensitive yeasts, but not the producer strain. This method was used to define
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medically important yeasts by their sensitivity to a sheet of killer yeasts in a simple 
plate assay (reviewed by McCullough et al., 1996; Magliani et al., 1997). However, 
the reproducibility of this method was not assessed.
1.1.8.1.8. Resistogram typing
This method of discriminating Candida strains is based upon susceptibility of 
Candida to various inhibitory substances at different concentrations (reviewed by 
McCullough et al., 1996). Registogram typing can discriminate C. albicans strains 
however; growth endpoint interpretatation can be a problem (Hunter and Frazer, 
1989).
1.1.8.1.9. Protein typing
Mutations during the yeast cell cycle produce proteins of differing physical 
properties between strains which may be distinguishable by gel electrophoresis. This 
method has been utilized to differentiate C. albicans at the sub-species level (Pitarch 
et al., 2003) that could provide a range of variation sufficient for epidemiological 
purposes.
1.1.8.2. Genetic methods to differentiate Candida species
Molecular methods provide definitive differentiation of species to characterize 
the genetic difference between C. albicans, C. dubliniensis and other species. A 
variety of methods are now available but the most common ones are polymerase chain 
reaction (PCR) based typing techniques, restriction fragment length polymorphism
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(RFLP), randomly amplified polymorphic DNA (RAPD) and electrophoretic 
karyotyping.
1.1.8.2.1. Polymerase Chain Reaction (PCR) based typing techniques
PCR based typing techniques have been used to identify Candida species to 
the species level by directing specific primers against the V3 region of the 25S rDNA 
and the intergenic transcribed spacer (ITS) of the rDNA. The amplicons of the V3- 
25S and ITS PCR are digested with restriction enzymes such as HaelII and Ddel. A 
further PCR is required to identify the genotypes of C. albicans utilizing primers 
directed against the transposable intron in the 25S rDNA region. Thus, C. albicans 
can be divided into subgroups depending upon the presence (genotype B), absence 
(genotype A) of this intron or partial presence of the intron (genotype C). However, 
C. dubliniensis has a much larger transposable intron in the same site of the 25S 
rDNA (McCullough et al., 1999b). All PCR amplicons and restriction digests are 
separated via agarose gel electrophoresis and visualized by UV transillumination. 
This method is reproducible and simple in species differentiation and in dividing C. 
albicans into subgroups (McCullough et al., 1999b). Hence it will be employed in the 
present research.
1.1.8.2.2. Restriction fragment length polymorphism (RFLP)
Restriction fragment length polymorphism (RFLP) of C. albicans was thought 
to be a useful criterion for distinguishing various isolates of Candida (Magee et al., 
1987). The extraction of DNA from the yeast form of Candida species, followed by 
digestion with restriction endonucleases and electrophoresis of DNA fragments to 
identify Candida species was first described by Scherer and Stevens (1987). This
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method was used for C. albicans strain differentiation by analyzing the restriction 
fragment length polymorphisms (RFLPs) of cellular DNA and dividing the isolates 
into two groups according to the position of a dimorphic band (group A strains have a 
band of 3.7 kb and group B strains have a band of 4.2 kb) (Scherer and Stevens, 
1987). This method was shown to be reliable and reproducible for epidemiological 
studies (Stevens et al., 1990). A further study using the same methodology reported 
the presence of C. albicans genotype C which contains the two bands at 3.7 and 4.2 
kb bands and genotype D with neither band (Clemons et al., 1997a). Recently, there 
has been an increase in the incidence of C. albicans genotypes C and C. dubliniensis 
(McCullough et al., 1999a). Restriction fragment length polymorphism (RFLP) of C. 
albicans and other Candida species is thought to be a useful measure for 
distinguishing between various isolates (Magee et al., 1987) by observing the 
variations of the fragments produced by restriction endonucleose digestion with 
FcoRI (Magee et al., 1987, McCullough et al., 1996).
I.I.8.2.3. Randomly amplified polymorphic DNA (RAPD)
Randomly amplified polymorphic DNA (RAPD) is based on the use of short 
PCR oligonucleotide primers of arbitrary sequence. These primers can bind and 
amplify to different size products. The fragments are then separated by agarose gel 
electrophoresis and detected by staining with ethidium bromide (Pujol et al., 1997a). 
This method requires small amounts of purified DNA (Clemons et al., 1997a). It is 
easy, rapid and relatively cost effective (Bautista-Munoz et al., 2003) but has less 
reproducibility than pulsed field electrophoresis (PFGE) (Sullivan et al., 1996; 
Clemons et al., 1997a ; Reiss et al., 1998).
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1.1.8.2.4. Electrophoretic karyotype analysis
Electrophoretic karyotype analysis is based upon pulsed-field gel 
electrophoresis (PFGE) or contour-clamped homogenous electric field (CHEF) 
electrophoresis which resolves large chromosome sized of DNA fragments through 
agarose gels using an alternating electric field direction (Magee et al., 1988; Williams 
and Lewis, 2000). This method is good in discriminating Candida species and useful 
in epidemiological typing of Candida strains but it is considered to be time 
consuming, expensive and requires special equipment (Williams and Lewis, 2000).
1.1.8.2.5. rRNA sequencing analysis
The nucleotide sequencing of the internal transcribed spacer (ITS) regions in 
the rRNA gene is a useful molecular method for identifying different Candida strains. 
The oligonucleotide primers for PCR have been designed based on the sequences of 
18S or 26S rDNA. This method is limited by the high levels of sequence similarity 
among some Candida species (Sugita et al., 1999).
1.1.8.2.6. Microsatellite regions
Microsatellites regions are tandemly repetitive DNA elements composed of 
short repeat units. These units are easy to identify and have been used widely as 
molecular markers for genetic mapping (Metzgar, et al., 1998). Microsatellite 
variation is performed by comparing the lengths of different alleles using PCR 
amplification of the repeat region (Metzgar et al., 1998; Lott et al., 2003). This 
method is considered to be reproducible (Botterel et al., 2001).
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1.1.8.2.7. Oligonucleotide fingerprinting
Cloning of DNA fingerprinting probes for C. albicans, C. glabrata, C. 
tropicalis and Aspergillus fumigatus, found in all cases that they contain repetitive 
species specific sequences. DNA fingerprinting of C. albicans can be achieved by 
several methods such as Southern blot hybridization with complex probes Ca3 and 
27A of C. albicans, randomly amplified polymorphic DNA (RAPD), PCR 
fingerprinting with repetitive DNA sequences, inter repeat PCR (IR-PCR), restriction 
fragment length polymorphism (RFLP) and contour-clamped homogenous electric 
field (CHEF) electrophoresis. These methods permit differentiation of the strains with 
similar phenotypic characteristics (Fidel et al., 1999; Soil, 2000). PCR fingerprinting 
using a repetitive DNA sequences method is similar to the randomly amplified 
polymorphic DNA method with the advantage of the former that the primers are 
longer (in base pairs) and the annealing temperature is higher thus avoiding problems 
with reproducibility that are frequently associated with RAPD. This method, 
therefore, will be employed in the present research to differentiate C. albicans strains.
1.1.9. Common causes and treatment of fungal infections in bone 
marrow transplant recipients
Following bone marrow transplantation, all components of the immune system 
are impaired and the recipients of BMT are prone to fungal infection (Richardson and 
Kokki, 1998; Marr and Bowden, 1999). The main risk factors for fungal infections are 
neutropenia and acute graft-versus-host disease (GvHD). Other factors, including 
damage to the epithelial barriers, impaired monocyte function, and altered cell- 
mediated immunity, increase the risks for fungal infection following BMT although 
these aspects all generally repair within 12-15 months (Marr and Bowden, 1999). The
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risk of fungal infection at a later stage may be due to a delay of lymphocyte and 
neutrophil recovery, graft failure and prolonged intake of GvHD prophylaxis 
(Richardson and Kokki, 1998) and therefore, the elimination of underlying factors 
responsible for the development of candidosis (local or systemic) is essential to 
reduce or prevent the incidence of infection, for example by the withdrawal or 
substitution of broad-spectrum antibiotics (Farah et al., 2000; Sitheeque and 
Samaranayake, 2003). In addition, saliva replacement in those who experience 
xerostomia may prevent oral colonization with Candida.
The development of a prevention regimen for the invasive fungi and moulds 
remains a challenge in BMT recipients. However, the introduction of new antifungal 
drugs and adjunctive therapy to improve the immune function may be beneficial in 
decreasing morbidity and mortality associated with fungal infection (Marr and 
Bowden, 1999). In addition, Candida isolates should be identified to the species level 
as early as possible. Although culturing of these organisms from blood is not easy, 
new strategies such as lysis centrifugation will increase the sensitivity of blood 
culturing methods (Marr and Bowden, 1999).
1.1.10. Agents used in the treatment of oral candidosis
Different agents are available for the treatment of oral and systemic candidal 
infections. The most common antifungal drugs in current clinical use are polyenes 
(amphotericin B and nystatin), azoles (fluconazole, itraconazole, clotrimazole, 
miconazole, ketaconazole and now voriconazole), 5-fluorocytosine and chlorhexidine 
gluconate. Novel triazoles (posaconazole, ravuconazole) are in development for 
clinical use (Espinel-Ingroff et al., 1998; 2001; Sanglard and Odds, 2002). Most
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recently, echinocandins have been developed for the treatment of systemic mycoses 
(Johnson and Kauffman, 2003).
1.1.10.1 Polyenes
1.1.10.1.1. Nystatin
Nystatin acts by inhibiting ergosterol biosynthesis in the fungal cell 
membrane. This inhibition of ergosterol biosynthesis alters the permeability of the 
yeast cell membrane, resulting in leakage of cell component and death (Ellepola and 
Samaranayake, 2000b). Nystatin has both a fungicidal and fungistatic action, 
depending upon the concentration administered (Wang et al., 1998, Ellepola and 
Samaranayake, 2000b). Nystatin is only available for topical application due to being 
too highly toxicity for systemic administration. It is ideal for treating superficial 
infections of C. albicans (Ellepola and Samaranayake, 2000b).
1.1.10.1.2. Amphotericin B
Amphotericin B inhibits fungi via an interaction with ergosterol in the cell 
wall, resulting in the loss of membrane-selective permeability and intracellular 
components (Ellepola and Samaranayake, 2000b). Amphotericin B efficacy can be 
either fungistatic or fungicidal depending upon drug concentration. Amphotericin B 
has the broadest spectrum among antifungal agents and may still be considered as the 
gold standard for the treatment of invasive fungal infection (Comely et al., 2003; 
Wingard and Leather, 2004). Amphotericin B is used topically (as ointments, 
suspensions, creams and lozenges) for the treatment of mucocutaneous candidal
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infection and intravenously for the treatment of systemic mycoses (Comely et al., 
2003). In addition, amphotericin B as a prophylaxis for Candida and Aspergillus 
infection has been found to be effective in patients undergoing bone marrow 
transplantation (Wingard, 1999) by reducing both fungal colonization and the 
incidence of superficial candidosis (Richardson and Kokki, 1998; Comely et al., 
2003) but the risk of nephrotoxicity limits its parenteral application (Wingard, 1999; 
Comely et al., 2003; Sanglard and Odds, 2002).
1.1.10.1.3. Lipids form of amphotericin B
Liposomal amphotericin (AmBisome) is a lipid form of amphotericin B. It is 
as effective as amphotericin B with the advantage of reduction drug-related toxicity 
associated with conventional amphotericin B (Richardson and Kokki, 1998). 
However, this preparation is very expensive and its application is thus reserved 
mainly for the treatment of life-threatening invasive infections particularly in 
allogenic stem cell transplantation (Marr and Bowden, 1999; Groll and Walsh, 2002).
1.1.10.2. Azoles
The azole antifungal agents in clinical use are classified as imidazoles 
(ketoconazole, miconazole, clotrimazole) and triazoles (fluconazole and itraconazole). 
In addition, a new generation of other triazole agents (posaconazole, ravuconazole, 
and voriconazole) has been developed (Espinel-Ingroff et al., 1998; Sanglard and 
Odds, 2002). The azole agents can block the 14 a-demethylation step in the synthesis 
of ergosterol that normally contributes to a variety of cellular functions, including 
fluidity and integrity of the cell membrane (Ellepola and Samaranayake 2000b). At
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high concentrations, the azoles may exert an antifungal action by direct interaction 
with lipids in the cell membrane (Ellepola and Samaranayake 2000b). The azoles are 
all fungistatic and not fungicidal.
1.1.10.2.1. Clotrimazole
Clotrimazole has broad spectrum activity against candidal and staphylococcal 
infections (Ellepola and Samaranayake 2000b). It tends to be the first-line treatment 
of oral candidosis in the USA especially in immunocompromised individuals such as 
HIV-infected patients and transplant recipients. It is only available as a topical 
preparation (Ellepola and Samaranayake 2000b; Rex et al., 2000).
1.1.10.2.2. Miconazole
Miconazole acts against fungal infections such as Candida species and some 
Gram-positive bacteria, such as Staphylococcus aureus (Ellepola and Samaranayake 
2000b). Miconazole is generally used topically while systemic application is not 
undertaken as the other azoles are less toxic (Budtz-Jorgensen and Carlino, 1994; 
Konsberg and Axell, 1994; Dias et al., 1997). However, it has been previously 
reported that topical administration of miconazole has the ability to be systemically 
absorbed and interact with other drugs (Pemberton et al., 2004).
1.1.10.2.3. Ketoconazole
Ketoconazole is effective against a wide spectrum of fungi and is generally 
reserved for severe infections such as chronic mucocutaneous candidosis or HIV-
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related candidal infection (Ellepola and Samaranayake 2000b). Adverse side effects 
such as gastrointestinal intolerance, hepatotoxicity and nephrotoxicity have limited its 
clinical application particularly in view of the greater acceptability of fluconazole 
(Ellepola and Samaranayake 2000b).
1.1.10.2.4. Fluconazole
Fluconazole is a water soluble agent and active against most strains of C. 
albicans but it is less active against non-albicans Candida species, particularly C. 
krusei (which is intrinsically resistant to this agent) or C. glabrata (Ellepola and 
Samaranayake 2000b; Sanglard and Odds 2002, Comeley et al., 2003). Fluconazole is 
administered systemically (orally or intravenously), is well absorbed by the 
gastrointestinal tract and not metabolized in the liver (80% of the agent being excreted 
unchanged via the kidney) (Brammer et al, 1991). Fluconazole is very widely used as 
prophylaxis against fungal infection in BMT recipients up to 75 days following 
transplantation (Comeley et al., 2003). It is also used for the management of 
uncomplicated candidaemia in neutropenic patients but not in acute disseminated 
candidaemia (Groll and Walsh 2002).
1.1.10.2.5. Itraconazole
Itraconazole is a lipophilic drug and has a wide spectrum of antifungal activity 
(Ellepola and Samaranayake 2000b). It is generally well-absorbed and tolerated after 
oral administration (Ellepola and Samaranayake 2000b). Itraconazole may be a useful 
agent in the management of invasive fungal infections and in azole-resistant Candida 
(Ruhnke et al., 1994; Ellepola and Samaranayake 2000b; Sanglard and Odds 2002).
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However, its erratic absorption from the gastrointestinal tract may limit its use (Groll 
and Walsh, 2002).
1.1.10.2.6. Voriconazole
Voriconazole has the broadest antifungal spectrum of all licensed azole 
antifungal agents. In clinical trials, good antifungal responses have been noted against 
Aspergillus and Candida (including fluconazole-resistant) species, Fusarium and 
Scedosporium infections but not against Zygomycetes (Wingard, 1999; Ostrosky- 
Zeichner et al., 2003; Wingard and Leather, 2004). It has been demonstrated that
voriconazole is more effective than amphotericin B in the treatment of invasive
aspergillosis (Wingard and Leather, 2004). Voriconazole can cause photopsia (visual 
disturbance) and photosensitivity but both of the reactions are transient and reversible 
(Wingard and Leather, 2004).
1.1.10.3. 5-fluorocytosine
5-fluorocytosine (5-FC) is taken up into the fungal cells via a cytosine 
permease and deaminated into 5-fluorouracil (5-FU) by cytosine deaminase (White et 
al., 1998). 5-FU can be converted by cellular pyrimidine into a deoxynucleotide, 
which is a specific inhibitor of thymidylate synthetase (an essential enzyme for DNA 
synthesis) (White et al., 1998; Sanglard and Odds, 2002). In addition, 5-FC can be 
converted into a nucleoside triphosphate and when it incorporates with RNA, it may 
cause disruption of protein synthesis (White et al., 1998). 5-fluorocytosine is 
generally used for the treatment of deep systemic Candida infections and mainly 
given in combination with other antifungal agents (particularly with amphotericin B)
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due to the rapid development of resistance among clinically susceptible yeast species 
(White et al., 1998; Ellepola and Samaranayake 2000b; Sanglard and Odds 2002).
1.1.10.4. Echinocandins
The echinocandin group (caspofungin and micafungin) are amphophilic 
lipopeptides. They act by inhibiting fungal p 1, 3 glucan synthetase which results in 
the lysis of the organism by interfering with the synthesis of chitin (a cell wall 
constituent) (Wingard, 1999). Echinocandins were developed as alternatives to 
amphotericin B for the treatment of invasive candidosis and aspergillosis (Comely et 
al., 2003; Johnson and Kauffman, 2003; Wingard and Leather 2004). Caspofungin is 
the first agent of the echinocandin group available commercially and has been shown 
to be very effective against Candida species and Aspergillus species but not against 
Cryptococcus neoformans (Johnson and Perfect, 2003). In addition, caspofungin may 
have some effect on dimorphic fungi such as Histoplasma capsulatum and 
Coccidioides immitis (Johnson and Perfect, 2003). Furthermore, caspofungin has an 
excellent safety profile with reduced toxicities, compared to the other licensed 
antifungal agents such as amphotericin B (Johnson and Perfect, 2003). Nevertheless, 
caspofungin is extremely expensive.
1.1.10.5. Allylamines (terbinafine) agents
Terbinafine is a member of the allylamine group that can inhibit epoxidase in 
the ergosterol biosynthetic pathway. Terbinafine is fungicidal against dermatophytes 
and filamentous fungi and fungistatic against Candida species (Ryder et al., 1998).
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Terbinafine was also found to be highly active against Cryptococcus species (Ryder et 
al., 1998).
1.1.10.6. Yeast killer systems
Yeast killer toxins (KTs) are proteins or glycoproteins secreted by several 
yeasts, capable of killing susceptible cells belonging to the same species that have 
specific cell wall receptors (Magliani et al., 1997). The monoclonal killer
antiidiotypic antibody and the synthetic killer peptide act as internal images of 
microbicidal wide-spectrum yeast killer toxin (KT) (Polonelli et al., 1997). These 
agents have been shown to have candidacidal therapeutic activity against
experimental mucosal and systemic candidosis models caused by C. albicans (Cenci 
et al., 2002). However they are currently not clinically applicable.
1.1.10.7. Chlorhexidine
Chlorhexidine has been used as an adjunctive therapeutic supplement due to 
its antimicrobial activity against a broad spectrum of organisms including Candida 
(Epstein, 1990; Ellepola and Samaranayake, 2001). Chlorhexidine is effective in low 
concentration in the treatment of Candida-associated denture stomatitis and in 
pseudomembranous candidosis (Ellepola and Samaranayake, 2000b; Ellepola and 
Samaranayake, 2001). In addition, chlorhexidine has the ability to suppress candidal 
adhesion to denture acrylic surfaces and to buccal epithelial cells (Ellepola and 
Samaranayake, 2000b; Ellepola and Samaranayake, 2001). However, chlorhexidine 
interacts with nystatin and may render both agents ineffective (Ellepola and 
Samaranayake, 2000b).
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All antifungal agents can carry risk of adverse side effects and toxicities, or 
interact with other medication. In addition, they may not be effective against certain 
species or moulds due to intrinsic resistance to antifungal agents as summarised in 
Table 1.13.
Table 1.13 Yeast susceptibility and resistance to the most common licensed 
antifungal agents and their possible side effects (Sanglard, 2002; Wingard and
Leather, 2004)
Antifungal
agent Susceptible yeast Resistance yeast Side effects Associate risk
AmB
Most of Candida 
species and 
Aspergillus 
species
C. lusitaniae, C. 
guilliermondii, 
Fusarium species, 
Tricosporon 
beigelli
Nephrotoxicity
Concurrent 
therapy with 
ciclosporin or 
aminoglycosides
Flu
C. albicans, 
C. dubliniensis, 
C. tropicalis
C. krusei 
(C. glabrata and C. 
dubliniensis can be 
dose dependent)
Increased 
resistance to this 
agent with 
prolonged intake
Itra
Candida species 
Cryptococcus 
species 
Aspergillus 
species
Should be 
avoided in renal 
dysfunction
Vor
Aspergillus 
species Candida 
species (including 
those resistant to 
fluconazole), 
Fusarium species, 
Scedoporium 
infections
Zygomycetes
species
Photopsia and 
visual 
disturbance
Should be 
avoided in renal 
dysfunction
Casp
Aspergillus 
species, Candida 
species (including 
those resistant to 
fluconazole)
Cryptococcus
species
Few toxicities 
(increase 
hepatic 
transaminases)
5-FC
Candida species, 
Cryptococcus 
species
Aspergillus species 
and most moulds
Gastrointestinal
upset
Amb B: Amp lotericin B deoxycholate, Flu: Fluconazole, Itra: Itraconazole,
Vor: Voriconazole, Casp: caspofungin, 5-FC: Fluorocytosine
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1.1.11. Resistance to antifungal agents
Resistance to antifungal therapies has increased significantly in the past two 
decades in bone marrow transplant (BMT) recipients and in those receiving intensive 
chemotherapy, causing a resultant increase in mortality and morbidity (Fidel et al., 
1999; Paterson et al., 2001). Furthermore, developing resistance to these agents is 
increasing rapidly. The frequent administration of fluconazole as prophylaxis in 
immunocompromised patients (Kurtz et al., 1996, Baran et al., 2000), treatment of 
recurrent infection with fluconazole (Quabeck et al., 1992) or the rate of growth of the 
fungus (Sanglard and Odds 2002) can lead to the development of antifungal resistance 
by species such as C. glabrata, C. krusei and even C. albicans (Kurtz et al., 1996, 
Baran et al., 2000). The susceptibility of clinical infection by Candida to fluconazole 
is influenced by the virulence of the organism (Graybill et al., 1998), persistence of 
the same strain or the acquisition o f new drug-resistant strains (Diaz-Guerra et al., 
1998).
Resistance to antifungal agents may be classified into clinical and laboratory. 
Clinical resistance is due to insufficient dose of the antifungal agent or due to a defect 
in the host immune function and the presence of severely immunosuppressive states 
such as AIDS patients (Graybill et al., 1998; Loeffler and Stevens. 2003). In-vitro 
resistance is either due to primary or secondary resistance. Primary resistance 
(intrinsic resistance) is when the organism is naturally resistant to the antifungal 
agents, such as the resistance of C. krusei to fluconazole, whereas secondary 
resistance occurs when the isolate causing infection becomes resistant to the 
antifungal agents (Fidel et al., 1999; Loeffler and Stevens. 2003) over time (frequent 
exposure to the agent). In addition, secondary resistance can be either reversible, due
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to transient adaptation, or irreversible, due to one or more genetic alteration (Sanglard 
and Odds, 2002; White et al., 2002).
1.1.12. Testing susceptibility to fluconazole
Fungal infections pose an important challenge for the BMT clinician and 
therefore there is a need for accurate diagnostic tests to allow the initiation of 
treatment in the early stage of infection when the burden of organisms is more 
manageable (Wingard, 1999). Several methods have been developed to examine 
antifungal susceptibility including disk diffusion methods (Kirkpatrick and Turner, 
1998), E-test (Colombo et al., 1995), colorimetric methods (Li et al., 2000), and broth 
macrodilution and microdilution methods (NCCLS M27 A, 1997). The broth 
macrodilution and microdilution test is the NCCLS (National Committee for Clinical 
Laboratory Standards) reference method, and provides over 90% intralaboratory and 
interlaboratory reproducibility (Nucci and Colombo, 2002) however, this method is 
time consuming. Although, disk diffusion and E-test are effective in identifying 
susceptible strains, these methods do not adequately discriminate between resistant 
and intermediate or dose-dependent strains. Therefore, these methods may be useful 
as screening tests, but confirmation of resistant strains should be made with the 
NCCLS method (Nucci and Colombo, 2002).
The previous antifungal susceptibility tests of the National Committee for 
Clinical Laboratory Standards (NCCLS M27-P) of broth macrodilution (as employed 
in the early 1990s) (Espinel-Ingroff et al., 1995) was considered to be time consuming 
and the determination of the minimal inhibitory concentration (MIC) endpoint was
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often subjective. Therefore, this method may not be convenient and practical for 
routine use (Espinel-Ingroff et al., 1995). In the last 10 years, the broth microdilution 
method (NCCLS M27-A) has been developed as an alternative method for antifungal 
susceptibility tests in-vitro (Espinel-Ingroff et al., 1999). The broth microdilution 
assay is similar to the broth macrodilution assay except that it uses less material in a 
microtitre plate and is therefore cheaper and more convenient to perform (Espinel- 
Ingroff et al., 1999).
There are three methods to determine fluconazole resistance employing broth 
microdilution assay in-vitro: optical, colorimetric (e.g. utilizing Alamar blue 
indicator) and spectrophotometric methods (Espinel-Ingroff et al., 1995). The optical 
and colorimetric methods rely upon the subjective interpretation of prominent growth 
inhibition (Espinel-Ingroff et al., 1995) while the spectrophotometric method is more 
objective and efficient (Espinel-Ingroff et al., 1995). However, this method requires 
special laboratory equipment that is not available in many clinical laboratories 
(Espinel-Ingroff et al., 1995). The Alamar blue modified microdilution method is 
identical to the original method of NCCLS M27-A in terms of inoculum and medium 
preparation, drug dilution, and incubation with the exception that Alamar blue 
solution is added to the preparation medium (Tiballi et al., 1996). This colorimetric 
microdilution assay has been found to be easy to determine the endpoint (Espinel- 
Ingroff et al., 1995) therefore; this method will be employed in the present study to 
assess the in-vitro susceptibility of Candida species to fluconazole. Table 1.14 
describes the three available methods for determining the minimal inhibitory 
concentration utilizing broth microdilution assay.
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Table 1.14 Methods to determine the minimal inhibitory concentration in 
fluconazole susceptibility testing
Method Technique
Optically The well is observed for the presence or absence of visible growth 
with the aid of a reading mirror and then compared with well of the
control (drug-free)
A numerical score is employed ranging from 0 to 4 
0: optically clear, 1: slight hazy, 2: prominent decrease in turbidity, 
3: slight reduction in turbidity, 4: no reduction of turbidity
Colorimetric Uses Alamar blue dye which change blue to pink with yeast
Alamar Blue growth. The minimal inhibitory concentration (MIC) of this sample 
is the lowest drug concentration that preserves a blue or blue-pink
hue
Fluorescence Uses the spectrophotometer to determine yeast growth
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1.2. Bone Marrow and Stem Cell Transplantation
Bone marrow transplantation and stem cell transplantation have become the 
treatments of choice for curative therapy of a variety of malignant and non-malignant 
haematological (Seto et al., 1985, Verfaillie et al, 1991, Chen et al., 2002), 
congenital, metabolic and immunodeficiency disorders, and a number of solid 
tumours (Verfaillie et al, 1991).
Bone marrow transplant is a process of harvesting healthy cells from the bone 
marrow of a donor (or from the same patient) and implanting them into the body of 
the recipient in order to restore the production of blood cells, and restore to normal. 
Following transplantation, blood cells (white blood cells, red blood cells and platelets) 
develop from immature precursors, termed stem cells. The blood cells will replenish 
after bone marrow transplantation if  the graft is accepted.
Usually, the initial treatment for the haematological malignancy is carried out 
with conventional treatment such as chemotherapy and in some instances with 
adjuvant radiotherapy (Chen et al., 2002). However, BMT is indicated when the bone 
marrow is so diseased or damaged that it cannot function or respond to the 
conventional treatment, or there is disease relapse after initial successful treatment 
(Chen et al., 2002).
Stem cells can be obtained from the bone marrow, from the circulating blood 
(peripheral blood stem cells (PBSC)) or from the umbilical cord of newborn infants 
(Mogul, 2000). Bone marrow used to be the main source for BMT procedure.
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However, peripheral blood has emerged as an alternative to bone marrow 
transplantation as the white blood cells and platelets return to normal counts more 
rapidly (Flowers et al., 2002) following transplantation. Hence the risk of infection 
and duration of hospital stay will be reduced. However, as a result of insufficient 
numbers of stem cells circulating in the blood, it is possible to mobilise stem cells 
from the bone marrow by giving the patient growth factors or colony-stimulating 
factors such as granulocyte-colony stimulating factor (G-CSF), or granulocyte- 
macrophage colony stimulating factor (GM-CSF) (Appelbaum, 1996). Several 
harvesting sessions may be required to obtain sufficient stem cells (Appelbaum,
1996). This is generally beneficial by reducing the risk of severe neutropenic period 
and therefore any likelihood of infection. In addition, obtaining stem cells is not a 
surgical procedure thus avoiding the need for general anaesthesia (Appelbaum, 1996). 
An advantage of using stem cells derived from the umbilical cord of new-boms is that 
the immune cells will not have been exposed to the outside environment and therefore 
the risk of graft rejection or the development of graft versus host disease (GvHD) is 
low (Mogul, 2000). Stem cell procedures involving umbilically-derived cells are 
particularly indicated for children with malignant disease, as the number of required 
harvested stem cells is generally low.
1.2.1. Indication of bone marrow or stem cell transplantation
Bone marrow transplantation or stem cell transplantation is the treatment of
choice when conventional treatment of that particular disease has failed or become
ineffective. Most of the haematological diseases that required BMT or haematopoietic 
stem cell transplantation (HSCT) are leukaemias (acute and chronic), Hodgkin’s 
lymphoma, Non-Hodgkin’s lymphoma, multiple myeloma, myelodysplastic
91
syndromes (MDS), and the myeloproliferative disorders (Soutar and King, 1995; 
Duncombe, 1997; Saba et al., 2000; Storb, 2003). Bone marrow transplantation can 
be the treatment of choice for certain metastatic solid tumours such as breast cancer or 
non-haematological conditions such as genetic disorders (hemoglobinopathies and 
enzyme deficiency disorders), diseases caused by self-reactive lymphocytes 
(autoimmune diseases such as multiple sclerosis) (Burt et al., 2004 ; Marmont, 2004) 
and bone marrow failure (aplastic anaemia) (Georges and Storb, 2002). The main 
non-malignant disorders that may require BMT are listed in Table 1.15.
Table 1.15 Indications of BMT for non-malignant syndromes
Immune deficient 
disorders (Otsu and 
Candotti, 2002)
Severe combined immunodeficiency 
X-linked lymphoproliferative syndrome
Enzyme deficiency 
disease(Slavin et al., 
2001)
Gaucher's disease 
Hurler’s syndrome
Autoimmune diseases 
(Burt et al., 2004 ; 
Marmont, 2004)
Systemic sclerosis 
Multiple sclerosis 
Rheumatoid arthritis 
Systemic lupus erythematosus 
Crohn's disease and ulcerative colitis 
Psoriasis and psoriatic arthritis
Severe bone marrow 
failure (Slavin et al., 
1998; Georges and 
Storb, 2002)
Fanconi anaemia 
P-thalassemia major 
Blackfan Diamond anemia 
Aplastic anaemia
Metabolic disease 
(Sakata ef al., 2004)
Mucopolysaccharidosis
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1.2.2. Preparation for bone marrow transplantation
Patients undergoing BMT receive an intensive conditioning regimen 
consisting of chemotherapy, with or without radiation, for several days to destroy the 
bone marrow and cancerous cells. The exact regimen of chemotherapy and / or 
radiation varies according to the disease, age and general health of the patient 
(Appelbaum, 1996). The most commonly conditioning therapies in use include 
alkylating agents (cyclophosphamide, busulfan, thiotepa, melphalan and carmustine), 
etoposide, and cytarabine (Appelbaum, 1996). Chemotherapy and other drugs are 
usually administered through a Hickman line or central venous line inserted into a 
large vein in the patient’s chest. However, Hickman lines can be a source of pathogen 
entry, particularly during the subsequent neutropenic phase.
Granulocytopenia and lymphocytopenia start approximately five days after 
commencing chemotherapy and last for two to three weeks; during this period, the 
patient becomes more vulnerable to bacterial, viral and fungal infections. When the 
neutrophil counts is less than 100/mm3 in peripheral blood, there is a 50% chance of 
opportunistic infection (Dreizen et al., 1986).
1.2.3. Types of transplantation
Bone marrow or stem cell can be obtained from the same patients or from a 
matched tissue donor (Meyers, 1985; Appelbaum, 1996) and is thus classified into:
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1.2.3.1. Autologous transplant
The bone marrow or stem cells are collected from the same patient either prior 
to the disease or before intensive treatment has started (Meyers, 1985; Ferretti et al., 
1988) and reinfused to the patient to re-establish hematopoietic function after the 
administration of a high dose of chemotherapy or combination chemotherapy and 
radiotherapy (Appelbaum, 1996). The patient’s own marrow may be treated 
chemically or by using biological agents to eradicate all cancerous cells. There is, 
however, a risk of contamination with tumour cells from both stem cells and bone 
marrow for the autologous transplant that may cause later relapse (Soutar and King, 
1995; Saba et al., 2000; Dalton et al., 2001; Kyle, 2001). The remission bone marrow 
may harbour leukaemic cells that contribute to treatment relapse (Saba et al., 2000) 
although the risk can be smaller with peripheral blood cells (PBSC) (Saba et al., 
2000).
1.2.3.2. Allogenous transplant
The bone marrow or stem cells are obtained from a donor. The types of donations are 
divided into three categories:
a) Syngeneic transplant from an identical twin. Syngeneic transplant is the best
match of tissue typing because a graft from an identical twin will not be 
contaminated with tumor cells. In addition, the syngeneic transplants have less 
rejection complications than other allogenous transplants (Appelbaum, 1996);
b) Related matched tissue donor usually from a brother or sister;
c) Matched unrelated donor (MUD) (Table 1.16).
94
Table 1.16 Types of bone marrow transplantation
Allogenic marrow Autologous marrow
transplantation transplantation
Syngeneic transplant from an identical twin
Matched histocompatibility transplant from 
sibling or half-matched family member called 
haplotype transplant
The patient’s own 
previously stored 
marrow or stem cells
Matched histocompatibility transplant from
unrelated donor (MUD)
Although tissue matched donations are suitable for transplant, there are 
differences in minor tissue type (human leukocyte antigen (HLA)) markers which 
may influence immune reactions between the donor and patient tissues (Williamson et 
al., 1999).
The mini-transplant has become more common in the past few years 
particularly in old patients, young patients with severe organ damage or toxicities, or 
those who are not eligible for conventional transplant (Carella et al., 2000). Mini­
transplant does not require complete ablation of the host bone marrow and therefore 
may reduce the toxicity produced by the preparative regimen and reduce the incidence 
of GvHD and marrow rejection (Waldmann, 2001). Consequently, this procedure may 
reduce the mortality rate associated with this procedure but prolonged follow up will 
be required as the long term effect of this procedure is still unknown (Besien et al., 
2001; Kimby et al., 2001). Mini or non-myeloablative transplants require less 
intensive preparation with chemotherapy and radiation and in turn lessen transplant-
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related morbidity and mortality while providing sufficient immunosupression to allow 
engraftment of the donor’s cells (Kyle, 2001; Pawson et al., 2001).
Recently, cord blood stem cells transplantations have been developed in an 
attempt to reduce the complications of allogenic BMT that results in graft rejection or 
GvHD particularly from matched unrelated donors or mismatched related donors 
(Gluckman et al., 1999). The presently available tests may not be able to differentiate 
minor histocompatibility differences. However, advances in molecular biology 
techniques may help to provide a full HLA matching donor (Gluckman et al., 1999). 
The immunity of the new-born cells is usually immature and therefore there is little 
chance of transmitting infection from the donor cells (Gluckman et al., 1999). 
However, studies showed that cord blood stem cells transplantation from related 
donors had a better survival rate than from matched unrelated donors (Gluckman et 
a l , 1999).
1.2.4. Complications of BMT
The main complications of BMT and conditioning therapy (chemotherapy and 
/ or radiotherapy) are disease recurrence and graft versus host disease. Other major 
complications are listed in Table 1.17 (Heslop et al., 1999). However, the present 
review will focus upon the complications that can affect directly or indirectly the oral 
cavity (Table 1.17).
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Table 1.17 Systemic and oral complications o f bone marrow transplantation
(including radiotherapy and chemotherapy)
Systemic complications Oral complications
GvHD (acute or chronic) GvHD (acute or chronic)
Hepatic veno-occlusive disease Mucositis (pain and bleeding)
Disease recurrence and marrow 
purging
Oral infections (fungal, bacterial 
and viral)
Systemic infections Xerostomia
Haemorrhage
Craniofacial anomalies (including 
teeth)
Nutritional problems Caries
Secondary malignancies Mucosal pallor
Severe cardiomyopathy Non-specific ulceration
Chronic renal failure Oral petechiae and haemorrhage
Pulmonary complications Trismus
Endocrine complications Osteoradionecrosis
1.2.4.1. Acute and chronic graft-versus host disease (GvHD)
Patients who have had allogeneic transplants are at risk of developing graft 
versus host disease (Meyers, 1985; Heslop et al., 1999), in which the recipient’s 
“new” immune system attacks the recipient’s existing tissues. In most allogenic 
transplants (except identical twins), the donor’s tissue types will only be a partial 
match with the recipients (Heslop et al., 1999) and therefore graft versus host disease 
(GvHD) may occur in 30% to 60% of human leukocyte antigen-matched transplant
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recipients (Penn and Soong, 2002). Paradoxically, GvHD may also be beneficial as it 
may destroy any residual leukaemia cells (graft versus leukaemia effect (GvL)).
Acute GvHD arises within weeks of BMT, while the features of chronic 
GvHD may take many months before manifesting. The clinical features of acute and 
chronic GvHD are summarised in Table 1.18. The oral features of acute GvHD 
comprise mucositis-like disease, while chronic GvHD may give rise to xerostomia 
and lichen planus-like disease (Nakamura et al., 1996).
Table 1.18 Clinical features of graft versus host disease (GvHD)
Acute GvHD Chronic GvHD
Erythematous mucosa Xerostomia
Maculopapular skin rash Atrophic oral mucosal surfaces
Diarrhoea
Scleroderma-like disease 
lichenoid
Hepatic enzyme elevation Skin rash, dryness, itching
Anorexia Arthritis
Nausea and vomiting Obliterative bronchiolitis
Abdominal pain Keratoconjunctivitis sicca
Patients who develop chronic GvHD have delayed reconstitution and therefore 
these patients will be at a prolonged high risk of infection particularly with 
encapsulated organisms such as Streptococcus pneumoniae (Heslop et al., 1999).
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1.2.4.1.1. Prevention and treatment of GvHD
All patients undergoing allogenic BMT require a GvHD prophylaxis such as 
methotrexate with prednisone or ciclosporin. In acute GvHD, prednisone is the drug 
of choice while in chronic GvHD, patients usually respond to treatment with 
immunosuppressive drugs (ciclosporin, prednisone and azathioprine) (Heslop et al., 
1999).
1.2.4.2. Graft-versus-leukaemia (GvL)
The same immune cells which cause GvHD also attack any leukaemic cells 
remaining in the bone marrow recipient body. This beneficial effect is called graft 
versus leukaemia (GvL) effect. The immune-mediated graft-versus-leukaemia (GvL) 
effects constitute a major benefit o f allogeneic BMT and therefore, when the original 
disease returns, it may induce GvL effect by giving lymphocytes from the same donor 
(Slavin et al., 1998). The main therapeutic component of allogeneic BMT may be 
attributed to T-cell-mediated GvL effects rather than to the physical elimination of all 
tumour cells by high dose cytotoxic drug therapy in conditioning prior to 
transplantation (Slavin et al., 1998; Slavin et al., 2003).
1.2.4.3. Oral complications of bone marrow transplantation
The oral complications of bone marrow transplant can possibly be life- 
threatening, increase the length of hospital stay and treatment costs, and adversely 
affect the patient’s comfort and quality of life. The most common oral complications 
are mucositis, infection, graft versus host disease (GvHD) and pain (Table 1.17).
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Other oral complications such as xerostomia, dental decay and hemorrhage are not
uncommon.
I.2.4.3.I. Oral mucositis
Oral mucositis is a painful debilitating condition (Labar et al., 1993) caused by 
various chemotherapeutic regimes and radiotherapy to the oral mucosa. The pain and 
discomfort of oral mucositis can adversely affect the quality of life of the affected 
patients (Plevova, 1999). Oral mucositis is the most common oral complication 
(Epstein, 1990; Graham et al., 1993; Kennedy and Diamond, 1997; Epstein and 
Schubert, 1999) of head and neck irradiation, bone marrow transplantation and 
chemotherapy (Herrstedt, 2000; El-Sayed et al., 2002). The frequency of mucositis 
varies with the underlying disease (Pico et al., 1998; Kostler et al., 2001), age and 
nutritional status of the patient, pre-treatment neutrophil count, level of oral health 
and type, dose and frequency of drug administration (Pico et al., 1998). The pain and 
ulceration of oral mucositis may limit the patient’s ability to tolerate chemotherapy, 
and hence can influence the effectiveness of therapy of malignant disease.
Irradiation to the head and neck regions decreases oral epithelial cell turnover 
(Lynch et al., 1994). The oral epithelium has a high mitotic rate hence the oral 
mucosa is susceptible to the effect of local irradiation or systemic chemotherapy 
(Sung, 1995; Kennedy and Diamond, 1997). Furthermore, chemotherapy and local 
irradiation causes oral mucosal atrophy and loss of protective barriers (Labar et al., 
1993; Barasch et al, 1995; Sung, 1995; Kennedy and Diamond, 1997, Epstein and
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Schubert, 1999), and ultimately, can predispose to local (Woo et al., 2000) and / or 
systemic infection (Labar et al., 1993; Woo et al., 2000).
Other factors that may induce or enhance mucositis include salivary gland 
dysfunction, mucosal trauma (physical, chemical or thermal), GvHD (Seto et al., 
1985, Epstein and Schubert, 1999), myelosuppression, reduced salivary secretory IgA 
(Epstein and Schubert, 1999) and concurrent infection (Seto et al., 1985, Epstein and 
Schubert, 1999) (Table 1.19). Moreover, mucositis may be induced by the defects in 
certain metabolic enzymes and DNA repair mechanisms, and deficiencies of folic acid 
and vitamin B 1 2 (Kostler et al., 2001).
Table 1.19 Factors contributing to oropharyngeal mucositis 
(after Epstein and Schubert, 1999)
Direct factors Indirect factors
Radiation (dose and duration) Myelosuppression
Chemotherapy (e.g. 5-fluorouracil 
and methotrexate)
Immunosupression (T cell and 
B cell)
BMT (chemotherapy and 
radiotherapy)
Reduced salivary secretory 
IgA
Salivary gland dysfunction
Infections (bacterial, viral and 
fungal)
Mucosal trauma (physical, 
chemical or thermal)
Folate deficiency
Oral flora
UlcerationGvHD manifestations, prophylaxis 
or therapy
Patient susceptibility
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1.2.4.3.1.1. Clinical features of mucositis
The earliest manifestation of the oral mucositis is a burning sensation of the 
mucosa (Dreizen et al., 1986) followed by painful mucosal erythema and oedema, 
ulceration and the formation of plaques of necrotic mucosal tissue (Plevova, 1999). 
The epithelial breakdown phase of oral mucositis occurs days after the initiation of 
anti-neoplastic treatment (Kostler et al., 2001). The ulcerative phase is the most 
symptomatic and biologically complex of all four phases, being painful, restricting 
oral intake and predisposing to systemic viral, fungal and bacterial infections (Pico et 
al., 1998). Furthermore, treatment with methotrexate as a prophylaxis for graft- 
versus-host disease (GvHD) in BMT recipients will worsen the severity of mucositis 
(Epstein and Schubert, 1999). According to Ferretti and co-workers (1988), the 
severity and the symptoms of the mucositis can be divided into four grades (Table 
1.20).
Table 1.20 Categories of the oral mucositis (after Ferretti et al., 1988)
Grade Signs and Symptoms
0 (None) No symptoms
1 (Mild) Mucosal redness with one or two small ulcerations 
(< 1 cm) and minimal discomfort
2 (Moderate) Mucosal ulcerations with one or two large ulcerations 
(> 1 cm), considerable discomfort but patient able to
eat
3 (Severe) Multiple mucosal ulcerations with severe discomfort, 
patient unable to eat.
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However, a more recent scoring system of oral mucositis by the World Health 
Organization divides the severity of the mucositis into five stages (Wilkes, 1998) 
(Table 1.21).
Table 1.21 Grades of oral mucositis by The World Health Organization
(WHO) (after Wilkes, 1998)
Grade Symptoms
0 None
I Painless ulcers, erythema, or mild soreness
II Painful erythema, edema or ulcers but can eat
III Painful erythema, edema or ulcers but cannot eat
IV Require parenteral support
A further classification of mucositis, based upon the symptoms and signs was 
proposed by Eilers and co-workers (1988) (Table 1.22). Mucosal lesions mostly 
develop on the non-keratinised mucosa of the floor of the mouth, lips, ventral surface 
of the tongue, buccal mucosa and soft palate (Barasch et al., 1995, Wilkes, 1998; 
Karthaus et al., 1999) while mucosal lesions are less frequent on the hard palate and 
gingivae possibly due to their relatively low rate of epithelial cell turnover compared 
with other oral mucosal surfaces.
I.2.4.3.I.2. Duration and severity of oral mucositis
Oral mucositis commences within 7 to 10 days after the administration of 
chemotherapy or local radiotherapy (Pico et al., 1998; Epstein and Schubert, 1999) 
and resolves within two to three weeks which coincides with the recovery of the white 
cell count (Pico et al., 1998; Epstein and Schubert, 1999). The duration of mucositis is
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longer and more severe in poor and fair oral hygiene patients than those with good 
oral hygiene (Seto et al., 1985; Epstein and Schubert, 1999) and the risk of mucositis 
is greater among younger patients than older (Pico et al., 1998). In general, mucositis 
in children and adults depends on the underlying malignancies and the intensity of 
their therapies (Wilkes, 1998). Furthermore, in re-transplantation, oral mucositis can 
be more severe and has longer duration (Epstein and Schubert, 1999).
The ulcerative lesions of mucositis can cause dysphasia leading to a reduction 
in food and fluid intake which may necessitate parenteral nutrition. In addition, 
secondary infection (Ferretti et al., 1988; Labar et al., 1993; Barasch et al., 1995; 
Kennedy and Diamond, 1997; Pico et al., 1998; Larson et al., 1998; Wilkes 1998; 
Epstein and Schubert, 1999; Clarkson et al., 2000; Kostler et al., 2001) consequently 
requires additional medical care, and hence increases the economic cost and duration 
of the hospital stay (Ferretti et al., 1988; Pico et al., 1998; Ruescher et al., 1998; 
Epstein and Schubert, 1999). Oral mucositis is particularly associated with certain 
chemotherapeutic agents such as those containing 5-fluorouracil, doxorubicin, 
etoposide and methotrexate (Karthaus et al., 1999).
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Table 1.22 Mucositis scoring for patients undergoing BMT (Eilers et al., 1988)
Category Tools for assessment
Methods of 
measurement Numerical and descriptive ratings
1 2 3
Voice Auditory Converse with patient Normal
Deeper or 
raspy
Difficulty 
talking or 
painful
Swallow Observation
Ask patient to 
swallow / check 
gagging reflex
Normal
swallow
Some pain 
on swallow
Unable to 
swallow
Lips Visual / palpatory
Observe / feel 
tissue
Smooth, 
pink and 
moist
Dry or 
cracked
Ulcerated or 
bleeding
Tongue Visual / palpatory
Feel and observe 
appearance of 
tissues
Pink and 
moist 
and 
papillae 
present
Coated or 
less of 
papillae 
with a shiny 
appearance 
with or 
without 
redness
Blistered or 
cracked
Saliva Tongueblade
Insert blade into 
mouth, touching 
the centre of the 
tongue and the 
floor of the 
mouth
Watery Thick or ropy Absent
Mucous
membrane Visual
Observe 
appearance of 
tissue
Pink and 
moist
Reddened or 
coated 
(increased 
whiteness 
without 
ulcerations)
Ulcerative 
with or 
without 
bleeding
Gingival
Tongue 
blade / 
Visual
Gently press 
tissue with tip of 
blade
Pink, 
stippled 
and firm
Oedematous 
with or 
without 
redness
Spontaneous 
bleeding or 
bleeding with 
pressure
Teeth or 
dentures
Visual
Observe 
appearance of 
teeth or denture 
bearing area
Clean 
and no 
debris
Plaque or 
debris in 
localized 
areas 
(between 
teeth)
Plaque or 
debris 
generalized 
along 
gingival line 
or denture 
bearing area
Pain Auditory Ask the patient No pain M ild/discomfort Severe pain
1: normal findings, 2 : mild alteration without severe compromise of either epithelial integrity 
or systemic function, 3: compromise of either mucosal integrity or systemic fimction
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1.2.4.3.1.3. Aetiology of mucositis
The exact aetiology of oral mucositis is not known, but it seems most likely 
that it reflects direct inhibitory effects of chemotherapy and radiotherapy upon DNA 
replication and mucosal cell proliferation, resulting in a reduction in the renewal 
capabilities of the basal epithelium (Pico et al., 1998). When the epithelial growth and 
repair is exceeded by the effects of cancer therapy there is epithelial thinning, erosion, 
ulceration (Seto et al., 1985; Lynch et al., 1994; Pico et al., 1998), and collagen 
breakdown (Pico et al., 1998). Other proposed aetiologies have focused upon the rate 
of Gram negative bacteria and gastrointestinal anaerobes (Pico et al., 1998). 
Associations between candidosis and the aetiology of mucositis have also been 
reported (Seto et al., 1985; Epstein et al., 1992; Epstein and Schubert, 1999).
1.2.4.3.1.4. Infection with mucositis
Oral ulceration due to mucositis has been implicated as a significant portal of 
entry of Streptococci (Ruescher et al., 1998) and may predispose the neutropenic 
patient to candidaemia and bacteraemia (Karthaus et al., 1999). It has been reported 
that the risk of developing a-hemolytic streptococcal bacteraemia was three times 
greater in patients with ulcerative oral mucositis than those without this oral 
complication (Ruescher et al., 1998).
1.2.4.3.1.5. Management of mucositis
There is no standard effective regimen for the treatment of oral mucositis 
(Plevova, 1999) and most would seem to be generally ineffective (Pico et al., 1998). 
Therefore, the treatment of mucositis is symptomatic, and comprises effective oral
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care, dietary modifications, topical mucosal protectants and topical and systemic 
analgesics (Pico et al., 1998). Effective infection prevention and reduced duration of 
profound neutropenia may be beneficial in reducing the severity of mucositis. 
Controlling pain by using non-opoid or opoid analgesics depends upon the patient’s 
needs. Non-steroidal analgesics are not recommended as they may cause damage to 
the gastric mucosa, liver, kidneys and may reduce platelet function or count (Epstein 
and Schubert, 1999). Lidocaine mouthwash (Elad et al., 1999), topical dyclonine HC1 
or benzydamine HC1 may be effective in reducing mucositis pain (Epstein and 
Schubert, 1999). Vigorous oral hygiene and elimination of local irritants may reduce 
the development of mucositis and improve quality of life for patients during the 
myelosuppression period. There is thus a requirement for good patient education 
regarding effective oral practical methods of maintaining good oral hygiene 
(Coleman, 1995). When the ulcers develop, coating agents like aluminum chloride, 
aluminum hydroxide (Lynch et al., 1994) or topical use of a bioadhesive 
hydroxypropyl-cellulose (HPC)-based film may provide a protective shield over the 
oral ulceration and lessen pain (Lynch et al., 1994; Karthaus et al., 1999). Lip 
lubricants may ameliorate lip discomfort.
A variety of newer methods of preventing, or reducing, oral mucositis have 
been suggested. Systemic use of granulocyte macrophage colony-stimulating factor 
(GM-CSF) and granulocyte colony-stimulating factor (G-CSF) is known to accelerate 
the recovery of neutrophil count following myelosuppresive chemotherapy (Karthaus 
et al., 1999) and may also reduce the severity of oral mucositis (Karthaus et al., 1999; 
Epstein and Schubert, 1999; Peterson, 1999; Plevova, 1999; Woo et al., 2000; 
Herrstedt, 2000) by their effect upon the proliferation of oral mucosal cells (Wilkes,
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1998). Topical application of P-transforming growth factor (P-TGF) to the oral 
mucosa may also cause a significant reduction in the incidence, severity and duration 
of oral mucositis (Toth et al., 1995; Karthaus et al., 1999; Wymenga et al., 1999).
Prostaglandins are known to be cytoprotective. Some preliminary results 
suggest that topical application of prostaglandin Ei and E2 (PGE) could be effective in 
the prevention of oral mucositis by cytoprotective actions (Labar et al., 1993). 
However, in other studies prostaglandins have been found to be ineffective in the 
treatment of oral mucositis (Herrstedt, 2000; Woo et al., 2000).
Soft lasers may be effective in reducing mucositis (Barasch et al., 1995; 
Herrstedt, 2000), but such therapy is unlikely to be available in many clinical centers 
(Plevova, 1999). Cryotherapy or chipped ice reduces the severity of bolus 5- 
fluorouracil-induced oral mucositis (Plevova, 1999; Epstein and Schubert, 1999; 
Herrstedt, 2000). These therapies presumably cause local vasoconstriction and hence 
reduce blood flow and the amount of drug reaching the oral mucosa (Wilkes, 1998; 
Karthaus et al., 1999; Epstein and Schubert, 1999). Indeed in a retrospective study 
(Clarkson et al., 2000) ice chips were the only effective agent for the prevention of 
oral mucositis.
Glutamine may stimulate mucosal epithelial cells growth and repair. This 
amino acid is decreased in the blood with sepsis or diet depletion (Anderson et al., 
1998; Ziegler, 2002). Administrating glutamine has been found to be effective in
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reducing the duration and severity of oral mucositis associated with methotrexate, and 
in reducing associated bacteraemia in rats (Anderson et al., 1998).
Topical antimicrobials that affect the Gram-negative bacteria have shown 
reduction in ulcerative mucositis during radiation (Epstein and Schubert, 1999). Non­
absorbable antibiotic oral lozenges containing polymyxin, tobramycin and 
amphotericin B have affected colonization of Gram-negative bacilli and Candida and 
therefore, in preventing or reducing the severity of mucositis (Spijkervet et al., 1991; 
Lynch et al., 1994). Although chlorhexidine is effective in reducing oral Candida 
colonization, dental plaque and caries, it is rarely of benefit for the treatment of oral 
mucositis (Lynch et al., 1994; Cousin, 1997; Epstein and Schubert, 1999; Barker, 
1999; Karthaus et al., 1999; Herrstedt, 2000; Woo et al., 2000).
Pentoxifylline reduces mucositis symptoms and hence the duration of 
parenteral nutrition in some patients receiving chemotherapy prior to BMT (Bianco et 
al., 1991). Allopurinol mouthwash has been found to be effective in reducing oral 
mucositis in some (Toth et al., 1995; Wymenga et al., 1999) but not all studies 
(Herrstedt, 2000; Woo et al., 2000).
Various cytokines may be of use in reducing epithelial cell sensitivity to the 
toxic effect of chemotherapy and / or for the stimulation of repair of the damaged 
tissue (Epstein and Schubert, 1999). For example, it was demonstrated in one study 
that systemic Interleukin-11 (IL-11) resulted in decreased incidence, severity and 
duration of oral mucositis in experimental hamsters (Karthaus et a l , 1999).
109
Systemic retinoids may reduce the severity of mucositis (Wilkes, 1998; 
Karthaus et al., 1999) while magnesium hydroxide oral suspension may dissolve the 
mucin film and reduce mucositis symptoms (Wilkes, 1998). Sodium bicarbonate or 
dilute hydrogen peroxide mouthwashes may neutralise the pH of the mouth, minimise 
mucosal breakdown and enhance tissue healing (Lynch et al., 1994; Barker, 1999). 
However, it has been demonstrated that the alteration of oral pH by sodium 
bicarbonate and hydrogen peroxide may disturb mucosal regeneration (Karthaus et 
al., 1999). In addition, hydrogen peroxide should not be used excessively as this may 
impair actual healing (Wilkes, 1998).
Despite the wide range of suggested therapies, no one agent is reliably 
effective for the prevention and / or treatment of oral mucositis (Herrstedt, 2000; Woo 
et al., 2000,). Modifications in chemotherapeutic regimes can however reduce 
mucosal toxicity (Plevova, 1999). In addition, simple strategies such as the 
maintenance of good oral hygiene may lessen the risk of oral mucositis.
1.2.4.4. Infections
Neutropenia predisposes to a wide range of oral infections in patients 
undergoing BMT. The liability to infection rises when the neutrophil count falls 
below 1.5x109/L. Thus the mucosal barriers will be further impaired by allowing 
direct access of pathogenic organisms into deeper tissues (Meyers, 1985; Ferretti et 
al., 1988). Humoral and cell-mediated immunodeficiencies will increase the risk of 
opportunistic infections, the latter particularly predisposing to fungal oral infection. 
The improved long-term survival of immunocompromised patients has resulted in
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such individuals becoming more susceptible to opportunistic infections (Velasco et 
al., 2000). Indeed, infection has become the major cause of morbidity and mortality in 
BMT recipients (Velasco et al., 2000).
1.2.4.4.1. Bacterial infections
Bacterial infection in BMT patients is usually caused by Gram-positive, and to 
lesser extent Gram-negative bacteria (Williamson, et al., 1999). However, prolonged 
hospitalisation may shift the microflora to a more Gram-negative picture (Barker,
1999).
The incidence of infection is increased with the use of Hickman catheters in 
BMT recipients (Barker, 1999, Williamson et al., 1999). Moreover around two thirds 
of the neutropenic patients develop fever during this period. It has been reported that 
most of the cases with late bacteraemia were thought to be associated with Hickman 
catheters (Williamson et al., 1999). Prolonged use of broad spectrum antibiotics may 
develop resistance to the treatment (Barker, 1999) and therefore the treatment 
becomes more difficult. Streptococci serve as an indicator of the total oral microbial 
load which may predispose patients with oral mucositis to septicaemia (Ruescher et 
al., 1998). With mucosal ulceration, bacteraemia caused by viridans Streptococci may 
not be avoidable even in the presence of broad spectrum antibiotics (Epstein and 
Schubert, 1999). Therefore, reducing the severity of mucositis is more important than 
relying on systemic antibiotic prophylaxis which is usually given to the patients 
during neutropenic periods (Epstein and Schubert, 1999).
I l l
The oral cavity is a frequent site of bacterial infections and considered to be an 
important portal of entry of infection in BMT recipients (Heimdahl et al., 1989; 
Rueschar et al., 1998). Endogenous bacteria from the oral microflora, can be 
responsible for bacteraemia in neutropenic patients (Heimdahl et al., 1989). 
Breakdown of the oral mucosa and the loss of oral epithelium as a protective barrier 
results in local infections and may provide entry of the microorganisms to the blood 
stream and cause systemic infection (Ruescher et al., 1998; Saavedra et al., 2002). 
Earlier studies have demonstrated that patients receiving chemotherapy had oral 
infection caused by Gram-negative bacilli such as Pseudomonas species, Klebsiella 
species and, to a lesser degree, by Gram-positive colli such as Staphylococcus aureus 
and Streptococcus epidermidis (Dreizen et al., 1983; Ruescher et al., 1998; Tunkel 
and Sepkowitz, 2002) while in the 1990s, Gram-positive organisms were reported to 
be the most common organisms in those patients (Ruescher et al., 1998, Tunkel and 
Sepkowitz, 2002). In two studies of viridans Streptococci (Seto et al., 1985, Tunkel 
and Sepkowitz, 2002) and to a lesser degree Staphylococcus (Seto et al., 1985) were 
the most prevalent Gram positive organisms isolated from the mouth of BMT 
recipients and severely neutropenic patients.
The increased incidence of oral Streptococci during the neutropenic period 
particularly a-hemolytic Streptococci in BMT recipients may be as a result of 
receiving quinolones as an antibiotic prophylaxis that reduces the incidence of Gram- 
negative bacteria (Momin and Chandraseker, 1995; Ford et al., 1998; Ruescher et al., 
1998; Saba et al., 2000; Tunkel and Sepkowitz, 2002). However, it has been reported 
that infection caused by oral Gram-negative bacteria was greater during the follow up 
period following BMT (e.g. two years) (Saavedra et al., 2002).
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1.2.4.4.2. Viral infection
Viral infections of the mouth in BMT patients usually arise as consequences of 
reactivation of latent infections such as cytomegalovirus (CMV), Epstein-Barr virus 
(EBV), herpes simplex and varicella zoster viruses. Such viral infections can lead to 
significant oral and systemic disease in the immunodeficient host.
Cytomegalovirus (CMV) can cause morbidity and mortality in bone marrow 
transplantation (BMT) recipients, with clinical manifestations that could vary from 
completely asymptomatic infection to organ failure (Castagnola et al., 2004). CMV 
serology of both donor and recipient, type of donor and GvHD are strictly linked in 
determining the risk of CMV reactivation or disease (Castagnola et al., 2004). 
However, positive pretransplant CMV serology is the only risk factor that has been 
identified for CMV infection. In autologous BMT recipients the probability of CMV 
infection has been reported to be 60% in seropositive patients and 23% in 
seronegative patients (Castagnola et al., 2004). Early diagnosis and treatment of 
cytomegalovirus (CMV) infection with new antiviral drugs have dramatically reduced 
the incidence and mortality from CMV disease (Noble and Faulds, 1998). It has been 
reported that, ganciclovir is the only antiviral chemotherapy which reduces the risk of 
CMV infection following major transplantations (Noble and Faulds 1998).
Herpes simplex virus (HSV) reactivation can occur in 50-90% of seropositive 
patients and less than 2% of seronegative patients undergoing BMT (Labar et al., 
1993, Wilkes, 1998). In addition, oral mucositis can be more severe and of longer 
duration in HSV seropositive patients (Wilkes, 1998). Herpes zoster reactivation can 
be initiated as an early consequence of chemotherapy before transplantation
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(Christiansen et al., 1991) while infection with human herpes virus-8 (HHV-8) can be 
a late feature of long-term immunosuppression (Leao et al., 2002). Furthermore, it has 
been reported that reactivation of latent EB V in immunodeficient hosts (such as BMT 
recipients) can provide a basis for the development of malignant lymphomas (Hoshida 
and Aozasa, 2004).
I.2.4.4.3. Fungal infection
The factors that predispose to fungal infection in recipients of BMT include 
prolonged granulocytopenia, central venous access devices (and other invasive 
monitoring devices) and disruption of normal mucosal barriers by chemotherapy, 
radiation, graft-versus host disease (Morrison and McGlave, 1993; Wamock, 1998) 
and prolonged intake of the graft-versus host disease prophylaxis (Richardson and 
Kokki, 1998). In addition, the use of antibacterial and antifungal prophylaxis, and the 
increasing intensity of antineoplastic therapy, all contribute to the emergence of 
fungal infection (Epstein et al., 1996; Anaissie et al., 1998; Wamock, 1998). Fungal 
infections in BMT recipients can be higher with older age and T-cell depletion (Koot 
et al., 1997; Wamock, 1998).
The majority of opportunistic fungal infections is caused by different Candida 
species and occurs during the neutropenic phase early after transplantation (Epstein et 
al., 1992; Wamock, 1998; Tollemar et al., 1999). C. albicans is the most frequently 
species isolated (Karthaus et al., 1999) and the most common cause of infection (Seto 
et al., 1985; Epstein, 1990; Darouche 1998). It has been reported that 57% to 89% of 
patients with cancer will have positive oral cultures for Candida species (Wilkes,
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1998) and superficial fungal infection with C. albicans occurs in 60% to 90% of 
patients receiving cancer therapy (Pico et al., 1998). In contrast however; C. albicans 
has been reported to be responsible for only 7% of cases of candidaemia in BMT 
patients (Marr et al., 2000).
Other opportunistic Candida species that can occur in BMT recipients 
(Karthaus et al., 1999; Marr et al., 2000; Paterson et al., 2001) include C. tropicalis, 
C. krusei, C. parapsilosis and C. glabrata. It has been reported that the most common 
Candida species causing infection post BMT transplant were C. glabrata (47%), C. 
parapsilosis (23%), C. krusei (20%). The least common species to cause infection 
were C. albicans and C. guillermondii (3%) (Marr et al., 2000). In a different study, 
the mortality rate from infection caused by C. tropicalis and C. albicans was 38.8% 
(Lam and Althaus, 1995) while the death caused by C. krusei and C. glabrata was 
thought to be less as patients usually recover following appropriate antifungal therapy 
(Lam and Althaus, 1995).
Other serious fungal infections in immunocompromised patients include 
Aspergillus species and Mucormycosis (rhinocerebral zygomycosis) (Epstein, 1990; 
Richardson and Kokk, 1998). Aspergillus species are filamentous saprophytes that 
live in soil and plants. Aspergillosis affects patients with profound neutropenia such 
as BMT recipients particularly in recipients of grafts from unrelated donors 
(Williamson et al., 1999). Systemic aspergillosis can be associated with mortality in 
BMT recipients (Tollemar et al., 1999). Infection by Mucormycosis is usually fatal; 
the infection can spread to the paranasal sinuses, orbits and brain. In one study, the
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incidence of infection caused by Mucormycosis in BMT patients was 0.9%, although 
Mucormycosis was the cause of death in 77% of these patients (Morrison and 
McGlave, 1993). Early diagnosis, proper antifungal treatment and surgical resection 
of infected tissue can, however, be successful (Pavie et al., 2004).
1.2.4.5. Xerostomia
Xerostomia is a common consequence of radiotherapy of the head and neck 
(Porter et al., 2004), but can also arise with chemotherapy (Blomgren et al., 2002). 
Patients with longstanding xerostomia develop dysarthria, dysphasia, oral mucosal 
soreness, liability to candidal infection and bacterial sialadenitis and reduced upper 
denture retention (Porter et al., 2004).
The management of longstanding xerostomia is reviewed in detail elsewhere 
(Porter et al., 2004) but principally comprises salivary replacement and / or enhanced 
stimulation and the prevention and treatment of infections (Table 1.23).
Table 1.23 The management of radiotherapy associated xerostomia
Avoidance of factors that may worsen xerostomia 
Salivary substitutes 
Prevention of oral complications (mucositis, e.g. candidal infection) 
Pilocarpine or cevimeline
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1.2.4.6. Dentofacial abnormalities
Chemotherapy in childhood may lead to failure or arrest the development of 
the teeth and / or jaws (Welbury, 1997). Cranio-facial anomalies can include 
malocclusions, facial asymmetry (Barker, 1999) micrognathia and retrognathia 
(Rosenberg, 1990; Lynch et al; 1994). There can be altered root development, enamel 
hypocalcification (Dahllof et al., 1988; Rosenberg, 1990) and an increased incidence 
of caries (Rosenberg, 1990). Other suggested dental complications include 
microdontia, hypodontia, taurodontia, delayed teeth eruption, over-retention of 
primary teeth (Kaste and Hopkines, 1994; Maguire and Welbury, 1996; Kaste et al.,
1997) and odontomes (Maguire and Welbury, 1996). Radiation may affect the growth 
of the facial skeleton and cause micrognathia, retrognathia and asymmetric growth of 
the face (Rosenberg, 1990; Lynch et al., 1994). In one study, the effect of 
chemotherapy and radiotherapy on children with leukaemia resulted in 55.5% of 
patients having dento-facial abnormalities, 62.9% having tooth abnormalities and 
33% having root hypoplasia (Uderzo et al., 1997). However, the exact frequency and 
severity of craniofacial and dental anomalies may be dependent upon the child’s age 
at the time of therapy, the chemotherapy protocol, and the dose of irradiation (Kaste 
and Hopkines, 1994; Maguire and Welbury, 1996; Kaste et al., 1997). It is difficult to 
distinguish if the facial and dental anomalies in growing children are caused by 
chemotherapy or radiotherapy (Kaste and Hopkines, 1994). Some studies have 
reported that the greatest effect of cancer therapy occurs before the age of five years 
(Sonis et al., 1990; Maguire and Welbury, 1996) and in rapidly growing pubertal 
children undergoing puberty (Maguire and Welbury, 1996). A different study reported 
that increased severity of irradiation therapy occurs before the age of 8 years (Kaste et 
al., 1997).
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1.2.4.7. Trismus
Irradiation therapy to the head and neck regions may cause endarteritis within 
muscle, with eventual fibrosis. The tongue can occasionally be affected, but more 
commonly the muscles of mastication are affected and the eventual fibrosis can cause 
some degree of limited mouth opening (Pajari et al., 1996).
1.2.4.8. Osteoradionecrosis
Osteoradionecrosis is a rare, but clinically significant complication of patients 
who received radiotherapy. Although increasingly uncommon it can arise following 
dental surgery in the area of previous radiotherapy (Rosenberg, 1990, Lynch et al.,
1994). It is, however, unusual in patients receiving BMT.
1.2.4.9. Oral petechiae and haemorrhage
Petechiae of the gingiva or oral mucosa arise if the platelet count falls below 
50x109/L (Fayle and Curzon 1991). The low platelet count can complicate dental 
extractions, although generally, if the platelet count is above 40,000/mm3, post- 
surgical haemorrhage is unlikely (De Paola et al., 1986).
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1.3. Summary
Candida species can cause opportunistic infection and occasional serious 
clinical illness in immunocompromised groups such as recipients of bone marrow 
transplantation. Knowledge of the epidemiology, virulence and treatment of candidal 
infection has greatly increased in the past two decades. However, there are few 
contemporary detailed studies of the epidemiology and character of oral candidal 
isolates of patients who have undergone bone marrow transplantation. As bone 
marrow transplantation has become an established therapy for a wide range of 
congenital and acquired disorders, it is timely to examine, in detail, aspects of the 
molecular epidemiology, virulence, diversity and anti-fungal resistance of candidal 
isolates from the mouth of patients who have undergone and survived bone marrow 
transplantation. The present work has thus examined a number of relevant aspects of 
oral candidal isolates of individuals with mucosal or non- mucosal abnormalities and 
persons who have undergone bone marrow transplantation in different geographic 
regions of the world.
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CHAPTER 2 
Patients, Materials and Methods
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2.1. Patient population
2.1.1. Ethical approval
Ethical approval for the study was granted by the Joint University College of 
London / University College o f London Hospital Trust Committee on the Ethics of 
Human Research. The purpose and nature o f the study was explained to each 
participating patient and the voluntary nature of their participation detailed. A written 
consent form was signed by each patient or by the parent / guardian of children under 
the age of 16 years or those adults unable to give their own consent.
2.1.2. Patients from different dental settings in the UK (non-BMT recipients)
This group comprised two hundred and fifty seven patients attending 5 diverse 
dental settings (148 females and 109 males) o f the Eastman Dental Institute (EDI) and 
a private dental clinic in London, UK.
2.1.2.1. Oral medicine patients
Seventy three patients (54 female and 19 male) age 17 to 83 years were 
attendees of an Oral Medicine Unit at the EDI and were diagnosed with a variety of 
mucosal and non-mucosal conditions (as detailed in Table 2.1). Fifty seven patients 
(44 females and 13 males) of the 73 oral medicine attendees had oral mucosal 
diseases (lichen planus, recurrent aphthous stomatitis, vesiculo bullous disease or 
leukoplakia / oral epithelial dysplasia) unrelated to Candida infection. The remaining 
16 patients ( 1 0  females and 6  males) had normal oral mucosa but had other oral 
problems (e.g. tempromandibular joint dysfunction, chronic gingivitis, dysphasia or
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cheek biting). Fourteen o f the 57 patients with mucosal diseases and 2 of the 16 
patients with non-mucosal diseases were tobacco smokers. The patients were either 
dentate or wearing partial or complete dentures as shown in Table 2.1.
2.1.2.2. Private dental surgery patients
This group o f 44 patients (27 female and 17 male) age 16 to 80 years were 
attending a private dental surgery in London for routine dental treatment. All of the 
patients were generally healthy, dentate and did not have any mucosal disease. Six 
patients were regular smokers from this group of patients.
2.1.2.3. Orthodontic patients
This group comprising 64 patients (33 female and 31 male) age 8 - 4 4  years 
were receiving fixed or removable orthodontic appliances and attending the 
Orthodontic Unit o f the Eastman Dental Institute, London, UK. Four of the 64 
orthodontic patients were regular smokers.
2.1.2.4. Prosthodontic patients
This group comprising 32 patients (18 female and 14 male) age 39 -  93 years 
were either edentulous or partially dentate, attending a specialist Prosthodontic Clinic 
of the Eastman Dental Institute and requesting partial or complete dentures. Five 
patients from this group were smokers.
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Table 2.1 Oral conditions, denture status and gender of all patients from different
dental settings in the UK
Patient cohort
Denture status: 
Full, partial or dentate
Total 
number of 
patients
Female Male
Full 6 4 2
Patients with oral lichen Partial 8 8 0
planus Dentate 23 17 6
Total 37 29 8
Full 0 0 0
Patients with recurrent Partial 3 3 0
aphthous stomatitis Dentate 8 4 4
Total 11 7 4
Full 0 0 0
Patients with vesiculo- Partial 1 0 1
bullous disease Dentate 4 4 0
Total 5 4 1
Patients with leukoplakia / Dentate 4 4 0dysplasia
Oral medicine patients
with non-mucosal Dentate 16 10 6
disorders
Patients attending a Dentate 44 27 17private dental clinic
Full 17 9 8
Partial 15 9 6
Prosthodontic patients
Dentate 0 0 0
Total 32 18 14
Fixed* 41 24 17
Orthodontic patients Removable* 23 9 14
Total 64 33 31
Full 0 0 0
Patients with scleroderma Partial 3 3 0
and SLE Dentate 7 4 3
Total 10 7 3
Full 3 0 3
Patients with mental and / Partial 1 0 1
or physical disabilities Dentate 30 9 21
Total 34 9 25
Total 257 148 109
* Orthodontic appliance type
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2.1.2.5. Special needs patients
This final group comprised 44 (16 female and 28 male) patients with special needs. 
The age of these patients ranges from 25 to 81 years. These individuals had 
scleroderma (n = 6 ), systemic lupus erythematosus (SLE) (n = 4) or other significant 
disabilities (mental, physical or both) (n = 34). Seven of the 44 patients were wearing 
partial (n = 4) or complete (n = 3) dentures. In addition, fourteen patients with special 
needs were regular tobacco smokers. Forty five percent of these patients were on 
medications such as steroids but none of them were immunocompromised.
2.1.3 Bone marrow transplant (BMT) recipients
2.1.3.1. Bone marrow transplant (BMT) recipients from the UK
This group comprised 56 patients (19 females and 37 males) age 16 to 62 
years who had undergone bone marrow transplantation and were attending the out­
patient clinic at the Department of Haematology, University College London 
Hospitals (UCLH), London. Bone marrow transplant was performed for the treatment 
of haematological diseases when conventional treatment had failed to cure the 
disease. Patients who suffered from multiple myeloma accounted the highest figure of
BMT recipients in the UK (26.8%). The haematological malignancies from the UK
patients are noted in Table 2.2.
All of the BMT recipients had received conditioning chemotherapy 
(busulphan and cyclophosphamide, fludarabine and melphalan or cyclophosphamide
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and thiotepa). 48 o f them had also received total body irradiation. Nine of the 56 
BMT recipients had previously undergone autologous BMT.
Table 2.2 Haematological malignancies o f the UK BMT recipients
Haematological disease Number of patients (%)
Multiple Myeloma (MM) 15 (26.8)
Chronic Myeloid Leukaemia (CML) 12 (21.4)
Acute Myeloid Leukaemia (AML) 7 (12.5)
Acute Lymphoblastic Leukaemia (ALL) 6 (10.7)
Non-Hodgkin’s Lymphoma (NHL) 6 (10.7)
Hodgkin’s Lymphoma (HL) 5 (8.9)
Chronic Lymphocytic Leukaemia (CLL) 3 (5.4)
T Cell Prolymphocytic Leukaemia (CPL) 1 (1.8)
Myelofibrosis 1 (1.8)
Total 56
Two of the patients had undergone autologous BMT while the remaining 54 
patients had undergone allogenous BMT (Table 2.7). The recipients of allogenous 
grafts were either from matched-related (n = 36) or matched-unrelated donors (MUD) 
(n = 18).
Following allogenous transplantation, 22 patients experienced acute (n = 8 ) or 
chronic (n = 14) forms of graft versus host disease (GvHD). Nineteen of the 56 BMT 
recipients were receiving ciclosporin and methotrexate as prophylaxis for GvHD at 
the time of oral examination. In addition, 41 of the 56 patients experienced mucositis
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following graft transplantation. The severity of mucositis and GvHD are summarized 
in Table 2.3.
Table 2.3 Severity of mucositis and GvHD from the UK BMT recipients
Mucositis GvHD
Grade 0 15 34
Grade 1 2 0 14
Grade 2 1 0 1
Grade 3 1 1 4
Grade 4 - 3
Total 56 56
Grade 0: no mucositis or GvHD, 1: mild, 2: moderate, 3: severe, 4: very severe
Thirty two of the 56 BMT recipients were receiving antibiotics and 31 patients 
were receiving antiviral prophylaxis at the time o f oral evaluation and mouth swill 
collection. Furthermore, 22 patients were on antifungal therapy or had received 
anti fungal therapy in the past 6  months of oral examination (Table 2.5). The number 
of patients who had infections following transplantation and antimicrobial therapies 
received by the patients at the time of oral swill collection is summarized in table 2.4.
Two patients were partially dentate and none of them had any denture. Oral 
complications include: oral ulceration (n = 9), erythema (n = 4), xerostomia (n = 14), 
pseudomembranous candidosis (n = 5), leukoplakia (n = 5), burning mouth sensation 
(n = 6 ), oral candidosis (n = 2) and taste alteration (n = 4). Ten of the 56 BMT 
recipients (17.9%) from the UK were tobacco smokers.
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Table 2.4 Number o f  infected patients following BMT and treatment received
Infection
15 Bacterial infections (Gram positive and Gram negative bacteria) 
23 Viral infections (19 reactivation of CMV)
7 Fungal infections (aspergillosis and candidosis)
Antibiotic
therapy
32 Co-trimoxazole, penicillin V, erythromycin, amoxicillin, 
clarithromycin or septrin
Antiviral
therapy
31 Aciclovir, valaciclovir or ganciclovir
Antifungal
therapy
22 Fluconazole, itraconazole, amphotericin B, AmBisome, 
voriconazole or miconazole
2.1.3.2. Bone marrow transplant recipients from Greece
Twenty two Greek patients (12 females and 10 males) age 18 to 51 years who 
had undergone bone marrow transplantation were enrolled in this study. All attended 
an out-patient clinic of the Department o f Haematology, University Hospital of Rio- 
Patras, Greece.
The Greek patients had undergone bone marrow transplant for the treatment of 
acute leukaemia (n = 9), chronic leukaemia (n = 1) and the remaining 12 patients had 
had Hodgkin’s disease, Non-Hodgkin’s disease or multiple myloma. The conditioning 
regimen received by the Greek patients was mitoxantrone, busulfan, cytarabine, 
fludarabin, indarubicin, etoposide, vousoulfan, cyclophosphamide, fosphamide, and 
ciclosporine. Furthermore, 17 of the 22 patients had undergone autologous BMT and 
the remaining 5 had received allogenous BMT (Table 2.6). One patient experienced 
GvHD following allogenous transplantation.
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Thirteen patients from Greece were receiving antibiotics (vancomycin, 
ciprofloxacin, teicoplanin, clindamycin, metronidazole, amoxacillin and penicillin V) 
and 7 patients were receiving antiviral therapy (aciclovir and ganciclovir) at the time 
of mouth swill collection. Furthermore, eleven of the Greek patients were on 
antifungal therapy (fluconazole, amphoterecin B, itraconazole and topical nystatin) at 
the time of oral examination. Summary of antifungal therapy in BMT recipients from 
the UK and Greece is noted in Table 2.5.
Table 2.5 Summary of antifungal therapy in BMT recipients from the UK and
Greece
Source of 
BMT 
recipients
No of 
patients
No of 
patients 
receiving 
antifungal 
therapy
No of 
patients 
receiving 
azoles
No of 
patients 
receiving 
polyenes
No of 
patients 
receiving 
azoles and 
polyenes
UK 56 2 2 1 0 7 5
Greece 2 2 1 1 8 3 0
An oral assessment of the Greek BMT recipients showed that 4 patients had 
oral ulceration, erythema (n = 1 ), xerostomia (n = 2 ), leukoplakia (n = 2 ) and gingival 
hyperplasia (n = 1). One Greek patient was partially dentate and 4 patients were 
smokers.
2.1.3.3. Bone marrow transplant recipients from Italy
Forty three Italian patients (21 females and 22 males) age 19 to 62 years who 
had undergone bone marrow transplantation were enrolled in the study. These patients
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were either hospitalized or attending the out-patient clinic of the Department of 
Haematology, Trapianto di Midollo Osseo Marcora, Ospedale Policlinico di Milano, 
Italy.
Seventeen patients had had Hodgkin’s or Non-Hodgkin’s disease, 8  had had 
chronic myeloid leukaemia, the remainder had had acute myeloid leukaemia, multiple 
myloma or other haematological malignancies (Table 2.6). The conditioning regimen 
and chemotherapy used in Italy was busulfan, cyclophosphamide, VP 16, melphalan 
and alkeran. Seventeen patients had received autologous transplant while the 
remaining patients had received allogenic transplant from matched-related or 
matched-unrelated donors (Table 2.7). Five patients had GvHD following allogenous 
BMT. Furthermore, 9 of the Italian BMT recipients were on antifungal therapy but the 
antibiotics and antiviral therapy were not accessible from the Italian patients.
Table 2.6 Number o f patients with haematological diseases required BMT from the
UK, Italy, Greece and Brazil
Type of the 
disease UK Italy Greece Brazil
Acute
leukaemia 13 (23.2%) 6  (14%) 9 (40.9%) 5 (7.7%)
Chronic
leukaemia 16 (28.6%) 8  (18.6%) 1 (4.5%) 49 (75.4%)
Other
haematological
malignancies
27 (48.2%) 29 (67.4%) 12 (54.5%) 11 (16.9%)
Total 56 43 2 2 65
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2.1.3.4. Bone marrow transplant recipients from Brazil
Sixty five Brazilian patients (18 females and 47 males) age 12 to 47 years who 
had undergone bone marrow transplantation were enrolled in the study. All attended 
an out-patient clinic of the Department of Haematology, University Hospital of the 
State, University of Campinas, Sao Paulo, Brazil.
Transplantation had been performed mainly for the treatment of chronic 
myeloid leukaemia (CML) 49/65. The remainder of patients had undergone BMT for 
the treatment o f aplastic anaemia and acute lymphoblastic leukaemia (ALL). All of 
the Brazilian patients had undergone allogenous BMT. Table 2.7 lists the number of 
patients who undergone allogenous and autologus BMT from different geographical 
regions.
Table 2.7 Type of bone marrow transplantation from four geographical regions
Type of BMT UK Italy Greece Brazil
Number of patients (%) with 54 26 5 65
allogenic BMT (96.4) (60.5) (22.7) ( 1 0 0 )
Number of patients (%) with 
autologus BMT
2
(3.6)
17
(39.5)
17
(77.3)
0
Total number of patients 56 43 2 2 65
Seven o f the 65 Brazilian BMT recipients were receiving antifungal therapy at 
the time of oral examination. However, the conditioning regimen, antibiotics and 
antiviral therapy from the Brazilian patients were not available. The oral examination 
of the Brazilian BMT recipients revealed that 3 patients had oral ulcerations, 12
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patients had erythema, 40 patients suffered from xerostomia, 5 patients with 
pseudomembranous and 1 1  patients had leukoplakia.
The oral problems o f the UK, Greek and Brazilian BMT recipients are 
summarised in Table 2.8. However, the oral problems of the Italian patients were not 
available. In addition, smoking history was not available from the Italian and 
Brazilian BMT recipients.
Table 2.8 Number of patients who had different oral conditions at the time of oral 
examination from the UK, Greek and Brazilian BMT recipients
Ulceration Erythema Xerostomia PM Leukoplakia BMS OOP Smoking
UK 9 4 14 5 5 6 4 10
GR 4 1 2 0 2 0 4 4
BR 3 12 40 5 11 0 UN UN
PM: Psuedomembranous, BMS: burning mouth syndrome, OOP: Other oral problems such as 
lack of taste, difficulty of mouth opening, angular stomatitis, gingival hyperplasia and oral 
lichen planus, UN: unknown,GR: Greece, BR: Brazil
2.1.3.5. Time period between BMT and oral examinations from the UK
Italy, Greece and Brazil
The time period between bone marrow transplantation and oral examination 
from the patients lived in four diverse regions varied from a few weeks post 
transplantation to several years and therefore all patients were divided into 3 groups to 
describe the time between bone transplantation and mouth swill collection as shown 
in Table 2.9.
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Table 2.9 Time interval (in years) between bone marrow graft and oral examination 
and mouth swill collection from BMT recipients from four diverse countries
Source
of
patients
No of 
patients
No of patients 
(%) who had 
mouth rinse in 
less than 1 year 
of BMT
No of patients (%) 
who had mouth rinse 
in more than 1 year 
and less than 3 years 
of BMT
No of patients 
(%) who had 
mouth rinse in 
more than 3 
years of BMT
UK 56 34 (60.7%)* 20 (35.7%) 2 (3.6%)
Greece 2 2 16 (72.7%) 4 (18.2%) 2 (9.1%)
Italy 43 23 (53.5%) 14 (32.6%) 6  (14%)
Brazil 65 25 (38.5%) 14 (21.5%) 26 (40%)
Total 186 98 (52.7%) 52 (28%) 36 (19.3%)
* = % of BMT recipients of relevant country
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2.2. Materials and methods
2.2.1. Oral examination and mouth swill collection
After receiving informed consent from each patient, an oral evaluation that 
included presence of dentures (either partial or full) and presence of any mucosal 
abnormalities was performed on all patients. An oral rinse sample was then obtained 
by asking each patient to rinse his / her mouth with 1 0  ml of sterile distilled water for 
thirty seconds (Al-Karaawi et al., 2002). Subjects who were wearing dentures or 
removable orthodontic appliances were asked to remove the prosthesis before oral 
rinse. This method is simple and suitable for patients who may suffer from xerostomia 
as a result o f cancer therapy. More than one oral rinse was obtained from some o f the 
UK and Greek BMT recipients. There was an interval of at least 4 weeks between 
sampling of the patients.
2.2.2. Culturing of samples
Each mouth swill was vortexed and 1 ml was cultured on freshly prepared 
Sabouraud Dextrose Agar (SDA) (Sigma-Aldritch, Dorset, UK) containing 
chloramphenicol (Sigma-Aldritch, Dorset, UK) within a few hours of collection. The 
isolates were then incubated aerobically at 37°C for 48 h.
2.2.3. Preparation of Sabouraud agar plates
65 g o f Sabouraud dextrose agar (Sigma-Aldritch, Dorset, UK) was 
thoroughly mixed with one litre of distilled water (dEUO). 10 pi / L of 
chloramphenicol was added after autoclaving at 121°C. The mixture was then poured
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into Petri dishes (BDH Merck, UK) under sterile conditions and allowed to cool. The 
plates were kept sealed at 4 °C for up to 3 to 4 weeks.
2.2.4. Colony forming unit (cfu) /ml
After growing the yeasts, cfu / ml were counted by visual methods, and 
divided into either high cfu / ml (if the yeast count was > than 1 0 0 ), or low cfu / ml (if 
they were < than 100 cfu / ml). Non-identical single colonies were isolated and re­
grown to confluence.
2.2.5. Storage of Candida isolates
A small amount of all freshly grown yeast (~50 pi) was inoculated into 1 ml of 
LB broth (Lennox L Broth Base) (Sigma-Aldritch, Dorset, UK) storage medium (2 g 
of LB broth with 50 ml o f water and 50 ml of glycerol) and stored at -20 °C for further 
analysis.
2.2.6. Species determination
2.2.6.1. Phenotypic methods for identifying isolates to the species level
Each isolate was assessed for the production of germ tubes after incubation of 
a yeast inoculate in 1 ml of horse serum (Sigma-Aldrich, Dorset, UK) at 37 °C 
incubated on a heat block for 90 min. The suspension was vortexed and one drop of 
the suspension placed on a glass slide and visualized under a light microscope for the 
presence or absence of germ tubes (McCullough et al., 1999b; Al-Karaawi et al.,
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2002). Samples were then classified as either C. albicans or C. dubliniensis (with positive 
germ tubes) (Figure 2.1) or species other than albicans or dubliniensis (with negative 
germ tubes). Although the CHROMagar test and carbohydrate assimilation test (API 
system) are the most common methods used to identify Candida species, these methods 
were not employed in the present research because at the time of commencing this study 
(1999), these methods were not reliable to identify C. dubliniensis. Therefore all isolates 
were divided into two groups either C. albicans or C. dubliniensis (first group) or non- 
albicans Candida (second group) to carry out specific PCR-based, genetic methods for 
identifying Candida species as discussed and outlined later (Section 2 2.6.2.2 and 
2.26.2.3).
Figure 2.1 Germ tubes production after incubation in a horse serum
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2.2.6.2. Genotypic methods for yeast identification
2.2.6.2.I. Genomic DNA extraction
Genomic DNA was extracted from all samples using previously described 
methods (Scherer and Stevens, 1987; Clemons et al., 1997b). A fully grown culture 
after 48 h incubation at 37°C on SDA was added to 1 ml of 1 M of Sorbitol (18.2 g / 
100 ml) (BDH Merck, UK) for 10 min. Following centrifuging at 5000 x g, the 
supernatant was removed and 1 ml o f spheroplast buffer [42 pi (0.1%) 2- 
Mercaptoethanol (Sigma-Aldritch, Dorset, UK), 0.2 pg zymolase (Sigma-Aldritch, 
Dorset, UK), 2 ml (50 mM) phosphate buffer (Sigma-Aldritch, Dorset, UK), and 40 
ml of 1 M Sorbitol, pH 7.5] was added. The cells were incubated overnight at room 
temperature.
The supernatant was removed after centrifuging at 5000 x g for 10 min and re­
suspended in 1 ml of lysis buffer [0.94 g (50 mM) EDTA (Ethylenediaminetetra- 
acetic acid) (Sigma-Aldritch, Dorset, UK) and 1 g of 20% SDS (Sodium dodecyl 
sulphate) (Sigma-Aldritch, Dorset, UK) in 50 ml of water, pH 8.5]. Spheroplasts were 
incubated on a heat block for 1 h at 70°C. The lysed cells were allowed to cool at 
room temperature then 50 pi of potassium acetate (5 M) was added. The suspension 
was then left on ice for 1 h to allow for complete precipitation of SDS and protein. 
0.5 ml of the centrifuged supernatant was added to 1 ml of 100% ethanol. Following 
centrifuging at 1 0 0 0 0  x g for 1 0  min, the supernatant was poured off and genomic 
DNA was allowed to dry in air. 0.5 ml of 1% Tris-EDTA (TE buffer) (Sigma- 
Aldritch, Dorset, UK) and 1% of Ribonuclease A from bovine pancreas (Sigma- 
Aldritch, Dorset, UK) (500 pg of Ribonuclease A with 50 ml of TE buffer) were then
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added to the formed pellet (to remove any residual RNA) (Soil, 2000) and left 
overnight at room temperature.
The following day, DNA was re-precipitated by the addition of 100% 
isopropanol (Sigma-Aldritch, Dorset, UK) and centrifuged at 10000 x g for 10 min. 
After discarding the supernatant, the pellet was re-suspended in 1 ml of 75% ethanol 
and centrifuged at 10000 x g for 1 min. The DNA pellet was dried and suspended in 
200 pi of TE buffer and stored at 4°C. The neat DNA was diluted with TE buffer 1:10 
for PCR amplification. A range of concentrations of the genomic DNA were assessed 
and it was shown that this dilution o f genomic DNA allowed for reproducible PCR.
2.2.6.2.2. PCR for species identification
After extraction of genomic DNA from all samples, two PCRs were 
undertaken o f all germ-tube negative yeast isolates to identify them to the species 
level (McCullough et al., 1999b). PCR primers were directed against the V3 region of 
the 25S rDNA, and the intergenic transcribed spacer region (ITS) of the rDNA.
Primers for PCR were designed for two separate areas of the DNA encoding 
relevant area of the mRNA. The first pair of the primers 25S V3-L (5' - TCT TAA 
CAG CTT ATC ACC CTG GAA TTG GTT - 3 ') and V3-R (5' - ATT GTG TCA 
ACA TCA CTT TCT GAC CAT CAC - 3') (Sigma genosys, UK), were designed 
from sequences submitted to GenBank (McCullough, et al., 1999b) to give an 
expected PCR product that spans the V3 region of the 25S rDNA (Sullivan et al., 
1995). The second pair of primers give an expected PCR product extending from the
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5' end of the 18S rDNA to the 3' end of the 25S rDNA were ITS-1 (5' - TCC GTA 
GGT GAA CCT GCG G -  3 ) and ITS-4 (5' - TCC TCC GCT TAT TGA TAT GC - 
3 ') (Sigma genosys, UK) (McCullough et al., 1999b).
For DNA amplification by PCR, 2 pi (approximately 100 ng) of genomic 
DNA (McCullough et al., 1995) was amplified in a buffer (contains MgC^) supplied 
by the Taq polymerase manufacturer (Sigma-Aldritch, Dorset, UK), in a 20 pi volume 
containing 1 pM primers, 2 pM of Taq buffer, 0.5 U (0.5 pi) of red Taq polymerase, 
200 pM dATP, 200 pM dCTP, 200 pM dGTP and 200 pM dTTP (McCullough et al.,
1995).
The reactions were performed using an automated heated-lid thermocycler 
(Genius, Techne, UK). DNA samples were denatured by incubation for 3 min at 94 °C 
before 40 cycles o f 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1 min. After 
completion o f 40 cycles, a further 5 min at 72°C was extended for expansion 
(McCullough et al., 1999b).
For analyzing the restriction fragment length polymorphisms (RFLPs) of V3 
25S rDNA region and ITS region, the purified PCR products were digested with the 
restriction enzymes Hae III and Dde I respectively (Roche, UK) (McCullough et al., 
1999b). Endonuclease digestion was undertaken by overnight incubation of the PCR 
product of V3 and ITS with 10 U of enzyme at 37°C and corresponding buffer 
(McCullough et al., 1999b). This method has been shown to discriminate between all
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medically important species of Candida. However, it is still not possible by this 
method to differentiate C. albicans genotypes and C. dubliniensis.
2% Agarose gel electrophoresis (Sigma-Aldritch, Dorset, UK) was performed 
on 10 pi of PCR product of V3 and ITS and a further 10 pi of the PCR product 
following endonuclease digestions were separated by electrophoresis in TAE buffer 
(40 mM Tris-acetate, 0.2 mM EDTA) (Sigma-Aldritch, Dorset, UK) for 1 h at a speed 
of 60 V/cm and visualised by UV transillumination after 0.1% pg o f ethidium 
bromide staining) (Figure 2.2).
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Figure 2.2 Representative samples of species identification from 11 isolates showing 
PCR product of Hae of the V3 region (A) and Dde of the ITS region (B). Arrows in 
the left side represent the molecular marker used <J)xl47 DNA/ B5wRI (HaeIII) (MBI
Fermentas, UK)
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2.2.6.2.3. PCR for differentiation of C. dubliniensis and genotypic sub-groups of 
C. albicans
The primers used for PCR to identify C. dubliniensis and genomic DNA of 
C. albicans, directed against the transposable intron in the 25S rDNA (McCullough et 
al., 1999b), were CA-INT-R (5' -  CCT TGG CTG TGG TTT CGC TAG ATA GTA
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GTA GAT- 3 ) and CA-INT-L (5' -  ATA AGG GAA GTC GGC AAA ATA GAT 
CCG TAA -  3 ') (Sigma genosys. UK).
This method allows the differentiation of genotypes according to the size of 
intron and thus divides C. albicans isolates genotypically into sub-groups A, B, C or 
C. dubliniensis dependent upon the presence or absence of this 25S rDNA 
transposable intron (Scherer and Stevens, 1987; Stevens et al., 1990; Clemons et al., 
1991; Clemons et al., 1997a; McCullough et al., 1999b).
Genotype A does not have the intron in 25S rDNA (~ 450 bp), genotype B 
does have the intron (~ 840 bp) and genotype C has the intron in part of 25S rDNA (~ 
450 bp and ~ 840 bp). C. dubliniensis has a larger transposable intron in the same site 
of 25S rDNA (above 840bp) and so has an intron that is larger than that of the C. 
albicans genotype B intron. Thus the two can be differentiated.
The DNA amplification and PCR reactions employed to differentiate C. 
albicans and C dubliniensis were the same as those used for species identification 
(2.2.6.2.2). The PCR products for genomic C. albicans and C. dubliniensis were 
separated with 2 % agarose gel and visualized by ultraviolet transillumination after 
ethidium bromide staining using molecular marker (j)xl47 DNA/ BswRI (HaeWY) 
(MBI Fermentas, UK) (Figure 2.3).
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Figure 2.3 Showing C. albicans genotype A (lane 4, 5, 6 , 7) without the intron in 
25S rDNA, genotype B (lane 8 , 10, 12, 13) with the intron and genotype C (lane 2, 9) 
has the intron in part of 25S rDNA and C. dubliniensis (lane 3) has a much larger 
transposable intron in the same site of 25S rDNA. Arrows in the left side represent 
the molecular marker used (j)xl47 DNA/ BswRI {HaeIII) (MBI Fermentas, UK)
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The Chi square test and Fisher Exact test (when one or more of the variants 
are less than 2) were employed to analyze Candida colonization, Candida species 
identification and genotypes of C. albicans. Differences between examined groups 
were assumed to be significant when the probability (p) was less than or equal to 0.05.
2.2.6.2.4. PCR for strain delineation of C. albicans by PCR fingerprinting
Genomic DNAs of all C. albicans isolates from BMT recipients from the UK 
(including subsequent strains from patients who provided more than one sample), 
Greece, Italy and Brazil were amplified with five different oligonucleotide primers to 
assess strain similarity genotypically (Xu et al., 2000). Candida albicans strains from 
non-BMT recipients from the UK (strains from patients who attended a private dental 
clinic and Oral Medicine clinic) were also combined as a control group and amplified
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with the same oligonucleotide primers. The sequences of the primers are listed in 
Table 2.10.
Table 2.10 Primers used in PCR fingerprinting (Xu et al., 2000)
Oligonucleotide Primer Sequence of the primer
The M l3 phage core sequence 5 - GAG GGT GGC GGT TCT -  3'
The intergenic spacer repeat 
of tRNA T3B
5 - AGG TCG CGG GTT CGA ATC C- 3'
The simple repeat sequences 
(GACA ) 4
5' - GAC AGA CAG ACA GAC A- 3'
The telomeric core sequence 
TELOl
5' - TGG GTG TGT GGG TGT GTG GGT 
G T G -3 '
OPA-03 from Operon 
Technologies
5' -AGT CAG CCA C- 3'
For all PCRs, 2 pi (approximately 100 ng) (McCullough et al., 1995) of 
genomic DNA was amplified in a buffer (contains MgCh) supplied by the Taq 
polymerase manufacturer (Sigma-Aldritch, Dorset, UK) in a 20 pi volume containing 
1 pM of the primer, 2 pM of Taq buffer, 1 U o f Taq polymerase, 200 pM dATP, 200 
pM dCTP, 200 pM dGTP and 200 pM dTTP (Sigma-Aldritch, Dorset, UK) 
(McCullough et al., 1995). The reactions were performed using an automated thermal 
cycler. For primers T3B, M l3, TELO 01 and GACA4 , DNA samples were denatured 
by incubation for three min at 97 °C before 40 cycles of 93 °C for 40 sec, 50 °C for 
two min and 72 °C for 40 sec. After completion of 40 cycles, a further 10 minutes at 
72°C was extended for expansion. However, as the OPA-03 primer is very short, a 
longer time for amplification was required. For that reason, the PCR cycles for this 
primer were 45 cycles at 93°C for 1 min, 36°C for 2 min and 72°C for 2 min (Xu et
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al., 2000). All PCR amplicons were separated in 2 % agarose gel in TAE buffer (40 
mM of Tris-acetate and 0.2 mM of EDTA; pH, 8.3) for 2 - 5 h at 2 V/cm and 
visualized by ultraviolet transillumination after 0 .1% pg of ethidium-bromide 
staining. Figure 2.4 represents examples of electrophoretic separation for each of the 5 
primers.
Figure 2.4 Examples of electrophoretic separation of PCR fingerprinting obtained by 
amplifying genomic DNA from 14 strains of C. albicans using GACA4 (A), T3B (B), 
TEL04 (C), M l3 core sequence (D) and OPA-03 (E) as single primers. Arrows in 
the right side of each image represent the polymorphic bands for each primer that 
commonly spread throughout the genome. Arrows in the left side represent the 
molecular marker (j)xl47 DNA/ BswRI (Haelll) (MBI Fermentas, UK)
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D (M l3 phage core sequence)
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The results of the 5 PCR fingerprinting experiments using different primers set 
were combined by selecting 2 to 5 polymorphic bands for each primer resulting in 17 
polymorphic bands that have been shown to be widely spread through the genome 
(Figure 2.4.). Each band was analyzed visually and scored as either present (1) or 
absent (0) (Xu et al., 2000).
The results were then phylogenetically analysed using the computer program 
PAUP 4.08. Simple analyses were undertaken utilizing the optimal criterion as 
distance and pair-wise distances between each of the isolates measured. To aid in the 
visualization o f the relationship between isolates based on this analysis, a phenogram 
was generated by the unweighted pair-group method with arithmetic mean (UPGMA). 
Ties (if encountered) were broken systematically and the distance measure was set to 
mean character difference.
Student t-test and ANOVA were used to compare the genetic similarities 
between different groups of isolates. These comparisons were to differentiate the 
genetic subgroups of C. albicans (A, B and C) (t-test) and strain relatedness of 
isolates from different groups of patients (ANOVA). It was assumed that the 
similarities between each isolate were normally distributed and the t-test was used for 
a comparison between two groups while the ANOVA test was used for a comparison 
between more than two groups. Differences between examined groups were assumed 
to be significant when the probability (p) was less than or equal to 0.05.
2.2.7. Adhesion
2.2.7.1. Preparation of the Dynabeads coated with fibronectin
Paramagnetic beads (Dynabeads® M-450 Tosylactivated, Dynal, UK) were 
employed (Gaur and Klotz, 1997; Gaur et al., 1999; Gaur and Klotz, 2000) in the 
present assay. For these analyses, 300 pi o f Dynabeads were placed in a magnetic 
separator (Dynal, UK) and washed three times with 1 ml of 0.1 M phosphate buffer A
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[2.62 g NaH2P 0 4 (0.019 M) and 1.49 g Na2H P04 (0.081 M) / L, pH adjusted to 7.4] 
before adding 5 pg of fibronectin (Sigma-Aldritch, Dorset, UK) in 1 ml of buffer A. 
The resultant mixture was then incubated at 37°C for 10 min. The mixture was 
enhanced with 10% of Bovine Serum Albumin (BSA) (Sigma-Aldritch, Dorset, UK) 
and left overnight at 37°C. On the following day, the supernatant was removed and 1 
ml of buffer B [PBS buffer with 0.1% o f BSA] was added and left at 4°C for 5 min. 
The supernatant was removed carefully and 1 ml of buffer C [24.2 g of Tris (Sigma- 
Aldritch, Dorset, UK) / 1 L of water and 1 g of BSA, pH 8.5] was added. The 
suspension was incubated at 37°C for 4-6 h. The supernatant was removed and 
washed twice with buffer B. The concentration o f the beads was adjusted to 108 beads 
/ ml of buffer B ((Dynal MPC®) and stored at 4°C until use. At the time of adhesion 
assay, the beads were diluted to be 106 beads / ml (Dynal MPC®).
22.1.1. Preparation of Candida suspension for the adherence assay
50 pi of the stocked Candida in LB Broth from BMT recipients from four 
diverse regions (including subsequent isolates from the UK and Greek patients) and 
Candida isolates from the private dental clinic subjects and oral medicine patients 
with non-mucosal diseases (healthy control subjects) were recovered and grown in 5 
ml of YPD [10 g of yeast extract (Sigma-Aldritch, Dorset, UK), 20 g of peptone 
(Sigma-Aldritch, Dorset, UK) and 20 g dextrose (Sigma-Aldritch, Dorset, UK) / 1 L 
of distilled water] for 16 h at 37°C shaking at 150 rpm. An additional 45 ml of YPD 
was added to the yeast for a further 6-7 h shaking at 37°C. The grown Candida was 
then centrifuged and washed three times with 1% Tris- EDTA buffer (TE buffer) 
(Sigma-Aldritch, Dorset, UK). The resultant mixture was re-suspended in 1 ml of TE
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buffer to obtain a cell concentration of 108 cells / ml. The cells were then counted 
under the light microscope using a haematocytometer.
2.2.7.3. Adhesion assay
40 pi of fibronectin-coated magnetic beads at a concentration of 106 bead / ml 
were added to the Candida cells at a concentration of 108 cell / ml as recommended by 
the manufacturers (Dynal MPC®). The total volume was adjusted to 200 pi with TE 
buffer (lOmM Tris, 1 mM EDTA, pH 7.0) in neutral wells of 96 units (BDH Merck, 
UK) and incubated shaking at room temperature for 30 min. The cells were then 
washed several times with TE Buffer using a magnet (Dynal MPC®) to remove the 
unbound yeast cells. Collected dynabeads and yeast cells were suspended in 150 pi of 
0.1 N NaOH for 15 min shaking at room temperature to separate the cells from the 
beads. The cells and beads were then counted with a haematocytometer (Figure 2.5. 
and 2.6). In-vitro adhesion was assessed by quantitating the adherence of Candida 
cells to paramagnetic beads coated to fibronectin for all isolates. Results were 
expressed as cells / bead. The median o f all isolates according to the number of cells 
per beads was determined and each isolate was considered as having high adherence 
if the reading was equal to or above the median or low adherence if the reading was 
below the median.
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Figure 2.5 Cells (light brown) and Dynabeads (dark brown) before separation
Figure 2.6 Cells (light brown) and Dynabeads (dark brown) after separation
2.2.8. Proteinase assay
The secreted aspartyl proteinase protocol of MacDonald and Odds (1980) was 
employed to determine the proteinase activity of Candida in-vitro. Candida isolates 
from the stocked solution were recovered and grown in Sabouraud dextrose agar
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(SDA) for 24 h at 37 °C. The examined isolates used in this assay were the same 
isolates employed in the adhesion assay (Section 2.2.7). A small amount of grown 
cells was suspended in 1 ml of culture medium. The culture medium comprised 
synthetic vitamin solution (biotin 20 pg, nicotinic acid 400 pg, riboflavin 200 pg, 
thiamine 400 pg, pyridoxal hydrochloride 400 pg) (Sigma-Aldritch, Dorset, UK) with 
20 g dextrose (Sigma-Aldritch, Dorset, UK), 2 g of bovine serum albumin (BSA) 
fraction V (Sigma-Aldritch, Dorset, UK), 1 g of potassium phosphate buffer and 0.5 g 
MgSo4  in 1 L / o f water. Cells in the culture medium were shaken at 150 rpm at room 
temperature for 5 days (pH falls to 2.9). Candida was then vortexed and counted in a 
haematocytometer. The tubes were then centrifuged at 5000 x g for 30 min to remove 
Candida. 0.5 ml of the supernatant was added to 2 ml of BSA in citric buffer [1.47 g 
(0.05 M) of tri sodium citrate powder (BDH Merck, UK) and 1 g of BSA / 100 ml of 
water]. The pH was adjusted to 3.2 using concentrated acetic acid and the cells 
incubated for 30 min at 37 °C. 5% of trichloroacetic acid (TCA) (Sigma-Aldritch, 
Dorset, UK) was then added to the mixture on ice to stop the reaction. The solution 
was left on ice for at least 15 min to allow for complete precipitation of the undigested 
albumin. The suspension was then centrifuged at 2900 x g for 15 min at room 
temperature and the absorbance at 280 nm of 1 ml of the supernatant determined by 
spectrophotometry against a citrate-buffer. Each strain was tested in triplicate and the 
mean of the three tests used for further statistical analysis.
As an appropriate control 2 ml of BSA and citric buffer was added to 5% of 
TCA on ice for 15 min (no incubation). The absorbance at 280 nm of this solution 
was then determined. The difference in absorbance between the tested sample and the 
control sample was divided by the number of cells per 1 ml to give the activity of
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extracellular proteinase of the examined Candida species. Results were expressed as 
U / ml (Kretschmar et al., 1999). The median of all isolate readings was determined. 
Hence, each isolate was considered as having high proteinase activity if  the reading 
was equal to or above the median or low proteinase activity if  the reading was below 
the median.
Statistical analyses using the Chi square test and Fisher Exact test (when one 
or more of the variants were less than 2) were employed to analyze the in-vitro 
adhesion and proteinase activity of Candida species. Differences between examined 
groups were assumed to be significant when the probability ip) was less than or equal 
to 0.05.
2.2.9. Minimal inhibitory concentration (MIC) of fluconazole
In the present experiment, the broth microdilution assay for determining the 
minimum inhibitory concentration (MIC) was employed using a broth microdilution 
method specified by the National Committee for Clinical Laboratory Standards 
(NCCLS) document M27-A (National Committee for Clinical Laboratory Standards, 
Wayne, 1997). Alamar blue (Trek Diagnostic Systems Ltd, UK) was employed for 
accurate assessment of growth endpoints. The medium used was 10.4g RPMI 1640 
(Sigma-Aldritch, Dorset, UK) buffered with 34.53 g of MOPS (Sigma-Aldritch, 
Dorset, UK) in 1L o f water to give a final molarity o f 0.165 and adjusted to a pH of 
7.0 with 10 M NaOH (BDH Merck, UK).
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All Candida isolates from the BMT recipients (UK, Italy, Greece and Brazil) 
and control subjects (subjects from the private dental clinic and oral medicine patients 
with non-mucosal disease) were recovered from the stock solution and cultured on 
Sabouraud dextrose agar for 24 h. To assess the effect of time upon fluconazole 
resistance, subsequent isolates from the UK and Greek BMT recipients were also 
examined. Furthermore, two strains of C. albicans were served as quality control 
organisms. One o f them was in-vitro susceptible to fluconazole (ATCC 90028) while 
the other was resistant to fluconazole (ATCC 64550) (Espinel-Ingroff et al., 1995).
The yeast cells were then suspended in sterile 0.85% w/v saline and the 
mixture was adjusted by spectrophotometry (at 530 nm wavelength) to give a final 
transmission between 0.08 and 1. The yeast cell suspension and anti-fungal were 
further diluted in RPMI to give the test concentrations in sterile disposable 
microtitration multiwell plates (Nunclon ™ A Delta, UK) as previously described 
(NCCLS, 1997). The microtitre plates were incubated in an oven at 35 °C and read at 
24 h and 48 h. MIC endpoints were read when the Alamar blue colour changed from 
blue to pink or bluish pink.
2.2.9.I. Classification of the in-vitro fluconazole resistance
In previous studies (Lopez-Ribot et al., 1999; Sandven, 1999) an MIC 
endpoint reading (utilizing NCCLS method M-27A (1997)) below 8 pg / ml was 
considered as clinically susceptible, an MIC equal to, or between 8 and 16 pg /ml, 
was considered as dose dependent susceptibility (DD-S), while an MIC of 32 pg / ml 
or higher was regarded as being clinically resistant.
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According to these criteria, it has been found in the present study that 6.8% of 
the examined strains were dose dependent susceptible and 13.6% were resistant. To 
better understand more subtle variation in fluconazole susceptibility that may exist 
among strains analysed in the present study, it was considered that strains with an 
MIC of 2 pg / ml and above showed enhanced resistance (R) to fluconazole, while 
strains with an MIC below 2 pg / ml were regarded as being highly susceptible (S) to 
fluconazole. Therefore, the MIC of each isolate was recorded on a table designed to 
resemble the multiwell plates. Fluconazole concentrations of 64 pg / ml (the most 
resistant to the drug) down to 0.125 pg / ml (the most susceptible to fluconazole) were 
employed (Table 2.11). Figures 2.7 and 2.8 show examples of the MIC endpoints of 
some isolates utilizing Alamar blue dye showing colour changed and Candida growth.
Table 2.11 Example of the minimal inhibitory concentration (MIC) record for each
sample
Fluconazole 
concentration 
(pg / ml)
64 32 16 8 4 2 1 0.5 0.25 0.125 ^Controlsterility7
Sample
number 01 02 03 04 05 06 07 08 09 10 11
A R R R R R R S S S s
B
C
D
E
F
G
H
*Control sterility: Drug free medium used as a blank well. R: enhanced resistant to 
fluconazole, S: susceptible to fluconazole
Statistical analyses utilized the Chi square test and Fisher Exact test (when one 
or more of the variants were less than 2) were employed to analyze the in-vitro
154
fluconazole susceptibility of Candida species. Differences between examined groups 
were assumed to be significant when the probability (p) was less than or equal to 0.05.
Figure 2.7 Multiwell plate showing MIC endpoints of 8 isolates utilizing Alamar blue
Figure 2.8 Magnified picture showing MIC endpoints and Candida growth of 5 isolates
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All statistical analyses in Sections 3.2, 3.4 and 3.5 were performed firstly 
between isolates obtained from the UK BMT recipients compared with isolates from 
healthy subjects (to study the influence o f host immune status and therapy received 
upon Candida carriage, species diversity, virulence attributes and in-vitro fluconazole 
susceptibility) and secondly between isolates collected from BMT recipients who 
lived in four geographical diverse regions (to study the effect of locale and treatment 
received among immunocompromised patients upon Candida carriage, species 
diversity, virulence attributes and in-vitro fluconazole susceptibility).
2.2.10. Reverse Transcriptase (RT) PCR of the agglutinin- like sequence 
{ALS) and secreted aspartyl proteinase (SAP) gene families
2.2.10.1. Strains selection for the RT PCR assay
Fourteen strains of C. albicans genotypes A and B were carefully selected and 
examined for the RT PCR assay (7 strains from the UK BMT recipients and 7 strains 
from the private dental clinic and oral medicine patients) (Table 2.12). The proteinase 
activity of these strains (above or below the median), the in-vitro adhesion (above or 
below the median) level of oral colonization (< or > 100 cfu / ml) and the in-vitro 
susceptibility to fluconazole (MIC < or > 2) were all determined previously (Sections 
2.2.8, 2.2.7, 2.2.4, 2.2.9 respectively). Those 14 strains were found to be the most 
appropriate strains that met both genotypic and phenotypic criteria required for the 
present assay (either high or low proteinase activity (Section 3.4), in-vitro adhesion 
(Section 3.4), yeast colonization (Section 3.2), or susceptible to fluconazole (Section
3.5). The 14 strains chosen for the present assay and their genotypic and phenotypic 
attributes are outlined in Table 2.12.
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Table 2.12 Phenotypic and genotypic descriptions of the 14 strains used for gene
expression analyses
Candida
strain
In-vitro
adhesion
Proteinase
activity
Fluconazole
susceptibility
Cfu / ml 
< or > 100
C. albicans 
genotype
1 high low resistance high B
2 high high resistance high A
3 low low susceptible high B
4 high low susceptible high A
5 high high susceptible high A
6 low low susceptible low B
7 low high susceptible low A
8 high low susceptible low A
9 low low susceptible high B
10 low low susceptible low A
11 high high susceptible high B
12 high high susceptible low A
13 high high susceptible high B
14 low low resistance high A
2.2.10.2. Growth media for the RT PCR assay
Candida albicans strains were grown in 4 different media. For the ALS 
genes assay strains were grown in YPD (10% yeast extract, 20% peptone and 20% 
dextrose) alone and in YPD containing beads coated with fibronectin, as previously 
described in the adhesion assay (Section 2.2.7). For the SAP genes assay, Candida 
cells were recovered from LB Broth and grown on SDA for 24 h at 37°C to provide 
freshly grown Candida. A small amount of Candida was grown in a culture medium 
with BSA as used to assess proteinase activity of Candida species (Section 2.2.8) and 
the culture medium without the addition of BSA (to assess the expression of SAP 
genes without the addition of protein).
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2.2.10.3. RNA Extraction
RNA was extracted from the cells using RNeasy® Mini Kit (Qiagen, UK). 
Candida strains were grown for 4 days in YPD at room temperature and then vortexed 
as previously described (2.2.7). Cells were washed 3 times with TE buffer. 2 ml of the 
cells in TE buffer were resuspended in 2 ml of Y1 buffer (1 M of sorbitol, 0.1M 
EDTA pH 7.4, 0.1% p -  mercaptoethanol (p ME) and 50 U of zymolase). Yeast in 
buffer Y1 was then incubated for 30 min at 30°C with gentle shaking to prepare the 
spheroblasts. After centrifuging and removal of the supernatant, 350 pi of buffer RLT 
(provided with the kit) was added together with 350 pi of 70% ethanol. The solution 
was transferred to the RNeasy® mini spin column located within a 2 ml collection 
tube (provided) for the absorption of RNA to a membrane. The solution was then 
centrifuged for 15 sec at 8000 x g and the supernatant was removed. RNA was 
washed firstly with 700 pi with RW1 buffer (provided) and then twice with 500 pi of 
RPE buffer (provided) to remove contaminants. The solution was then centrifuged at 
a maximum speed (13000 x g) for 2 min to dry the RNeasy® membrane. The 
RNeasy® column was transferred into a new 1.5 ml collection tube (supplied) and 30- 
50 pi of RNase-ffee water were applied directly onto the RNeasy® membrane to 
collect the RNA subsequent to the centrifuging for 1 min at 8000 x g. The extracted 
RNA was then stored at -70 °C until required.
The method of RNA extraction from strains grown on the other three media 
(YPD with beads coated with fibronectin, culture medium with BSA and culture 
medium without BSA) was the same as the one performed to extract RNA in YPD 
medium alone.
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2.2.10.4. Preparation of complementary DNA (cDNA)
Complementary DNA was prepared from RNA extracts using Superscript1"1 
II RNase H' Reverse Transcriptase (RT) (Invitrogen, UK). This enzyme is used to 
synthesize the first strand o f cDNA and gives high yields of cDNA. 2 pi of RNA from 
Candida cells was incubated with 0.5 pi Decameron (Ambion; Europe, Ltd) in 9.5 pi 
of nuclease-free water (to obtain 12 pi volumes) at 70°C for 10 min. Following 
cooling to room temperature, 1 U o f RT enzyme with 4 pi of the corresponding 
buffer, 2 pi (0.1 M) of DTT and 100 pM dATP, 100 pM dCTP, 100 pM dGTP and 
100 pM dTTP were added to the 12 pi of the RNA mixture to achieve a final volume 
of 20 pi. The mixture was then incubated at 42 °C for 1 h. The prepared cDNA was 
stored at -70°C.
2.2.10.5. ALS, SAP and EFB1 oligonucleotide primers
Six oligonucleotide primers from the agglutinin-like sequence gene family 
(ALS1, 2, 3, 6, 7 and 9) (Sigma genosys, UK) and 5 oligonucleotide primers from the 
secreted aspartyl proteinase gene family (SAP1, 2, 3, 6 and 8) (Sigma genosys, UK) 
were employed. All of the ALS and SAP genes were chosen carefully according to 
their characteristics as previously described in Chapter 1 (Hoyer, 2001; Hube and 
Naglik, 2001; Naglik et al., 2003). In addition, EFB1 elongation factor (Schaller et 
al., 1999) was used to assess its expression in comparison to the 18S rDNA house­
keeping control. The sequences o f ALS oligonucleotide primers were designed from 
the sequences submitted to GenBank {ALS P. L25902, ALS2: AH006927, A IS3: 
AY223552, ALS6: AY225310, ALS7: AY170875 and ALS9: AY269422) while the 
sequences of the oligonucleotide primers for SAP genes were previously published in 
a study by Schaller and co-workers (Schaller et al., 1999). The sequences of the
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primers for ALS, SAP genes and EFB1 elongation factor are listed in Table 2.13 and 
Table 2.14.
Table 2.13 Sequences o f the oligonucleotide primers used for ALS genes
Oligonucleotide
primers
Sequence
ALS1-L 
ALS1-R
5' - ACT GTG A ACG ACGCTTT G AA-3' 
5' -G ACG ACT GCC AGC AC AAGT A-3'
ALS2-L 
ALS2-R
5' -C AGC AAC AAC AAC AGC AAC A-3' 
5' -CCTGGTTGATTTCCTGGTTC-3'
ALS3-L 5-GAATGCTGTTTTGGGTTGGT-3'
5' -TC AG ATG AAACCGGATAATTCC-3'
ALS6- L 
ALS6- R
5' -TTC ACTGCTGGAACGAAC AC-3' 
5' -GGG ATC AAACGGT ATGTGG-3'
ALS7- L 
y4Z,S7-R
5' -CGT ACGAAACCTC AGT GC AA-3'
5' - AATCGC ATCC AC AAAAGGTC-3'
ALS9-L 
ALS9-R
5' -CGAT ATC AGTGGCTGTTCC A-3' 
5' -GCTGATCCC AAGTTC ACCTC-3'
160
Table 2.14 Sequences o f the oligonucleotide primers used for SAP genes and
The elongation factor EFB1
Oligonucleotide
primers
Sequence
SAP1-L 
SAP1-R
5' - AGGG AA AGGTATTTAC ACT-3'
5' -G ATTT GCTT AC AT AGT AAGT AC-3'
SAP2-L 
SAP2-R
5 -TGATTGTCAAGTCACTTATAGT- 3'
5' -CTT AGGTC AAGGC AG AAAT ACT G-3'
SAP3-L 
&4P5-R
5' -TGGATTGGAAC ATTTCTAATTC-3' 
5-CAATCTCCAGAGGAGTACTTCC-3'
SAP6-L
SAP6-R
5' -TTCTTC AAACGTTTT AATTCTCT-3'
5' -C ATAAATG ACTTC AAAAT AT AAAT-3'
SAPS- L 
SAPS-R
5' -CTCTATAAAGT AG AAAT ACTTG A-3' 
5' -GTT G AC AC AGGTT CTTCT G-3'
EFB1-L
EFB1-R
5' - ATTGA ACG AATTCTTGGCTGAC-3' 
5' -C ATCTTCTTC AAC AGC AGCTTG-3'
2.2.10.6. PCR for SAP and ALS  genes
A 20 pi volume for each SAP and ALS  gene containing 2 pi of prepared 
cDNA, 2 pM of the primer, 2 pM of Taq buffer, 1 U of Taq polymerase, 200 pM 
dATP, 200 pM dCTP, 200 pM dGTP and 200 pM dTTP and 2pl of 18S rDNA 
universal (Ambion, Europe, Ltd) with its competimer in ratios of 3:7, 2:8 or 1:9 
(Table 2.15) was used to show the optimum expression o f the internal control in 
comparison to the examined gene (ALS or SAP gene) or the elongation factor EFB1. 
The reactions were performed using an automated thermocycler. Depending upon the 
gene being examined, different numbers of PCR cycles were attempted until each 
primer showed optimum expression in relation to the 18S rDNA (Table 2.15). Each 
PCR cycle consisted of 1 min at 94 °C, 1 min at 56 °C and 1 min at 72 °C. No 
extended period was performed.
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Table 2.15 Number o f the PCR cycles for each gene and the ratio o f 18S rDNA
to the competimer
Gene Number of PCR cycles 18S : Competimer
ALS1 35 3:7
ALS2 35 3:7
ALS3 35 2:8
ALS6 35 2:8
ALS7 37 3:7
ALS9 35 2:8
SAP1 37 1:9
SAP2 28 1:9
SAP3 35 1:9
SAP6 35 1:9
SAP8 30 1:9
EFB1 30 2:8
The amplified products were electrophoresed at 70V in horizontal 2 % agarose 
gels in a Tris buffer containing 0.1% pg o f ethidium bromide for 1 h, and the products 
visualized under UV transilumination. Figure 2.9 shows a representative agarose gel 
electrophoresis of the RT-PCR products for the SAP genes studied while Figure 2.10 
shows a representative agarose gel electrophoresis of the RT-PCR products for the 
ALS genes studied.
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Figure 2.9 Representative sample of the RT-PCR products showing the expression of 
SAP1 in a defined medium with BSA (A) and in a defined medium alone (B). Arrows 
in the left side represent molecular marker used <j)xl47 DNA/ BsuRl (HaeIII) (MBI
Fermentas, UK)
SAP 1
(with BSA)
18S rDNA
M
SAP 1 
(no BSA)
18S rDNA
310
B
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Figure 2.10 Representative sample of the RT-PCR products showing the expression 
of ALS9 in a defined medium alone (A) and in a defined medium containing beads 
coated to fibronectin (B). Arrows in the left side represent molecular marker used 
<J)xl47 DNA/ BswRI (HaeIII) (MBI Fermentas, UK)
18S rDNA
ALS9 
(with FN)
18S rDNA
B
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2.2.10.7. Differential expression of ALS and SAP genes
The differential expressions of the agglutinin-like sequence genes, the secreted 
aspartyl proteinase genes and the elongation factor EFB1 were examined by using 
Phoretix Microsoft software to obtain the ratio of each gene in different media to the 
internal 18S rDNA. Therefore, the ratio of the YPD medium alone was deducted from 
the ratio of the YPD with beads coated to fibronectin medium and the ratio of the 
defined medium with vitamins alone was deducted from the defined medium 
containing BSA. However, the EFB1 gene was assessed in the YPD medium with 
beads coated to fibronectin in comparison to thel8S rDNA house-keeping. As shown 
in Figure 2.9 and 2.10, the pixel intensity of each band was measured with controlled 
standardized parameters. The ratio o f the intensity of the test gene RT-PCR product to 
the 18S rRNA RT-PCR product was used as a measure of the expression of that test 
gene for that assay.
Chi square t-test of mean difference and two samples t-tests for the differences 
in the mean of the four separate experiments o f the RT-PCR gene product (assuming 
equal variances with 95% confidence level) were used to assess statistical analysis for 
ALS and SAP genes activities.
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Figure 2.11 Phoretix analysis of one strain for SAP2 expression in a defined medium 
containing BSA. The first curve (1) is the pixel intensity of the RT-PCR product for 
the SAP2 gene while the second curve (2) is the pixel intensity of the RT-PCR 
product for the internal 18S gene with competimers. The area under the 
curve was used as a measure of each genes level of expression.
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Figure 2.12 Phoretix analysis of one strain for ALS9 expression in a medium 
containing beads coated to fibronectin. The first curve (1) is the pixel intensity of the 
RT-PCR product for the ALS9 gene while the second curve (2) is the pixel intensity of 
the RT-PCR product for the internal 18S gene with competimers. The area under the 
curve was used as a measure of each genes level of expression
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CHAPTER 3 
Results
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3.1. Molecular characterization of Candida species isolated from 
the oral cavity of patients from diverse clinical settings
3.1.1. Patients attending different dental settings in the UK (non-BMT 
recipients)
The total number of the examined patients was 257 as previously described 
(Section 2.1.2. and Table 2.1). All o f whom had no clinical signs of oral candidal 
infection. These patients were divided into 2 groups: healthy subjects (subjects 
attended a private dental clinic (n = 44), oral medicine clinic with non-mucosal 
disease (n = 16), prosthodontic clinic (n = 32) and orthodontic clinic (n = 64)); and 
diseased subjects (oral medicine patients with mucosal diseases (n = 57) and special 
needs patients (n = 44)).
3.1.2. Age and gender of all patients from different dental settings
The median age for all patients was 43.5 years. Table 3.1 demonstrates age 
distribution of all studied subjects according to the median age while Table 3.2 
demonstrates median age, range o f age and ratio of females to males for each dental 
setting. There were significant differences in the age group between all patients {p = 
0.001). Patients from the orthodontic unit were young individuals (1.6% above the 
median age) while most of the patients from the prosthodontic clinic and oral 
medicine clinic were above the median age (86.7%). There were significant 
differences in the females to males ratio (p = 0.002), the number of female patients 
from the oral medicine unit (with mucosal diseases) was significantly more than the 
male patients (Table 3.2).
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Table 3.1 Median age distribution o f patients from different dental settings
Median 
age in 
years
Orthodontic
subjects
Prosthodontic
subjects
Subjects 
attending a 
private 
dental clinic
Oral medicine 
patients (non- 
mucosal 
disease)
Oral
medicine
patients
(mucosal
disease)
Special
needs
patients
Above
43.5
1 30 17 13 47 20
Under
43.5
63 2 27 3 10 24
Total 64 32 44 16 57 44
Table 3.2 The median and range o f age for each group of patients and the ratio of
females to males
Orthodontic
subjects
Prosthodontic
subjects
Private
dental
clinic
subjects
Oral medicine 
patients (non- 
mucosal 
disease)
Oral
medicine
patients
(mucosal
disease)
Special
needs
patients
Median 
age in 
years
17 65 38 56 58 43
Range 
of age 
in years
8 - 44 39-93 16-80 27-78 17-83 25-81
*F : M 33:31 18:14 27:17 10:6 44:13 16: 28
* F: female, M: male
3.1.3. Presence and amount of oral Candida in all investigated patients
The clinical and laboratory data were gathered to assess the comparative effect 
of gender, age and mucosal abnormalities upon the presence, amount and species of 
Candida as well as the genotypic diversity of C. albicans isolates from the oral cavity 
of the different study groups of patients. Almost 53% (137/257) of all examined
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patients had detectable oral Candida, 60% of whom had cfu / ml greater than or equal 
to 100. In addition 125 of the 137 Candida isolates gave rise to positive germ tubes 
for C. albicans or C. dubliniensis. Details of oral conditions, denture status, positive 
Candida, candidal load (cfu / ml > 100 and positive germ tubes from different dental 
settings (healthy and diseased subjects) are summarised in Tables 3.3 and 3.4.
Table 3.3 Incidence, Candida carriage, load of Candida and positive germ tubes 
from patients attended oral medicine clinic (non-mucosal disorders), a private dental 
clinic, prosthodontic unit and orthodontic unit
Patient
cohort
Denture
status:
Full, partial, 
dentate
Total
number
of
patients
F° M*
Total 
number of 
patients 
grew 
Candida
Grown 
Candida 
with 
cfu/ml > 
100
Germ
tubes
positive
Candida
Non- mucosal
disorders Dentate 16 10 6 7 4 7
patients
Private dental 
clinic patients
Dentate 44 27 17 18 9 18
Full 17 9 8 10 7 7
Prosthodontic Partial 15 9 6 10 8 7
patients Dentate 0 0 0 0 0 0
Total 32 18 14 20 15 14
Fixed* 41 24 17 22 12 20
Orthodontic
patients
Removable* 23 9 14 6 4 6
Total 64 33 31 28 16 26
Total 156 88 68 73 44 65
* Orthodontic appliance type, F°: female, M*: male
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Table 3.4 Incidence, Candida carriage, load of Candida and positive germ tubes from 
patients attended oral medicine clinic (mucosal diseases) and special needs unit
Patient
cohort
Denture
status:
Full, partial, 
dentate
Total
number
of
patients
F° M*
Total 
number of 
patients 
grew 
Candida
Grown 
Candida 
with 
cfu/ml > 
100
Germ
tubes
positive
Candida
Full 6 4 2 3 3 3
Oral lichen Partial 8 8 0 6 3 6
planus
patients Dentate 23 17 6 13 6 13
Total 37 29 8 22 12 22
Full 0 0 0 0 0 0
Patients with
recurrent Partial 3 3 0 2 1 2
aphthous Dentate 8 4 4 2 1 2
stomatitis
Total 11 7 4 4 2 4
Full 0 0 0 0 0 0
Vesiculo-
bullous Partial 1 0 1 1 1 1
disease Dentate 4 4 0 2 1 2
patients
Total 5 4 1 3 2 3
Leukoplakia / Total 4 4 0 2 1 2dysplasia
Oral
medicine
patients with Total 57 44 13 31 17 31
mucosal
disease
Full 0 0 0 0 0 0
Patients with Partial 3 3 0 3 1 1
scleroderma
and SLE Dentate 7 4 3 4 3 4
Total 10 7 3 7 4 5
Full 3 0 3 3 2 1
Patients with
mental and / Partial 1 0 1 1 0 0
or physical Dentate 30 9 21 22 16 23
disabilities
Total 34 9 25 26 18 24
Special needs Total 44 16 28 33 22 29patients
Total 101 60 41 64 39 60
F°: female, M#: male
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3.1.4. Presence and amount of oral Candida in the diseased patients and 
healthy subjects
There was a significant difference in the presence of oral yeast between the 
diseased subjects (oral medicine patients with mucosal diseases and special needs 
patients) (64/101; 63.4%) and healthy subjects (patients from a private dental clinic, 
orthodontic unit, prosthodontic unit and oral medicine clinic with no signs of mucosal 
diseases) (73/156; 46.8%) p  = 0.025 (Tables 3.3 and 3.4). However, there was no 
difference in candidal load (in cfu/ml > 100) between the two groups of patients (p > 
0.05).
3.1.5. Species and G albicans genotypes of oral Candida isolates in 257 patients
Overall, 141 yeasts were isolated from the mouths of 137 patients (4/137 grew 
more than one different yeast). Candida albicans was the most commonly isolated 
species (83%). Furthermore, genotype A was the most frequently isolated C. albicans 
genotype (77.8%). However, non-albicans Candida species accounted for 17% of the 
isolates. Candida dubliniensis was isolated from 11% of all examined yeast (Table
3.5). The remaining 6% o f isolates comprised C. glabrata (5 isolates), C. 
guilliermondii (1 isolates), C. tropicalis (1 isolate), C. lusitaniae (1 isolate) and C. 
krusei (1 isolate).
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Table 3.5 Incidence o f  C. albicans genotypes A, B, and C, C. dubliniensis and other
non-albicans species isolated from the diseased and healthy subjects from different
dental settings
Patient cohort Denturestatus
G
albicans A0 B° C°
c.
dubliniensis
Other
species
Full 3 1 2 0 0 0
Patients with oral Partial 4 4 0 0 2 0
lichen planus" Dentate 12 10* 2 0 2* 0
Total 19 15 4 0 4 0
Full 1 1 0 0 0 0
Patients with recurrent Partial 1 1 0 0 0 0
aphthous stomatitis" Dentate 2 2 0 0 0 0
Total 4 4 0 0 0 0
Full 0 0 0 0 0 0
Patients with vesiculo- Partial 1 1* 0 0 0 1*
bullous disease" Dentate 2 0 1 1 0 0
Total 3 1 1 1 0 1
Patients with Dentate 1 1 0 0 1 0leukoplakia/ dysplasia"
Full 0 0 0 0 0 0
Patients with Partial 3 3 0 0 0 0
scleroderma and SLE" Dentate 4 4 0 0 0 0
Total 7 7 0 0 0 0
Full 3 2 0 1 0 0
Patients with mental Partial 1 1 0 0 0 0
and / or physical
disabilities" Dentate 16 11* 4* 1 7 0
Total 20 14 4 2 7 0
Oral medicine patients
with non- mucosal Total 6 6 0 0 1 0
disorders2
Patients attending a Total 18 16 2 0 0 0private dental clinic0
Full 7 5 2 0 0 3
Prosthodontic
Partial 7 6 1 0 1 3**
patients2
Total 14 11 3 0 1 6
Fixed 19 10 9 0 1 2
Orthodontic patients2 Removable 6 6 0 0 0 0
Total 25 16 9 0 1 2
Total 117 91 23 3 15 9
A : C. albicans genotype A, B : C. albicans genotype B, C : C. albicans genotype C 
*Patient had more than one Candida species or strain. diseased subjects, D: healthy subjects
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3.1.6. Comparison of Candida species and C. albicans genotypes of oral
Candida isolates in diseased and healthy subjects
From the total yeast grown, there was a significant difference in the presence 
of non-albicans Candida (except C. dubliniensis) in healthy subjects (8/74; 10.8%) in 
comparison with diseased subjects (1/67; 1.3%) p  = 0.024. C. dubliniensis was 
significantly isolated more frequently from the diseased subjects (12/67; 17.9%) in 
comparison with healthy subjects (3/74; 4.1%) p  = 0.008. However, there was no 
difference in C. albicans genotypes between the diseased and healthy subjects (p > 
0.05) (Table 3.6).
Table 3.6 Comparison of the incidence of C. albicans genotypes A, B and C, C. 
dubliniensis and other non-albicans Candida species isolated from the mouths of
diseased and healthy subjects
Patient
cohort
C.
albicans A° C°
C.
dubliniensis
Other
species
Diseased 54 42 9 3 12 1
patients (80.6%) (77.8%) (16.7%) (5.6%) (17.9%) (1.5%)
Healthy
subjects
63
(85.1%)
49
(77.8%)
14
(22.2%)
0
3
(4.1%)
8
(10.8%)
Total 117 91 23 3 15 9
• a   /  ............  1 —  ■ " ' ' AA : C. albicans genotype A, Bv: C. albicans genotype B, C : C. albicans genotype C
3.1.7. Candida dubliniensis
Candida dubliniensis was isolated from 5.8% (15/257) of all investigated 
patients. The frequency of isolation of C. dubliniensis from the special needs patients 
(n = 7), patients with oral lichen planus (n = 4) and leukoplakia (n = 1) (diseased 
subjects, 12/101) was significantly greater than that of healthy subjects (3/156) ip —
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0.001) but none of the patients with C. dubliniensis were immunocompromised and 
all were either fully or partially dentate. However, these patients had either local oral 
factors (e.g. lichen planus or leukoplakia) or mental and /or physical disabilities that 
may have enhanced the colonization by C. dubliniensis (none of the patients with 
scleroderma or SLE colonized by C. dubliniensis) (Table 3.5).
3.1.8. Age and gender associated with candidal carriage, Candida
species and C. albicans genotypes
3.1.8.1. Age
All patient data was collated and grouped into specific age ranges (<20, 20-30, 
30-40, 40-50, 50-60, 60-70 and >70 years). Patients who were over 70 years of age 
were significantly more likely to harbour more non-albicans (excluding C. 
dubliniensis) (4/39) than those of any other age group (4/218) ip = 0.005). In addition, 
C. dubliniensis was isolated significantly more often isolated (p = 0.002) in patients 
between the age of 40 and 50 years (6/34) compared with all other age groups (9/223). 
However, no other significant age related differences were found in the frequency or 
load of colonizing Candida or genotypic diversity of C. albicans.
3.1.8.2. Gender
There were no statistically significant differences in frequency of candidal 
carriage, Candida load (in cfu/ml > 100), genotypic diversity of C. albicans or 
isolation of non -albicans Candida between males and females in the complete group 
of patients, between diseased and healthy groups or within the individual related 
groups ip > 0.05).
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3.1.9. Influences of each dental setting on oral Candida
3.1.9.1. Patients attending oral medicine clinic
There were no statistically significant differences in the presence of Candida, 
level of Candida colonization, number of species isolated or genotypes of C. albicans, 
between attendees of the oral medicine clinic with mucosal diseases ip > 0.05) or 
patients with non-mucosal diseases (p > 0.05) when compared to those attending the 
other dental clinics. Of interest, although 38% of the patients attending the oral 
medicine clinic (with mucosal diseases) were receiving topical corticosteroid therapy, 
these agents did not influence any of the Candida-related factors examined.
3.1.9.2. Patients attending private dental clinic
There were no statistically significant differences in the presence of Candida, 
level of Candida colonization (cfii/ml), number of species isolated and genotypes of 
C. albicans, between attendees o f the private dental clinic when compared to those 
attended other dental settings ip > 0.05).
3.1.9.3. Patients attending prosthodontic clinic
There were no statistically significance differences in the presence of 
Candida, level of Candida colonization (cfu/ml) or genotypes of C. albicans, between 
attendees of the prosthodontic clinic when compared to those attended other dental 
clinics. The only notable observation was that subjects from the prothodontic clinic 
with dentures (either full or partial) had significantly ip = 0.04) more diverse yeast 
species (non-albicans Candida) isolated from their oral cavity than dentate patients
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from the other dental specialties. The non-albicans Candida from this group 
comprised C. glabrata (n = 5), C. krusei (n = 1) and C. dubliniensis (n = 1).
Interestingly, there were no statistically significant differences in the presence 
of Candida, level of Candida colonization (cfu/ml) or genotypes of C. albicans 
between denture wearers from other dental setting (oral medicine patients) when 
combined with prothodontic patients. However, those patients wear statistically 
carried more diverse Candida species {p = 0.03) than the dentate subjects.
3.1.9.4. Patients attending orthodontic clinic
There were no statistically significant differences in the presence of Candida, 
level of Candida colonization (cfu/ml) and number of species isolated between 
attendees of the orthodontic clinic when compared to those attending other dental 
clinics. Significantly more genotype B of C. albicans were isolated from the 
orthodontic patients 9/25 compared with the other carriers of C. albicans 17/92 ip = 
0.026). Interestingly, all isolates of C. albicans genotype B were isolated from 
patients wearing fixed appliances. In addition, the three non-albicans Candida (1C . 
dubliniensis, 1 C. tropicalis and 1 C. lusitaniae) from the orthodontic patients were 
from the subjects with fixed appliances.
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3.1.9.5. Patients attending special needs dentistry
The frequency of isolates of oral Candida from patients attended special needs 
dentistry was statistically much higher when compared with patients from the other 
dental settings {p = 0.002). However, there was no difference in oral Candida load (p 
= 0.2) nor genotypes o f C. albicans (p = 0.6) in this group of patients when compared 
with patients from other dental settings. Furthermore, C. dubliniensis was 
significantly more frequently isolated from special needs (physical and / or mental 
disabilities) patients when compared with other groups of patients (p = 0.002). All of 
the 7 patients who grew C. dubliniensis were dentate.
3.1.10. The effect of smoking upon Candida carriage in subjects from
different dental settings
A total of 14 o f the 57 patients from the oral medicine clinic and 14 of the 44 
special needs patients (diseased subjects) were regular tobacco smokers while only 19 
of the 157 healthy subjects from the other dental settings were smokers. Interestingly, 
smokers from the diseased subjects were colonized with oral Candida to a 
significantly greater extent than the healthy subjects (p = 0.003) (Table 3.7). 
However, the amount of oral Candida (cfu/ml > 100) and number of non-albicans 
Candida among smokers were not significantly different between the diseased and the 
healthy subjects (p > 0.05).
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Table 3.7 Number o f tobacco smokers and non-smokers and Candida species 
isolated from smokers of different dental settings
Patient
cohort
Tobacco
smokers
Non­
tobacco
smokers
Smokers
grew
Candida
Candida
species
Cfu/ml
> 1 0 0
Oral med 
patients 
(mucosal 
disease)
14 43 11 6 a* 5 d* 7
Special needs 
patients 14 30 10
5 a 
5 d 6
Total number 
of diseased 
patients
28 73 2 1 1 1  a 
1 0  d 13
Oral med 
patients (non- 
mucosal 
disease)
3 13 1 1 a 1
Private
patients 7 37 2 2 a 1
Prosthodontic
patients 5 27 2 2 g* 2
Orthodontic
patients 4 60 1 1 a 1
Total number 
of healthy 
subjects
19 137 6 4 a 
2 g
5
*a = C. albicans genotype A, *d = C. dubliniensis, *g = C. glabrata
Oral Candida isolates from patients with mucosal disease (n = 57) and patients 
with special needs (n = 44) were considered as being isolated from diseased patients 
and therefore not suitable to be compared with isolates from BMT recipients. Oral 
isolates from the prosthodontic patients and isolates from the orthodontic patients (n = 
96) had local factors (dentures or orthodontic appliances) that may have influenced 
oral Candida carriage, species (prosthodontic patients) and genotypic diversity 
(orthodontic patients) of C. albicans. Hence, they were considered as inappropriate 
subjects to be compared with BMT recipients. However, oral isolates from the 
subjects who attended a private dental clinic and the oral medicine unit with non- 
mucosal disease (n = 60) were thought to be suitable healthy suitable control subjects.
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3.2. Characterization of Candida species in bone marrow transplant 
recipients
3.2.1. Age and gender of all BMT recipients from different diverse regions
and control subjects
The median age of all BMT recipients from the four geographical diverse 
regions (n = 186) and the control subjects (n = 60) was 39 years. Table 3.8 
demonstrates age distribution of all studied individuals according to the median age 
while Table 3.9 demonstrates the median age, range of age and ratio of females to 
males for all BMT recipients from four diverse countries and the control subjects. 
There were significant differences in patients age between all examined patients (p = 
0.001). BMT recipients from Greece and Brazil were younger than those from the UK 
and Italy. However, there was no difference in age between BMT recipients from the 
UK and healthy control subjects (p = 0.54) (Table 3.8). The proportion of male to 
female BMT recipients from the UK and Brazil was significantly greater than those 
from Italy and Greece (p = 0.0001) or those from the control subjects (p = 0.003) 
(Table 3.9).
Table 3.8 Median age distribution o f BMT recipients from diverse regions
Median 
age in 
years
UK BMT 
recipients
Italian
BMT
recipients
Greek
BMT
recipients
Brazilian
BMT
recipients
Healthy
control
subjects
Above or 
equal 39
33 31 7 20 32
Under 39 23 12 15 45 28
Total 56 43 22 65 60
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Table 3.9 Median age, range of age of BMT recipients from different countries and 
UK healthy control subjects and the ratio of females to males
UK BMT 
recipients
Italian
BMT
recipients
Greek
BMT
recipients
Brazilian
BMT
recipients
Healthy
controls
Median age 
in years
40.6 46 31 31 43.5
Range of age 
in years
16-62 19-62 18-51 12-47 16-78
*F : M 19:37 21:22 12:10 18:47 37: 23
* F: female, M: male
3.2.2. Number of mouth swills
3.2.2.1. Number of mouth swills from the control subjects
Each of the control subjects (n = 60) provided one mouth rinse during the study 
period (Section 2.2.1), hence a total o f 60 mouth wills was obtained.
3.2.2.2. Number of mouth swills from the UK BMT recipients
Fourteen of the BMT recipients from the UK had only one mouth swill 
collected while the remaining 42 provided more than one oral sample (range from 2 to 
4) with the mean o f 2.5 mouth swill per patient during the ten month study period, the 
mean interval between sample collection being 14.5 weeks (range from 4 to 38.4 
weeks). Thus, a total of 118 oral samples were collected from the UK BMT recipients 
(Table 3.10).
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3.2.2.3. Number of mouth swills from BMT recipients from Greece, Italy and 
Brazil
Thirty-seven mouth swills were collected from the twenty-two Greek BMT 
recipients. Twelve patients provided only one sample while the remaining ten 
provided 2 or more samples beings an interval of four weeks or more between the 
samples (the mean interval between sample collection being 13 weeks, range from 4 
to 29 weeks). All of the 43 Italian BMT recipients and the 65 Brazilian BMT 
recipients provided one oral rinse as previously described.
Table 3.10 Summary of the number of mouth swills from the total groups of 
BMT recipients and control subjects
Category UK Italy Greece Brazil Control
Number of patients 56 43 2 2 65 60
Number of oral samples 118 43 37 65 60
3.2.3. Oral Candida carriage
3.2.3.I. Oral Candida carriage from the healthy controls
Twenty five (41.7%) of the 60 mouth swills from the control subjects yielded 
oral Candida. Thirteen of the 25 oral isolates (52%) had Candida of equal or greater 
than 100 cfu / ml.
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3.2.3.2. Oral Candida carriage from the initial mouth rinses from the UK 
BMT recipients
Candida isolates were obtained from 28 of the 56 mouth swills (50%) of UK 
BMT recipients. Two of the mouth swills had two different Candida species each 
hence a total of 30 isolates were obtained from the first oral sampling of the 56 UK 
patients. Twenty one isolates (70%) had Candida loads equal or greater than 100 cfu / 
ml.
3.2.3.3. Oral Candida carriage from the Italian BMT recipients
Eighteen of the 43 (41.9%) mouth swills from the Italian patients had detectable 
Candida. Thirteen swills (72.2%) had Candida loads of equal or greater than 100 cfu / 
ml.
3.2.3.4. Oral Candida carriage from the Greek BMT recipients
Oral Candida isolates were obtained from 8 of the 22 initial mouth swills 
(36.4%). Candida loads of equal or greater than 100 cfu / ml were obtained from 5 of 
the 8 isolates (62.5%).
3.2.3.5. Oral Candida carriage from the Brazilian BMT recipients
Thirty-seven (56.9%) of the 65 mouth swills from the Brazilian BMT 
recipients grew Candida. Twenty-eight (75.7%) of these swills had Candida loads of 
equal or greater than 100 cfu / ml. Table 3.11 summaries the frequency of oral 
Candida isolation and Candida load in the control subjects and the recipients of BMT.
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Table 3.11 Number of patients with oral Candida from the UK control subjects and
BMT recipients from diverse regions
Category
Control
subjects
UK Italy Greece Brazil
Number of patients (%) 25 28* 18 8 37
with oral Candida (41.7%) (50%) (41.9%) (36.4%) (56.9%)
Number of isolates (%) 13 21 13 5 28
with cfu/ml > 100 52% 70% 72.2% 62.5% 75.7%
* 2 Patients had two different Candida species from the oral swills
3.2.4. Candida species and C. albicans genotypes of Candida-positive
mouth swills
3.2.4.1. Candida species and C. albicans genotypes from the UK control 
subjects
Candida albicans was isolated from 24 (96%) of the 25 positive swills of the 
control subjects. Twenty-two of the 24 C. albicans isolates were genotype A (91.7%) 
while the remaining 2 were C. albicans genotype B. Non-albicans Candida species 
was isolated from one oral swill; this isolate was identified as C. dubliniensis (Table 
3.12).
3.2.4.2. Candida species and C. albicans genotypes from the UK BMT 
recipients
Candida albicans was isolated from 22 (73.3%) of the 30 oral Candida isolated 
from the UK BMT recipients. Sixteen of the 22 C. albicans isolates were genotype A 
while the remaining isolates were C. albicans genotypes B and C (Table 3.12). Non­
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albicans Candida species were present in 8 of the 30 oral Candida isolates. These 
non-albicans isolates were C. tropicalis (n = 3), C. glabrata (n = 2), C. dubliniensis (n 
= 1), C. parapsilosis (n = 1) and C. guillermondii (n = 1) (Table 3.12).
3.2.4.3. Candida species and C. albicans genotypes from the Italian BMT 
recipients
Candida albicans were isolated from 16 (89%) of the 18 Candida-positive 
swills from the Italian patients. Seven of the C. albicans were genotype A, 5 were B 
and the remaining 4 were genotype C. The two non-albicans isolates were C. 
parapsilosis (11%) (Table 3.14).
3.2.4.4. Candida species and C. albicans genotypes from the Greek BMT 
recipients
Candida albicans was isolated from 6 (75%) of the 8 Candida-positive swills 
of the patients from Greece. Five of the C. albicans isolates were genotype A, while 
the remaining 1 was genotype B. Non-albicans isolates were obtained from the two 
remaining mouth swills and comprised C. parapsilosis (1) and C. tropicalis (1) (Table 
3.14).
3.2.4.5. Candida species and C. albicans genotypes from the Brazilian 
BMT recipients
C. albicans was isolated from 29 (78.4%) of the 37 Candida-positive swills 
from the Brazilian patients. Twenty-four of the C. albicans were genotype A, 2 were
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genotype B and the remaining 3 were genotype C. The non-albicans Candida 
comprised C. glabrata (2), C. psuedoparapsilosis (2), C. tropicalis (1), C. krusei (1), 
C. guillermondii (1) and C. parapsilosis (1) (Table 3.14).
3.2.5. Summary of comparisons of the frequency of Candida carriage, load, 
C. albicans genotypes and the frequency of non-albicans Candida 
In the UK BMT recipients and UK control subjects
3.2.5.1. Oral Candida carriage and load (cfu/ml)
The frequency of oral Candida was not statistically different in the UK BMT 
recipients (50%) and control subjects (41.7%) (p = 0.37). In addition, the frequency of 
high-load Candida (cfu / ml > 100) in the BMT group (21/30) was not significantly 
different than that of the controls (13/ 25) (p = 0.17).
3.2.5.2. Candida species and genotypes of C. albicans
The oral carriage of non-albicans species from the UK BMT recipients (8/30) 
was significantly greater than that of the control subjects (1/25) {p = 0.024). C. 
dubliniensis was isolated once from the isolates of BMT recipients and once from the 
isolates of control subjects.
There was no significant difference in the genotypic variation of C. albicans 
between the isolates obtained from BMT recipients (6/22) and control subjects (2/24) 
(p = 0.09). Table 3.12 summaries the frequency of Candida species and C. albicans 
genotypes from the UK BMT recipients and UK control subjects.
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Table 3.12 Non-albicans species and C. albicans genotypes obtained from 
the swills of the UK BMT recipients and control subjects
Category
BMT
recipients
Healthy subjects
Non-albicans Candida 8 1
C. dubliniensis 1 1
C. glabrata 2 0
C. tropicalis 3 0
C. parapsilosis 1 0
C. guillermondii 1 0
C. albicans 2 2 24
Genotype A 16 22
Genotype B 5 2
Genotype C 1 0
There was no difference in the level of oral colonization (cfu/ml > 100) by C. 
albicans genotypes between isolates from BMT recipients and control subjects (p = 
0.2). Interestingly, six of the eight non-albicans species from the UK BMT recipients 
had high clinical loads of Candida (cfu/ml greater than 100) while the non-albicans 
isolate from the control subjects had low level of Candida colonization (Table 3.13).
Table 3.13 Non- albicans Candida colonization from the UK BMT 
recipients and the UK control subjects
BMT recipients Control subjects
Non-albicans Candida 6
0
cfu/ml > 100 (75%)
Non-albicans Candida 2 1
cfu/ml <100 (25%) (100%)
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3.2.6. Summary of comparisons of the frequency of oral Candida carriage,
load, C. albicans genotypes and the frequency of non-albicans 
Candida between BMT recipients from the UK, Italy, Greece and 
Brazil
3.2.6.1. Presence and load of oral Candida
There were no significant differences in Candida carriage ip = 0.23) nor 
Candida load (cfu/ml > 100) between the four groups of BMT recipients ip = 0.9) 
(Table 3.11).
3.2.6.2. Candida species in swills from four groups of BMT recipients
There were no statistically significant differences in Candida species isolated in 
four patient groups (p = 0.64). C. albicans was the most frequent species isolated in 
all four patient groups. Interestingly, C. dubliniensis was only isolated from the swills 
of the UK BMT recipients. Table 3.14 summarizes the frequency of Candida species 
and C. albicans genotypes in the recipients of BMT from the UK, Italy, Greece and 
Brazil. The load of non-albicans Candida (cfu/ml > 100) was not significantly 
different between the recipients of BMT from the four diverse regions ip = 0.2).
3.2.6.3. C. albicans genotypes from BMT recipients in four different
geographical regions
There were statistically significant differences in genotypic distribution of oral 
C. albicans between the four diverse countries ip = 0.041). C. albicans genotype A 
was the most commonly isolated genotype in the UK, Greece and Brazil, however in
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the swills from the Italian patients, C. albicans genotypes B and C were significantly 
more common than genotype A (Table 3.14).
Table 3.14 Non-albicans Candida species and C. albicans genotypes in oral 
swills from BMT recipients in the U K , Italy, Greece and Brazil
Candida species and 
genotypes of C. albicans
UK Italy Greece Brazil
Non-albicans Candida
8
(26.7%)
2
(1 1 .1 %)
2
(25%)
8
(2 1 .6 %)
C. dublinensis 1 0 0 0
C. tropicalis 3 0 1 1
C. glabrata 2 0 0 2
C. krusei 0 0 0 1
C. parapsilosis 1 2 1 2
C. pseudoparapsilosis 0 0 0 2
C. guillermondii 1 0 0 0
C. albicans
2 2
(73.3%)
16
(88.9%)
6
(75%)
29
(78.4%)
Genotype A 16 7 5 24
Genotype B 5 5 1 2
Genotype C 1 4 0 3
Total 30 18 8 37
3.2.7. Temporal variation in oral Candida in the UK and Greek BMT 
recipients
From the 118 mouth swills obtained from the UK BMT recipients, a total of 
64 (54.2%) oral Candida species were isolated. Fourteen patients from the UK 
provided single mouth swills while the remaining 42 provided more than one oral
190
samples as previously described (Section 3.2.2.2). Table 3.15 summaries the total 
number of mouth swills from consequent visits, the number of Candida carnage and 
the frequency of Candida species from subsequent mouth swills from the UK BMT 
recipients.
Table 3.15 Number of mouth swills, Candida isolates from subsequent mouth swills
from the UK BMT recipients
First
mouth
swills
Second
mouth
swills
Third
mouth
swills
Fourth
mouth
swills
Total
No of mouth swills 56 42 14 6 118
No of grown Candida 30* 2 1 8 5 64
No of C. albicans 2 2 14 3 2 41
No of C. albicans 
(genotype A)
16 1 2 2 2 32
No of C. albicans 
(genotypes B and C)
6 2 1 0 9
No of non- albicans 
Candida
8 7 5 3 23
* 2 mouth swills had 2 different Candida species each
The patients from Greece provided 37 mouth swills; twelve patients provided 
one sample while the remaining 10 provided 2 or 3 samples with an interval of four 
weeks or more between the samples. A total of 13 isolates were obtained from the 37 
mouth swills (35.1%) with only two patients had oral Candida from subsequent 
mouth swills (Table 3.16).
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Table 3.16 Number o f mouth swills and Candida isolates from the
Greek BMT recipients
First
mouth
swills
Second
mouth
swills
Third
mouth
swills
Total
No of mouth swills 22 10 5 37
No of grown Candida 8 4 1 13
No of C. albicans 6 2 0 8
No of non- albicans 2 2 1 5
There were no differences in the frequency of yeast growing ip = 0.8) nor in 
the frequency of isolation of diverse Candida species (p = 0.1) from subsequent 
sampling from the UK BMT recipients. Similarly, there were no differences in 
candidal carriage ip = 0.7) nor in the frequency of isolation of diverse Candida 
species ip = 0.2) from subsequent sampling from the Greek BMT recipients.
3.2.8. Candida species from subsequent mouth swills
Twenty of the fifty-six BMT recipients from the UK had more than one 
Candida isolate from subsequent mouth swills. Fifteen of the 20 UK BMT recipients 
(75%) had the same Candida species or C. albicans genotypes while the remaining 5 
(25%) patients had a change in their oral Candida from the second, third or fourth 
mouth rinse (Figure 3.1). The changes were from C. albicans to C. glabrata (n = 2) or 
C. dubliniensis (n = 2). The fifth patient had a shift from C. tropicalis to C. glabrata.
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The two patients from Greece who provided more than one sample grew 
different Candida species from subsequent sampling. The shift was from C. albicans 
to C. tropicalis while the other isolate was shifted from C. tropicalis to C. albicans.
Figure 3.1 Candida isolates from subsequent mouth swills 
from the UK BMT recipients
20 Patients with 
Candida isolates 
from subsequent
mouth swills
15 Patients 
retained the 
same Candida 
species
5 Patients had 
changed in oral 
Candida species
11C. albicans 4 Non -albicans 
Candida
4 C. albicans 
shifted to non- 
albicans Candida 
(2 C. dubliniensis 
and 2 C. glabrata)
1 Non-albicans 
Candida (C. 
tropicalis) shifted 
to another non- 
albicans (C. 
glabrata)
3.2.9. The effect of smoking upon Candida carriage in BMT recipients in
the UK and Greece
Seven of the 10 (70%) smokers from the UK BMT recipients grew oral 
Candida. Four of the 7 isolates had cfu/ml more than 100. In addition, 3 of the 7 
isolates were non-albicans Candida. None of the 4 smokers from the Greek BMT 
recipients grew any oral yeast. Furthermore, 3 of the 10 smokers from the healthy 
subjects (n = 60) grew yeast. There was no significant difference in the number of 
smokers between BMT recipients from the UK and Greece or between BMT 
recipients and control subjects ip > 0.05). Furthermore, Candida growth was not
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significantly different in tobacco smokers of the UK BMT recipients and control 
subjects (p = 0.07) (Table 3.17).
Table 3.17 Number of tobacco smokers and non smokers and Candida
species isolated from healthy subjects and BMT recipients
Patient
cohort Smokers
Non
smokers
Smokers
grew
Candida
Candida
species
Cfu/ml
>100
Healthy
subjects 1 0 50 3 3 a* 2
UK BMT 
recipients 1 0 46 7
4 a 
2 g* 
1 t*
4
Greek BMT 
recipients 4 18 0 - -
*a = C. albicans genotype A, *g = C. glabrata, *t = C. tropicalis
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3.3. Analysis of the strain relatedness of C. albicans isolates 
utilizing multiple PCR fingerprints
3.3.1. Candida albicans strains from the UK control subjects, UK BMT 
recipients and BMT recipients from diverse geographical regions
A total of 41 strains of C. albicans genotype A (n = 32) and genotypes B and 
C (n = 9) from subsequent sampling from the UK BMT recipients (Section 3.2.7) and 
51 strains of C. albicans genotype A (n = 43) and genotypes B and C (n = 8) from 
subjects attended a private dental clinic and patients attended oral medicine clinic as 
non-BMT recipients controls. The third group of C. albicans strains comprised strains 
from the Italian BMT recipients (n = 16), strains from the Greek BMT recipients (n = 
6) and strains from the Brazilian BMT recipients (n = 29).
PCR fingerprinting for strain delineation of C. albicans utilizing 5 
oligonucleotide primers was performed for all isolates as previously described 
(Section 2.2.6.2.4). However, some strains from the Italian, Greek and Brazilian BMT 
recipients failed to show any results of one or more of the primers, hence the total 
number of strains from this group comprised 27 strains of C. albicans genotype A 
and 12 strains of C. albicans genotypes B and C.
3.3.2. C. albicans from subsequent sampling from the UK BMT recipients 
(genetic variability of C. albicans with time)
From subsequent oral sampling, only 11 patients had C. albicans isolated in all 
occasions (Figure 3.1). Therefore, 25 strains of C. albicans were isolated from 11 
patients at various time intervals. For 9% (1/11) of these patients, the PCR fingerprint 
was identical using all PCR fingerprinting primers (Figure 3.2A). However, in 91%
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(10/11) of these patients, the PCR fingerprint of these consecutive isolates differed in 
one, or more than one, of the 5 experiments (Figure 3.2B).
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Figure 3.2 Representative PCR fingerprints for 16 C. albicans strains using two 
different primers: A shows PCR fingerprinting using the OPA-03 primer, while B 
shows PCR fingerprinting using the M l3 primer. Lanes marked M are the molecular 
weight markers. Strains from the same patient taken at different times are marked 
with the initial letter of the patient’s name. In Figure 3.2 A, strains in lanes 1, 2 and 4 
were taken from the same patient (J) with the left being the initial isolate, the second 
taken at 5.2 weeks, the third at 8.3 weeks; lanes 6 and 7 were taken from patient (P) 
initial and after 8.1 weeks; lanes marked 9 and 11 were from patient (C) with initial 
and week 10.2. In Figure 3.2B, strains in lanes 2, 11 and 15 were from patient (J); 
strains in lanes 13 and 16 were from patient (P); while strains from patient (C) were in 
lanes 12 and 14. As can be seen, strains in lanes marked P and C have identical PCR
fingerprints for both primers shown, while the PCR fingerprints in lanes marked J
differ significantly from each other 
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3.3.3. Comparison of genetic strain variability between BMT recipients and 
control subjects
Comparison were made between three groups: forty-one C. albicans strains 
from the UK BMT recipients, fifty-one C. albicans strains from the UK control 
subjects and 39 C. albicans strains from BMT recipients from Italy (n = 14), Greece 
(n = 5) and Brazil (n = 20) (combined as a non-UK BMT recipient group). As 
previously described (Section 2.2.6.2.4), each strain was given a designation that 
consisted of 17 digits. These digits were either 0 or 1, depending upon if the 
polymorphic band was either absent or present respectively. Genetic strain 
designation of the 51 strains from non-BMT subjects (controls), 41 strains from the 
UK BMT recipients and 39 strains from the BMT recipients from Italy, Greece and 
Brazil based on 17 polymorphic bands are listed in Tables 3.18, 3.19 and 3.20 
respectively.
Table 3.18 Genetic strain designation of the 51 strains from non-BMT subjects 
(controls) based on 17 polymorphic bands
Strain designation Oligonucleotide fingerprinting primer
Source of strain Genotype GAGA4 OPA-3 M13 Telol T3B
*C 1 A 100 11 001 0110 00001
C 2 A 111 01 001 0110 00000
C 3 A 000 01 001 0100 00000
C 4 A 110 01 001 0100 00011
C 5 A 110 01 111 0100 00000
C 6 A 110 01 111 0100 00011
C l A 110 01 111 0110 00011
C 8 B 110 01 001 0110 00011
C 9 A 110 01 111 0101 00011
C 10 A 010 01 001 0000 00000
C 11 A 110 01 001 0110 00001
C 12 A 100 00 001 0001 00000
C 13 B 110 11 111 0110 00001
C 14 A 110 11 111 0110 00001
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T able 3.18 Continued
Strain designation Oligonucleotide fingerprinting primer
Source of strain Genotype GAGA4 OPA-3 M13 Telol T3B
C 15 A 110 11 111 0110 00001
C 16 A 110 11 000 0110 00011
C 17 A 110 01 001 0110 00001
C 18 A 110 01 001 0110 00001
C 19 A 110 11 111 0110 00011
C 20 A 001 00 111 0001 00101
C 21 A 110 01 111 0110 00011
C 22 A 110 01 Oil 0110 00011
C 23 B 110 11 111 0110 00000
C 24 A 110 01 000 1010 00000
C 25 A 111 11 001 0110 00001
C 26 A Oil 01 111 0110 00000
C27 A 100 01 111 0110 00011
C 28 A 110 01 111 0110 00000
C29 B 000 01 000 0000 00000
C 30 A 000 01 000 0001 00000
C 31 A 110 01 001 0100 00111
C 32 A 000 01 001 0001 00000
C 33 B 110 01 111 0110 00000
C 34 A 110 01 100 1010 00001
C 35 A 110 01 111 0101 00001
C 36 A 110 10 111 0011 00001
C 37 A 110 01 001 0110 00000
C 38 A 110 01 001 0100 00000
C 39 A 111 01 111 0110 00000
C 40 A 111 11 111 0110 00000
C 41 C 111 11 111 0110 00000
C 42 A 110 11 111 0001 00000
C 43 A 110 01 111 0110 00000
C 44 A 111 01 111 0110 00000
C 45 B 110 01 001 0111 00000
C 46 A 111 00 001 0110 00100
C 47 A 111 11 001 0111 00000
C 48 A 111 01 111 0111 00000
C 49 A 111 01 111 0111 00000
C 50 A 110 01 111 0111 00000
C 51 B 111 01 111 0111 00000
*C = controls
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Table 3.19 Genetic strain designation of the 41 strains from the UK BMT recipients
based on 17 polymorphic bands
Strain designation Oligonucleotide fingerprinting primer
Source of strain Genotype GAGA4 OPA-3 M13 Telol T3B
UK 1 A 110 00 111 0010 01000
UK 2 A 010 10 001 0010 00001
UK 3 A 110 00 1 001 0010 01001
UK 4 B 110 01 000 0100 00100
UK 5 A 110 10 111 0000 01000
UK 6 A 100 01 111 0111 00100
UK 7 B 110 01 Oil 0110 11101
UK 8 B 110 01 111 0110 00100
UK 9 A 110 01 111 0110 11111
UK 10 A 110 01 111 0100 11111
UK 11 B 110 01 111 0110 11111
UK 12 A 110 01 111 0110 11111
UK 13 A 110 01 111 0110 11111
UK 14 A 110 01 111 0101 11111
UK 15 B 110 01 111 0110 11111
UK 16 A 110 11 111 0010 00000
UK 17 A 110 01 111 0011 10100
UK 18 A 110 10 111 0011 00001
UK 19 A 110 01 111 0100 11110
UK 20 B 110 01 111 0110 11111
UK 21 A 110 01 111 0110 11110
UK 22 B 110 01 111 0100 11110
UK 23 A 110 01 111 0110 11110
UK 24 A 110 01 111 0100 11111
UK 25 A 110 01 111 0110 11111
UK 26 A 111 01 111 0101 00000
UK 27 A 111 01 111 0100 11111
UK 28 A 110 01 111 0100 11110
UK 29 A 000 01 111 0010 10000
UK 30 B 100 01 111 0110 00001
UK 31 A 110 11 111 0110 00011
UK 32 A 110 01 111 0110 00001
UK 33 A 110 11 111 0100 00001
UK 34 A 110 11 111 0110 00001
UK 35 A 100 01 111 0101 00011
UK 36 C 110 11 111 0110 00001
UK 37 A 110 01 111 0101 00001
UK38 A 110 11 111 0101 00001
UK 39 A 110 01 111 0110 00001
UK 40 A 100 11 111 0110 00001
UK 41 A 110 01 111 0101 00001
UK = strain from the UK BMT recipients
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Table 3.20 Genetic strain designation o f the 39 strains from the Italian, Greek and
Brazilian BMT recipients based on 17 polymorphic bands
Strain designation Oligonucleotide fingerprinting primer
Source of strain Genotype GAGA4 OPA-3 M13 Telol T3B
♦IT 1 B 110 01 111 0101 00001
IT 2 B 110 11 111 0110 00001
IT 3 A 000 11 111 0001 00001
IT 4 A 000 11 111 0101 00011
IT 5 C 110 11 111 0110 00001
IT 6 B 110 11 111 0111 00011
IT 7 B 110 11 111 0111 00001
IT 8 B 110 11 111 0110 00001
IT 9 A 110 11 111 0101 00001
IT 10 C 110 11 111 0101 00001
IT 11 A 110 00 111 0010 00001
IT 12 A 110 11 111 0110 00001
IT 13 A 100 11 111 0110 00001
IT 14 A 000 11 Oil 0001 00101
*GR 1 A 110 01 Oil 1010 00001
GR 2 A 110 11 111 0110 00001
GR 3 B 110 11 111 0110 00001
GR 4 A 110 01 Oil 0110 00001
GR 5 A 110 11 111 0110 10001
*BR 1 A 111 11 Oil 0111 00000
BR 2 A 111 11 000 0011 00000
BR 3 A 111 11 111 0001 00000
BR 4 A 111 11 111 0011 00000
BR 5 A 111 00 111 1110 00000
BR 6 A 111 01 111 0010 00000
BR 7 A 111 01 001 0110 00000
BR 8 A 111 11 111 0011 00000
BR 9 A 111 01 111 0100 00000
BR 10 C 111 01 001 0110 00000
BR 11 A 111 01 111 0110 00000
BR 12 C 111 01 111 0111 00000
BR 13 A 111 11 001 0111 00000
BR 14 A 111 11 001 0111 00000
BR 15 A 111 01 111 0010 00000
BR 16 B 111 01 111 0010 00000
BR 17 A 111 01 001 0111 00000
BR 18 A 111 01 111 0111 00000
BR 19 A 111 01 111 0000 00000
BR 20 C 111 00 111 0010 00000
*IT = Italian strain, *GR = Greek strain, *BR = Brazilian strain
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The number of differences in the bands between strains was measured. As an 
example, Table 3.21 shows the differences in banding between 8 randomly selected 
isolates.
Table 3.21 Number of differences between 8 randomly selected strains for genetic 
strain designation as generated by the 17 polymorphic bands chosen from the 5 PCR
fingerprinting primers
A B C D E F G H
A -
B 9 -
C 9 0 -
D 10 1 1 -
E 9 4 4 3 -
F 6 3 3 4 3 -
G 6 3 3 4 3 0 -
H 10 1 1 0 3 4 4 -
Statistical analysis of these PCR fingerprint banding pattern differences (Table 
3.22) showed that there was an average of 5.31 differences between all strains, and 
that genotypes B and C of C. albicans were significantly more genetically coherent 
group than that of genotype A of all C. albicans strains {p < 0.0001). Moreover, 
strains from non-UK BMT recipients were the most genetically cohesive group with a 
mean difference of only 4.58 bands, while the strains from the control subjects had 
4.91 of mean differences and the strains from the UK BMT recipients had 
significantly more genetic diversity with a mean number of differences between 
strains of 5.06 (p < 0.0001; Table 3.22).
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Table 3.22 Statistical analysis of the PCR fingerprint banding pattern. N is the 
number of comparisons made between the strains resulting in the given mean
differences for each groups
Variable
Number 
of strains
N Mean (SD) p  value
All strains 131 11026 5.31 (2.35)
Genotype A 102 6786 5.51 (2.32) <0.0001#
Genotypes B and C 29 496 4.45 (2.41)
Strains from the UK
controls (non-BMT 51 1485 4.91 (2.31)
recipients)
Strains from the UK 
BMT recipients
41 820 5.06 (2.48)
<0.0001*
Strains from Italian,
Greek and Brazilian 39 1378 4.58 (2.16)
BMT recipients
# = t-test, * = ANOVA SD = standard deviation
Phylogenetic analysis of these isolates was graphically depicted by a 
phylogram, as shown in Figure 3.3. The distance shown at the bottom of this 
phylogram of 0.1 is the distance within which strains are 90% similar. The 131 C. 
albicans strains studied can thus be grouped and sub-grouped based on this 
phylogenetic analysis. Table 3.23 shows that these isolates can be divided into seven 
large genotypic groups (A to G) that are co-located on the phylogram (Figure 3.3) and 
are more than 85% genotypically similar, while the further 20 genotypic sub-groups 
(A1-A3, B1-B8, C1-C2, D, E, F1-F3 and G1-G2) are co-located and greater than 90% 
similar (Table 3.23).
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Figure 3.3 A First part (of two) of the phylogram of the 131 strains of C. albicans 
based on the analysis of the PCR fingerprinting results. Horizontal lines are shown to 
the right of which strains are 85% and 90% similar, vertical lines and designation 
shown on the right margin are based on these levels of similarity and are listed in
Table 3.23
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Figure 3.3 B Second part (of two) of the phylogram of the 131 C. albicans strains 
based on the analysis of the PCR fingerprinting results. Horizontal lines are shown to 
the right of which strains are 85% and 90% similar, vertical lines and designation 
shown on the right margin are based on these levels of similarity and are listed in
Table 3.23.
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Table 3.23 Genotypic distribution of 131 strains based on the phylogenetic analysis 
of the PCR fingerprinting results. The seven large genotypic groups (A to G) are 
strains that are co-located on the phylogram (Figure 3.3) and are more than 85% 
genotypically similar, while the further 20 genotypic subgroups (A1-A3, B1-B8, C l- 
C2, D, E, F1-F3 and G1-G2) are co-located and greater than 90% similar (Figure 3.3). 
The letters in the isolate designation indicate the source of the isolate: UK: UK BMT 
recipients, GR: Greek BMT recipients, IT: Italian BMT recipients, BR: Brazilian
BMT recipients and C: controls (non-BMT subjects)
Genotype
Group Isolate designation
A1 UK 1, UK 5
A2 ITll, IT3, UK18, C36
A3 UK 2, UK3
B1 UK 4
B2 C46
B3 GR 4, C18, Cl 1,C17, BR17, C2, BR7, BRIO, C45, C37, C38, Cl, C25
B4 C l6, C31, C4, C8
B5 BR2, BR1, C47, BR13, BR14
B6 BR5, C5, UK8, C43, C28, C33, UK16, C23, C40, C41, BR19, UK26, BR9, 
C26,BR20, BR16, BR6, BR15, C44, BR11,C39, C50, C51, C49, C48, BR12, 
BR18
B7 C42, BR3, BR4, BR8
B8 UK30, UK32, UK31, GR5, UK33, C14, C13, GR3, GR2, IT12, IT8, IT5, 
IT2, UK34, UK36, UK40, IT13, UK31, C15, C19 , IT6, IT7, C27, 
C22,C6, C7, C21, UK35, C9, C35, IT1, UK37, UK41, IT10, UK38, IT9
Cl UK29
C2 UK6, UK 17
D GR1, C24, C34
r; UK7,UK27,UK14,UK25,UK20,UK15,UK13,UK12,UK9,UK11,UK10, UK24,c
UK28, UK 19, UK22, UK21, UK23
FI C20
F2 IT4
F3 IT14
G1 C12
G2 C3, CIO, C32, C29, C30
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3.4. Analysis of virulence attributes of Candida species from 
BMT recipients from different geographical areas
A total of 30 Candida isolates from the initial sampling of the UK BMT 
recipients and 25 isolates from the UK control subjects (isolates from a private dental 
clinic subjects and oral medicine clinic subjects with non-mucosal disease) were 
recovered from stock solution (LB broth) (Section 2.2.5). A further of 8, 18 and 37 
Candida isolates from the Greek, Italian and Brazilian BMT recipients respectively 
were recovered to examine the extracellular proteinase activity and the in-vitro 
adhesion of these isolates. To study the virulence attributes of Candida species from 
the same patients with time, Candida isolates from subsequent sampling from the 20 
UK and 2 Greek BMT recipients were also included in the present assays. Therefore, 
the total number of isolates from the 20 UK BMT recipients and 2 Greek BMT 
recipients who had more than one isolates was 48 and 5 Candida isolates respectively.
In the initial studies, 30 isolates from the first oral rinse of the UK BMT 
recipients were included together with 8 isolates from the first oral rinse of the Greek 
BMT recipients. All isolates of the Italian and Brazilian patients were included in the 
initial analysis.
3.4.1. Proteinase production and adhesion of all examined oral Candida
isolates
As previously described (Section 2.2.7.3), the mean, median and standard 
deviation (SD) for the in-vitro adhesion and proteinase activity were calculated for all
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examined isolates. Table 3.24 provides a summary of proteolytic enzyme activity and 
the in-vitro adhesion of the initial Candida isolates from the UK BMT recipients and 
control subjects, while Table 3.25 provides details of all isolates from BMT recipients 
from the four geographic regions.
Table 3.24 Summary of proteinase activity and the in-vitro adhesion of Candida 
isolates from the UK BMT recipients and control subjects
Mean Median SD
Proteinase activity (U / ml) 0.410 0.349 0.247
Adhesion (cells / bead) 76.6 33.9 97.6
Table 3.25 Summary of proteinase activity and in-vitro adhesion of Candida 
isolates from the UK, Italian, Greek and Brazilian BMT recipients
Mean Median SD
Proteinase activity (U / ml) 0.353 0.329 0.200
Adhesion (cells / bead) 95.5 36.5 143.4
All of the isolates were then divided into two groups according to the median 
of the in-vitro adhesion and proteolytic enzyme activity. Hence, when the reading was 
equal or above the median reading, it was considered that particular isolate had 
enhanced adhesion or proteolytic enzyme activity.
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3.4.2. Proteolytic enzyme activity of Candida isolates from the UK BMT
recipients and control subjects
There was no significant difference (p = 0.49) in proteinase activity of oral 
Candida isolates from the UK BMT recipients (14/30; 46.7%) and UK control 
subjects (14/25; 56%). The mean, median and standard deviation (SD) of proteinase 
activity are summarised in Table 3.26.
Table 3.26 Summary of proteinase activity of Candida isolates from the 
UK BMT recipients and control subjects
Source of isolates
No of 
isolates
Mean Median SD
UK BMT recipients 30 0.3888 0.3345 0.2335
Control subjects 25 0.4358 0.3555 0.2658
Furthermore, high proteinase activity from the UK BMT recipients and control 
subjects had no influence upon Candida colonization (cfu/ml > 100), in-vitro 
adhesion nor enhanced in-vitro resistance to fluconazole (Section 3.5) ip > 0.05).
3.4.3. Proteolytic enzyme activity of Candida isolates from BMT recipients 
from the UK, Italy, Greece and Brazil
There were significant differences in the proteolytic enzyme activity of 
isolates from BMT recipients from the four geographically diverse regions (p = 
0.001). Candida isolates from the Brazilian BMT recipients produced significantly 
low levels of proteinase. The mean, median and standard deviation (SD) of proteinase 
activity of Candida species are summarised in Table 3.27.
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Table 3.27 Summary o f proteinase activity o f Candida isolates from
BMT recipients from the UK, Italy, Greece and Brazil
Country of BMT 
recipients
No of 
isolates
Mean Median SD
UK 30 0.3888 0.3345 0.2335
Italy 18 0.4033 0.4165 0.1397
Greece 8 0.4795 0.4727 0.1548
Brazil 37 0.2711 0.2453 0.1821
The high proteinase activity of Candida isolates of BMT recipients from the 
UK, Italy, Greece and Brazil did not influence Candida colonization (cfu/ml >100), 
in-vitro adhesion nor enhanced in-vitro resistance to fluconazole (Section 3.5) (p > 
0.05).
3.4.4. In-vitro adhesion of isolates from the UK BMT recipients and control 
subjects
Utilizing the present in-vitro measurement of adherence, oral Candida isolates 
from the BMT recipients (12/30; 40%) were less adherent than isolates obtained from 
the control subjects (16/25; 64%) but the difference was not statistically significant (p 
= 0.076). The mean, median and standard deviation (SD) of the in-vitro adhesion are 
summarised in Table 3.28.
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Table 3.28 Summary o f the in-vitro adhesion o f Candida isolates from
the UK BMT recipients and control subjects
Source of isolates
No of 
isolates
Mean Median SD
UK BMT recipients 30 73.4 22.1 115.5
Control subjects 25 80.4 65.6 72.6
Candida isolates that showed enhanced in-vitro adhesion from the UK BMT 
patients (11/12; 97%) colonized to a greater extent in the mouth than isolates from the 
control subjects (8/16; 50%) (p = 0.024). Furthermore, the isolates from BMT 
recipients with increased adhesion had a trend of enhanced resistance to fluconazole 
(8/12; 66.7%) (Section 3.5) than similar isolates from the control subjects (5/16; 
31.3%) (p = 0.063). However, enhanced in-vitro adhesion did not seem to be 
associated with proteinase activity of Candida isolates from both BMT recipients and 
control subjects {p > 0.05).
3.4.5. In-vitro adhesion of isolates from BMT recipients from the UK, Italy, 
Greece and Brazil
There was no significant difference in the in-vitro adhesion of Candida 
isolates of BMT recipients from the UK, Italy, Greece and Brazil (p = 0.3). The mean, 
median and standard deviation (SD) of the in-vitro adhesion are summarised in Table 
3.29.
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Table 3.29 Summary o f the in-vitro adhesion o f Candida isolates from
BMT recipients from the UK, Italy, Greece and Brazil
Country of BMT 
recipients
No of 
isolates
Mean Median SD
UK 30 73.4 22.1 115.5
Italy 18 101.4 34.3 168.5
Greece 8 72.9 29.3 113.1
Brazil 37 115.5 66.7 158.1
The isolates with enhanced in-vitro adhesion from all BMT recipients had no 
significant differences in proteinase activity (p = 0.3). However, these isolates showed 
significant differences in susceptibility to fluconazole (Section 3.5) from the UK 
(8/12; 66.7%), Italy (2/9; 22.2%), Greece (0/3; 0%) and Brazil (6/23; 26.1%) (p = 
0.012). Candida isolates from the UK BMT recipients with enhanced in-vitro 
adhesion were significantly more resistant to fluconazole.
A total of sixty three Candida isolates from BMT recipients from four diverse 
regions (n = 47) and UK control subjects (n = 16) showed enhanced levels of 
adhesion. Of the 63 isolates, 43 were found to be colonized in the oral cavity at high 
levels (cfu / ml > 100) and 20 isolates at low levels (cfu / ml < 100) but there was no 
significant difference in oral Candida colonization from the isolates that showed 
enhanced in-vitro adhesion from all BMT recipients (p > 0.05). Interestingly, 74.5% 
(35/47) of the isolates from the BMT recipients that exhibited high in-vitro adhesion 
were isolated from the oral cavity at high levels of oral colonization, whereas in the
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control patients these isolates were equally distributed between subjects with high and 
low levels of colonization (50%, 8/16) (p = 0.069) (Table 3.30).
Table 3.30 Enhanced in-vitro adhesion of Candida isolates colonized in the 
mouth from all BMT recipients and control subjects
Candida isolates UK Italian Greek Brazilian Control Total
Enhanced adhesion 
(cfu / ml > 1 0 0 )
1 1 7 3 14 8 43
Enhanced adhesion 
(cfu / ml < 1 0 0 )
1 2 0 9 8 2 0
3.4.6. Comparison of virulence attributes of G albicans and non-albicans
isolates in BMT recipients and control subjects (combined)
There were no differences in proteinase activity nor in-vitro adhesion between 
Candida albicans (25/46) and non-albicans Candida isolates (3/9) from both BMT 
recipients and the control subjects (p > 0.05) (Table 3.31). In addition, there were no 
differences in proteinase activity nor in-vitro adherence between C. albicans and C. 
dubliniensis from BMT recipients and the control subjects (p > 0.05) (Table 3.32).
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Table 3.31 Comparison o f proteinase activity and in-vitro adhesion o f C. albicans
and non-albicans isolates from the UK BMT recipients and control subjects
Candida
species
No of 
isolates
Proteinase activity In-vitro adherence
Mean Median SD Mean Median SD
C. albicans 46 0.4307 0.3558 0.2578 74.3 40.2 85.5
Non-
albicans
Candida
9 0.3053 0.2998 0.1579 88.3 2 1 151.7
Table 3.32 Comparison of proteinase activity and in-vitro adhesion of C. albicans 
and C. dubliniensis isolates from the UK BMT recipients and control subjects
Candida
species
No of 
isolates
Proteinase activity In-vitro adherence
Mean Median SD Mean Median SD
C. albicans 46 0.4307 0.3558 0.2578 74.3 40.2 85.5
C.
dubliniensis
2 0.3668 0.3668 0.0948 3 3 1.2
Furthermore, there were no differences in proteinase activity or in-vitro 
adherence between Candida albicans genotypes (A, B or C) in the UK BMT 
recipients and the control subjects (p > 0.05) (Table 3.33).
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Table 3.33 Comparison o f proteinase activity and in-vitro adhesion of C. albicans
genotypes from the mouth of BMT recipients and the control subjects
C. albicans 
genotype
No of 
isolates
Proteinase activity In-vitro adherence
Mean Median SD Mean Median SD
A 38 0.4499 0.3581 0.2575 77.8 46.3 90.5
B and C 8 0.3389 0.2202 0.2551 57.6 35.2 56.9
3.4.7. Comparison of virulence attributes of Candida albicans versus non-
albicans isolates from BMT recipients in different geographical regions
When all Candida isolates from BMT recipients from the UK, Italy, Greece and 
Brazil were combined, there were no differences in proteinase activity ip = 0.3) or in- 
vitro adherence (p = 0.7) between C. albicans and non-albicans Candida (Table 
3.34). Likewise, there were no significant differences in proteinase activity (p = 0.7) 
or in-vitro adherence ip = 0.5) between genotypes of C. albicans isolates collected 
from the mouth of all BMT recipients (Table 3.35).
Table 3.34 Comparison of proteinase activity and in-vitro adherence of C. albicans 
and non-albicans isolates from BMT recipients from four geographical regions
Candida
species
No of 
isolates
Proteinase activity In-vitro adherence
Mean Median SD Mean Median SD
C. alnicans 73 0.3661 0.3322 0.1960 88.4 30.6 128
Non-albicans 
Candida
20 0.3035 0.2793 0.2186 121.4 37.8 191.5
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Table 3.35 Comparison o f proteinase activity and in-vitro adherence o f C. albicans
genotypes (A, B or C) o f BMT recipients from the four geographical regions
C. albicans 
genotype
No of 
isolates
Proteinase activity In-vitro adherence
Mean Median SD Mean Median SD
A 52 0.3804 0.3322 0.208 96.9 45.4 139.9
B and C 2 1 0.3306 0.3322 0.1615 67.6 2 1 . 8 92.1
3.4.8. Change in the virulence attributes of Candida species with time
As discussed previously (Section 3.2.8) more than one isolate was obtained 
from 20 of the 56 UK BMT recipients (n = 48 isolates) and 2 of the 22 Greek BMT 
recipients (n = 5 isolates) at different times. Proteinase activity of Candida species 
was increased in 50% of the isolates from the UK and Greek BMT recipients (Table 
3.36). Furthermore, 50% of these isolates changed (increased or decreased) in 
adherence with time (Table 3.37). Figure 3.4 represents the percentage of changes in 
the virulence attributes of the isolates from the UK and Greek BMT recipients.
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Table 3.36 Change in proteinase activity of Candida isolates from BMT recipients
from the UK and Greece with time
Source of patients / isolates
Total
number
of
patients/
isolates
Proteinase activity
Enhanced 
proteinase 
activity with 
time
No change 
in
proteinase 
activity 
with time
Decreased 
proteinase 
activity 
with time
No of the UK BMT 
recipients
20 10 6 4
No of subsequent isolates 
from the UK BMT recipients
48 24 15 9
No of Greek BMT recipients 2 1 1 -
No of subsequent isolates 
from the Greek BMT 
recipients
5 3 2 -
Table 3.37 Change in the in-vitro adherence of Candida isolates from BMT 
recipients from the UK and Greece with time
Total
number
of
patients/
isolates
In-vitro adherence
Source of patients / isolates Enhanced 
adherence 
with time
No change 
in the 
adherence 
with time
Decreased 
adherence 
with time
No of the UK BMT recipients 20 4 10 6
No of the subsequent isolates 
from the UK BMT recipients
48 9 24 15
No of Greek BMT recipients 2 1 1 -
No of the subsequent isolates 
from the Greek BMT recipients
5 2 3 -
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Figure 3 .4 The percentage of the temporal effect in proteinase activity and in-vitro 
adhesion of oral Candida isolates in the UK and Greek BMT recipients
% of the 
examined 
isolates
Proteinase activity In-vitro adhesion 
Changes in the virulence attributes with time
□  Enhanced 
with time
I Not 
changed
with time
□  Decreased
with time
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3.5. Fluconazole resistance in oral Candida isolates from bone 
marrow transplant recipients
The isolates examined in the present assay were the same as those utilized in 
Section 3.4. Therefore, isolates from the UK BMT recipients and the control subjects 
comprised 30 and 25 Candida species respectively. Isolates from BMT recipients 
from the other geographical regions comprised 8 isolates from Greece, 18 isolates 
from Italy and 37 isolates from Brazil. All of the examined isolates were obtained 
from the first or only mouth rinse. To assess the effect of time upon fluconazole 
resistance, Candida isolates from subsequent sampling from the UK (n = 20) and 
Greek (n = 2) BMT recipients were assessed. Therefore, the total number of isolates 
from the UK and Greek BMT recipients who had more than one isolates was 48 and 5 
isolates respectively.
3.5.1. Fluconazole resistance of all oral Candida isolates from the UK BMT
recipients and the control subjects
Based upon the minimal inhibitory concentration (MIC), the oral Candida 
isolates from the initial isolates o f the UK BMT recipients showed significantly 
greater resistance to fluconazole (16/30) (p = 0.027) than isolates from the control 
subjects (6/25) (Figure 3.5).
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Figure 3.5 Percentage o f isolates showing enhanced resistance to
fluconazole from the BMT recipients and control subjects
% of isolates 
with enhanced 
resistance to 
fluconazole
10
UK BMT recepients Control subjects
Source of isolates
3.5.2. Comparison of fluconazole susceptibility of non-albicans Candida from
the UK BMT recipients and control subjects
Seven of the eight non-albicans Candida isolates from the UK BMT recipients 
showed enhanced resistance to fluconazole. These isolates were C. tropicalis (n = 3), 
C. glabrata (n = 2), C. parapsilosis (n = 1) and C. dubliniensis (n = 1). The only non- 
albicans Candida from the UK BMT recipients that showed susceptibility to 
fluconazole was C. guillermondii. C. dubliniensis (the only non -albicans Candida 
species) from the control subjects was susceptible to fluconazole (Table 3.38). 
Although the number o f isolates was very small, there was a large difference observed 
in fluconazole resistance of the non-albicans Candida between the isolates from the 
BMT recipients (7 of the 8 showed enhanced resistance) and the corresponding isolate 
from the control subjects (only one isolate and this was susceptible) (Table 3.38).
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Table 3.38 Fluconazole susceptibility o f non-albicans Candida
from the UK BMT recipients and control subjects
Susceptibility of non- 
albicans Candida to 
fluconazole
No of isolates 
from the UK 
BMT recipients
No of isolates 
from the UK 
control subjects
Total
Enhanced resistance to 7
0
7
fluconazole (87.5%) (77.8%)
1 1 2
Susceptible to fluconazole
(12.5%) (100%) (22.2%)
3.5.3. Comparison of fluconazole susceptibility of G albicans genotypes from
the UK BMT recipients and control subjects
There were no differences in C. albicans genotype A in susceptibility to 
fluconazole between isolates from the UK BMT recipients (5/16) and isolates from 
the control subjects (6/22) (p = 0.8). However, of note, while three of the 6 C. 
albicans genotypes B and C from the UK BMT recipients showed enhanced resistant 
to fluconazole, this did not occur in genotype B isolates from the control subjects 
(Table 3.39).
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Table 3.39 Fluconazole susceptibility o f C. albicans genotypes B and C
from the UK BMT recipients and control subjects
C. albicans Isolates from the Isolates from the Total
genotypes B and C UK BMT recipients control subjects
Enhanced resistance 3
0
3
to fluconazole (50%) (37.5%)
Susceptible to 3 2 5
fluconazole (50%) (100%) (62.5%)
3.5.4. Comparison of fluconazole susceptibility of C. albicans with non-albicans
isolates from both the UK BMT recipients and control subjects
Isolates of C. albicans from the mouth of both UK BMT recipients and control 
subjects were significantly more susceptible to fluconazole (30/46) {p = 0.017) in 
comparison with non-albicans Candida (2/9). Fluconazole susceptibility occurred in 
one of the two C. dubliniensis isolates while this only occurred in one of the seven 
non-albicans Candida isolates (Table 3.40).
Table 3.40 Susceptibility of C. dubliniensis to fluconazole in comparison with non- 
albicans Candida species from the UK BMT recipients and control subjects
Isolates from the UK 
BMT recipients and 
control subjects
C. dubliniensis
Other non- 
albicans 
Candida species
Total
Enhanced resistance to 1 6 7
fluconazole (50%) (85.7%) (77.8%)
Susceptible to 1 1 2
fluconazole (50%) (14.3%) (22.2%)
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3.5.5. Virulence attributes of oral Candida showing enhanced resistance to
fluconazole from the UK BMT recipients and control subjects
There were no statistically significant differences in Candida colonization (p = 
0.9), in-vitro adhesion {p = 0.5) nor production of extracellular proteinase (p = 0.6) 
between isolates that showed enhanced resistance to fluconazole from the UK BMT 
recipients compared with similar isolates from the control subjects.
3.5.6. Fluconazole resistance of oral Candida isolates from BMT recipients in
the UK, Italy, Greece and Brazil
There were statistically significant differences in the frequency of enhanced 
resistance to fluconazole of isolates from the UK (16/30), Italian (3/18), Greek (1/8) 
and Brazilian (8/37) BMT recipients (p = 0.009) (Table 3.41). Isolates from the UK 
BMT recipients with enhanced resistance to fluconazole was significantly greater than 
appropriate isolates from the other geographical regions (Figure 3.6).
Table 3.41 Fluconazole susceptibility of the isolates from BMT recipients from the
UK, Italy, Greece and Brazil
Candida isolates UK Italy Greece Brazil Total
No of isolates with 
enhanced resistance 
to fluconazole
16 
(53.3 %)
3
(16.7%)
1
(12.5%)
8
(21.6%)
28
(30.1%)
No of isolates 
susceptible to 
fluconazole
14
(46.7%)
15
(83.3%)
7
(87.5%)
29
(78.4%)
65
(69.9%)
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Figure 3.6 Percentage o f oral Candida isolates with enhanced resistance to
fluconazole in BMT recipients from four geographically diverse regions
6 0 !
% of C an dida  40 
isolates with 
enhanced ^0 
resistance to 
flucoconazole
Italy BrazilUK Greece
Source of the isolates
3.5.7. Comparison of fluconazole susceptibility of non-albicans Candida of
BMT recipients from the UK, Italy, Greece and Brazil
Non -albicans Candida isolates with enhanced resistance to fluconazole of 
BMT recipients from the UK (7/8), Italy (2/2), Greece (0/2) and Brazil (4/8) did not 
show significant difference in fluconazole susceptibility {p > 0.05).
3.5.8. Fluconazole susceptibility of C  albicans between BMT recipients
from the UK, Italy, Greece and Brazil
C. albicans isolates from the UK BMT recipients (9/22; 41.4 %) were 
statistically less susceptible to fluconazole than the isolates from Italy (1/16; 6.3%), 
Greece (1/6; 16.7%) and Brazil (4/29; 13.8%) (p = 0.036). All C. albicans genotypes 
B and C from Italy (9/9), Greece (1/1) and Brazil (5/5) were susceptible to
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fluconazole in-vitro while only half of C. albicans genotypes B and C from the UK 
BMT recipients (3/6) were susceptible to fluconazole (p = 0.041) (Table 3.42). There 
were no differences in C. albicans genotype A in susceptibility to fluconazole 
between isolates of BMT recipients from the four diverse regions (p = 0.37).
Table 3.42 Fluconazole susceptibility of C. albicans genotypes B and C in BMT 
recipients from the UK, Italy, Greece and Brazil
C. albicans genotypes 
B and C
UK Italy Greece Brazil Total
No of isolates with 
enhanced resistance to 
fluconazole
3
(50%)
0 0 0
3
(14.3%)
No of isolates 
susceptible to 
fluconazole
3
(50%)
9
(100%)
1
(100%)
5
(100%)
18
(85.7%)
3.5.9. Comparison of fluconazole susceptibility of all C. albicans with non- 
albicans isolates from BMT recipients from the UK, Italy, Greece and 
Brazil
The frequency of C. albicans isolates from all BMT recipients (combined) was 
significantly more susceptible to fluconazole (58/73; 79.5%) than the non-albicans 
Candida from the same patients’ groups (7/20; 35%) (p = 0.001) (Table 3.43).
225
Table 3.43 Fluconazole susceptibility o f all C. albicans and non-albicans Candida
from all BMT recipients
Candida isolates from all 
BMT recipients
C. albicans
Non-albicans
Candida
Total
Enhanced resistance to 15 13 28
fluconazole (20.5%) (65%) (30.1%)
58 7 65
Susceptible to fluconazole
(79.5%) (35%) (69.9%)
3.5.10. Virulence attributes of oral Candida that showed enhanced resistance
to fluconazole from BMT recipients from the UK, Italy, Greece and 
Brazil
There were no statistically significant differences in Candida colonization, in- 
vitro adhesion nor extracellular proteinase activity ip > 0.5) between isolates that 
showed enhanced resistant to fluconazole from BMT recipients from the four 
geographically diverse regions when compared to the isolates that were susceptible to 
fluconazole.
3.5.11. Influence of current or past antifungal therapy upon fluconazole 
resistance in BMT recipients
The total number of oral Candida present in the mouths of BMT recipients 
(UK 10/30 (33.3%), Italy 3/18 (16.7%), Greece 4/8 (50%) and Brazil 4/37 (10.8%)) 
while receiving antifungal treatment at the time of oral sampling, or had received such 
therapy in the past six months, were significantly different (p = 0.033) (Table 3.44).
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Furthermore, seven of the ten (70%) Candida isolates who were receiving 
antifungal therapy from the UK BMT recipients showed statistically enhanced 
resistance to fluconazole (p = 0.008) when compared with similar isolates from Italy 
(0/3), Greece (1/4; 25%) and Brazil (1/4; 25%) (Table 3.44) (Figure 3.7).
Table 3.44 Enhanced resistance to fluconazole of Candida isolates while receiving 
antifungal therapy from BMT recipients from the UK, Italy, Greece and Brazil
Source of 
isolates
Total 
number 
of isolates
Candida isolates 
in patients 
received 
antifungal 
therapy
Candida isolates in patients 
received antifungal therapy 
and showed enhanced 
resistance to fluconazole
UK 30 10 (33.3 %) 7/10 (70%)
Italy 18 3 (16.7%) 0/3 (0%)
Greece 8 4 (50%) 1/4 (25%)
Brazil 37 4 (10.8%) 1/4 (25%)
227
Figure 3.7 Enhanced resistance to fluconazole of oral isolates in patients received
antifungal therapy from BMT recipients in the UK, Italy, Greece and Brazil
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3.5.12. Influence of antifungal therapy in Candida diversity from the UK
and Greek BMT recipients
As previously described in Sections 2.1.3.1 and 2.1.3.2, details of antifungal 
therapy were obtained only from the UK and Greek BMT recipients. This section 
assessed the effect of antifungal therapy upon the growth of non -albicans Candida in 
the oral cavities of the UK and Greek BMT recipients. From the ten Candida isolates, 
6 were C. albicans and the remaining 4 were non-albicans species obtained from 9 
UK BMT recipients who were on antifungal therapy or were recently received such 
therapy. Furthermore, from the 4 Greek BMT recipients who grew oral Candida and 
were on antifungal therapy, 3 of these isolates were C. albicans while the remaining 
one was non -albicans Candida. There were no direct association between receiving 
antifungal therapy and the growth of non -albicans Candida from the UK (4/10; 40%) 
and Greek (1/4; 25%) BMT recipients ip > 0.05) as summarised in Tables 3.45 and 
3 .46 respectively. In addition, 5 of the 9 (55 .6%) UK BMT recipients and all 4 Greek 
BMT recipients were receiving azole therapy when Candida developed.
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Table 3.45 The influence o f antifungal therapy upon Candida diversity from
the UK BMT recipients
56 BMT recipients (UK)
28 patients grew oral Candida 28 patients did not grow oral Candida
9 patients were 
receiving antifungal 
therapy 0
(2 fluconazole
3 itraconazole
4 polynes)
19 patients were not 
receiving antifungal 
therapy 0
13 patients were 
receiving 
antifungal 
therapy
(4 fluconazole
4 itraconazole
5 polynes)
15 patients were 
not receiving 
antifungal 
therapy
6 C. albicans 16 C. albicans
4 Non-albicans 
Candida
4 Non-albicans 
Candida
0: One patient had 2 different oral Candida species
Table 3.46 The influence of antifungal therapy upon Candida diversity 
from the Greek BMT recipients
22 BMT recipients (Greece)
8  patients grew oral Candida 14 patients did not grow oral Candida
4 patients were 
receiving 
antifungal 
therapy
4 patients were not 
receiving 
antifungal therapy
7 patients were 
receiving 
antifungal therapy
7 patients were not 
receiving 
antifungal therapy
2 fluconazole 
2 itraconazole
-
5 fluconazole 
2 itraconazole
3 C. albicans
1 Non-albicans 
Candida
3 C. albicans
1 Non-albicans 
Candida
-
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3.5.13. Temporal effect of subsequent sampling on fluconazole susceptibility
and Candida diversity
Twenty of the UK BMT recipients and 2 of the Greek BMT recipients had 
Candida isolated from their mouths on more than one occasion (48 and 5 isolates 
from the UK and Greek BMT recipients respectively). Eight of the 20 patients from 
the UK had oral Candida showed enhanced resistance to fluconazole, 4 patients had 
isolates retained their susceptibility to fluconazole while the remaining 8 patients had 
oral Candida showed decreased susceptibility to fluconazole from subsequent 
sampling. The temporal effect upon fluconazole susceptibility and Candida species 
diversity from the UK recipients is summarised in Table 3.47.
Table 3.47 The temporal effect of subsequent sampling upon fluconazole 
susceptibility and Candida species diversity from the UK BMT recipients
Fluconazole
susceptibility
Number 
of BMT 
recipients
No of patients 
retained the same 
species from 
subsequent 
sampling
No of patients had 
Candida isolates shifted 
to different species from 
subsequent sampling
Enhanced 
resistance to 
fluconazole 
with time
8
4 C. albicans 
1 C. glabrata
1 C. albicans shifted to
C. dubliniensis
2 C. albicans shifted to
C. glabrata
No change in 
fluconazole 
susceptibility 
with time
4 3 C. albicans 
1 C. glabrata
-
Increased 
susceptibility to 
fluconazole 
with time
8
4 C. albicans 
1 C. glabrata 
1 C. tropicalis
1 C. albicans shifted to 
C. dubliniensis 
1 G albicans shifted to 
C. glabrata
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One of the 2 patients from Greece, who had subsequent sampling, had oral 
Candida showed enhanced resistance to fluconazole while the other patient had oral 
Candida retained fluconazole susceptibility with time. The isolate that showed 
enhanced resistance to fluconazole was shifted from C. albicans to C. tropicalis as 
shown in Table 3.48. Therefore, there was no association between subsequent 
sampling (time) upon fluconazole susceptibility nor development of non-albicans 
Candida (p > 0.05). The temporal effect upon fluconazole susceptibility and Candida 
species diversity from the Greek BMT recipients is summarised in Table 3.48.
Table 3.48 The temporal effect of subsequent sampling upon fluconazole 
susceptibility and Candida species diversity from the Greek BMT recipients
Fluconazole
susceptibility
Number 
of BMT 
recipients
No of patients 
retained the 
same species 
from subsequent 
sampling
No of patients had 
Candida isolates shifted 
to different species from 
subsequent sampling
Enhanced 
resistance to 
fluconazole with 
time
1 -
1 C. albicans shifted to 
C. tropicalis
No change in 
fluconazole 
susceptibility 
with time
1 - 1 C. tropicalis shifted to C. albicans
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3.6. Application of RT-PCR to study the differential expression of
Agglutinin-like sequence (ALS) and secreted aspartyl 
proteinase (SAP) genes in different growing media
As previously described (Section 2.2.10.1), fourteen isolates of C. albicans 
were grown in 4 media to assess the expressions of ALS and SAP gene families in 
different media. However, the elongation factor (EFB1) was assessed in one medium 
in comparison with the house-keeping 18S rDNA to assess the accuracy of EFB1 as 
control house-keeping.
3.6.1. EFB1
The expression of the 18S rDNA and EFB1 genes were assessed in a 
multiplex RT-PCR using a competimer for the 18S genes at a ratio of 2:8 (18S primer 
to the competimer). Significant variation was observed in the expression of the EFB1 
gene in this assay, as shown in Figure 3.8 below. This variation can be seen 
arithmetically (Table 3.49) with the standard error for the mean of the 18S rDNA 
being approximately 1/16 of the mean and the standard deviation 1/6 of the mean, 
while the same for the EFB1 gene expression was approximately 1/4 and 1/2 
respectively. Therefore, for all subsequent RT-PCR assays, the expression of the 18S 
ribosomal gene was used as a standard against which the expression of all other SAP 
and ALS genes was measured.
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Figure 3.8 Representative sample o f 8 strains of RT-PCR co-amplification of both
the EFBl gene and the 18S gene. The molecular marker used was 4>xl47 DNA/
BsmRI (HaeIII) (MBI Fermentas, UK)
M 1 2 3 4  5 6 7 8 M
E F B l
18S rDNA
Table 3.49 The summary statistics of the area under the curve of the pixel intensity 
for each band of the RT-PCR of the 18S and EFBl genes as analysed 
utilizing Phoretix software
18S EFBl
Mean pixel intensity 34373.6 239885.6
Standard Error of mean 2143.3 55345.1
Standard Deviation 5670.6 146429.2
3.6.2. SAP  genes
The expression of the 18S and SAP genes was assessed in a multiplex RT- 
PCR using a competimer for the 18S genes at different ratios (3:7, 2:8 or 1:9) 
depending upon the gene being examined as previously described (Section 2.2.10.6; 
Table 2.15).
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Tables 3.50 and 3.51 show the statistical analysis of these results, firstly 
between the isolates grown with BSA (Table 3.50) and then the contribution of the 
phenotypic markers (proteinase activity, in-vitro adhesion, C. albicans genotypes, 
cfu/ml and the in-vitro fluconazole susceptibility) that may have individual SAP gene 
expression (Table 3.51). The three isolates that were resistant in-vitro to fluconazole 
in this experiment did not express any SAP gene. Therefore, statistical analysis was 
not possible and is shown as not applicable (N/A) in Table 3.51. Furthermore, 
inconsistency in the observable RT-PCR product did not allow for the complete 
analysis for SAP6 and SAPS genes and these are reported as N/A in Table 3.51.
The addition of BSA to the defined medium was greatly up-regulated the 
expression of the SAP2 gene ip < 0.001) (Table 3.50). In contrast, the expression of 
SAP3 {p = 0.004) and SAP6 ip = 0.025) genes were significantly down-regulated with 
the addition of BSA to the defined medium, whilst the expression of SAP\ and SAPS 
genes was unchanged (Table 3.50).
Interestingly, the in-vitro adhesion for SAP1 was significantly down-regulated 
with BSA in a defined medium ip = 0.032). In contrast the adhesion of SAP2 was 
enhanced with the defined medium contained BSA ip = 0.045). Furthermore, SAP1 
with high proteinase activity was down-regulated with the medium containing BSA ip 
= 0.015) (Table 3.51).
SAP3 and SAP8 were significantly down-regulated ip = 0.034 and p  = 0.035 
respectively) with genotype A to a greater extent than genotype B when they were 
grown in a cultural medium containing BSA (Table 3.51).
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Table 3.50 Summary statistics of the ratio of the gene: 18S pixel intensity as 
analyzed by the Phoretix software for the SAP gene family
Gene
examined
Mean (SD) of ratio 
with BSA
Mean (SD*) of ratio 
without BSA
P  value
SAP1 1.116(0.418) 1.405 (0.732) p  > 0.05
SAP2 6.088 (2.087) 0.43 (0.264) p  < 0.001
SAP3 1.40(1.01) 5.48 (2.76) p  = 0.004
SAP6 0.388 (0.293) 0.786 (0.614) p  = 0.025
SAP8 0.225 (0.144) 0.263 (0.23) p  > 0.05
SD*: standarc deviation
Table 3.51 Statistical analysis of the comparison between strains with high and low 
phenotypic attributes (proteinase activity, adhesion, cfii / ml and fluconazole 
susceptibility) and the expression of individual SAP genes as observed in the 
RT-PCR assay when the isolates were grown in the presence of BSA
Gene
examined
Proteinase
activity
Adhesion
C. albicans 
genotypes
Cfu > 100
Fluconazole
susceptibility
SAP1 p  = 0.015 p  = 0.032 p  > 0.05 p>  0.05 N/A*
SAP2 p  > 0.05 p  = 0.045 p  > 0.05 p  > 0.05 N/A
SAP3 p  > 0.05 p  > 0.05 p  = 0.034 p  > 0.05 N/A
SAP6 N/A p  > 0.05 p  > 0.05 N/A N/A
SAP8 N/A N/A p  = 0.035 N/A N/A
NA* = not applicable
3.6.3. ALS genes
The expressions of the 18S and ALS genes were assessed using a competimer 
for the 18S genes at different ratios (3:7, 2:8 or 1:9) depending upon the gene being 
examined as previously described (Section 2.2.10.6; Table 2.15).
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Tables 3.52 and 3.53 show the statistical analysis of these results, firstly 
between the isolates grown with fibronectin coated beads (Table 3.52) and then the 
contribution of the phenotypic markers (proteinase activity, in-vitro adhesion, cfu / 
ml, C. albicans genotypes and in-vitro fluconazole susceptibility) (Table 3.53) that 
may have contributed to the individual ALS gene expression. The three isolates that 
were resistant in-vitro to fluconazole in this experiment did not express any ALS gene, 
except ALS9. Therefore, statistical analysis was not possible and is shown as not 
applicable (N/A) in Table 3.53. Furthermore, RT-PCR employed in the present assay 
could not detect the expression of ALS6 when fibronectin was added (Table 3.52) and 
hence reported as N/A in Table 3.53.
The expression of ALS2 (p < 0.001), ALS3 (p = 0.004), and ALS7 (p = 0.001) 
genes were all down-regulated more when isolates were grown in a YPD medium 
containing fibronectin, than when grown in YPD medium alone. However, no 
differential expression was observed between the two growing media for ALS1 and 
ALS9 (Table 3.52).
ALS9 with high proteinase activity was significantly enhanced (p = 0.028) in 
YPD medium containing beads coated to fibronectin than in YPD medium alone. The 
proteinase activity of the other ALS genes was not affected by the presence of 
fibronectin in the growing medium (Table 3.53).
ALS3 gene was significantly down-regulated with C. albicans genotype A than 
with genotype B (p = 0.042) in YPD medium containing beads coated to fibronictin
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than in a medium containing YPD alone. However, all of the other ALS genes showed 
no differences with C. albicans genotype A or B in either of the growing media.
Table 3.52 Summary statistics of the ratio of the gene: 18S pixel intensity as 
analyzed by the Phoretix software for the ALS gene family
Gene
examined
Mean (SD) of ratio 
with fibronectin
Mean (SD*) of ratio 
without fibronectin
P  value
ALS1 0.648 (0.285) 0.805 (0.241) p  > 0.05
ALS2 0.68 (0.314) 1.718(0.32) p  < 0.001
ALS3 0.14(0.08) 7.91 (2.91) p  = 0.004
ALS6
Did not express with the 
addition of fibronectin
- -
ALS7 0.089 (0.044) 1.205 (0.318) p  = 0.001
ALS9 1.73 (0.761) 1.571 (0.322) p  > 0.05
SD*: standarc deviation
Table 3.53 Statistical analysis of the comparison between strains with high and low 
phenotypic attributes (proteinase activity, in-vitro adhesion, cfu / ml, C. albicans 
genotypes and fluconazole susceptibility) and the expression of individual ALS 
genes as observed in the RT-PCR assay when the isolates were grown in 
the presence of beads coated to fibronectin
Gene
examined
Proteinase
activity
Adhesion
C. albicans 
genotypes
Cfu > 100
Fluconazole
susceptibility
ALS1 p  > 0.05 p > 0.05 p > 0.05 p> 0.05 N/A
ALS2 p  > 0.05 p  > 0.05 p  > 0.05 p> 0.05 N/A
ALS3 p > 0.05 p  > 0.05 p  = 0.042 p > 0.05 N/A
ALS6 N/A N/A N/A N/A N/A
ALS7 p > 0.05 p>  0.05 p  > 0.05 p  > 0.05 N/A
ALS9 p  = 0.028 p> 0.05 p> 0.05 p > 0.05 p > 0.05
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CHAPTER 4 
Discussion and Conclusion
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4.1. Discussion
4.1.1. Molecular characterization of Candida species isolated from the oral
cavity of patients from diverse clinical settings
The results of the present and previous research indicate that oral Candida 
colonization and the degree of colonization have no relationship with the patient age, 
gender, denture status or the presence of oral mucosal disease, even if  Candida may 
be the cause of this mucosal disease. Other factors such as salivary flow may play a 
role in Candida colonization. Previous research, has shown that patients with 
objective xerostomia and Sjogren’s Syndrome may be more likely to harbour yeast in 
their oral cavity (Wahlin, 1991; Abraham et al., 1998) than healthy persons. Although 
low salivary pH has been suggested, it may be a more important cause of increased 
yeast colonization and resultant disease than low salivary flow rate (Bercier et al.,
1999). However, in a different study, it has been reported that 67.9 % of patients with 
xerostomia carry Candida in their mouths (Torres et al., 2002). Nevertheless, most of 
these patients with xerostomia were under treatment for different underlying disease 
(Torres et al., 2002). It had been reported that patients with dry mouth as a result of 
radiation therapy to the head and neck, Sjogren’s syndrome, certain medication or 
autoimmune disease are more likely to harbour higher numbers of oral Candida than 
healthy individuals (Torres et al., 2002; Almstahl et al., 2003). The results of the 
present study may also support this observation as 33 of the presently examined 44 
patients with special needs had oral Candida species. Some of these patients had 
scleroderma, SLE or other physical or mental disabilities, or were receiving 
medication that may affect the quality or quantity of saliva. In addition, some of the 
special needs patients had disabilities that may influence Candida carriage due to lack
239
of dexterities that may interfere with keeping good oral hygiene. This would support 
the notion that the presence of local factors in the mouth of these patients is highly 
correlated with the increased carriage of oral Candida. Further, the amount of caries 
present in the oral cavity has also been shown to directly correlate with the degree of 
oral yeast colonization (Sziegoleit et al., 1999). Research has repeatedly shown there 
to be a direct association between low salivary pH and dental caries. Therefore these 
findings may well be linked. Previous investigators (Sziegoleit et al., 1999) have 
postulated that C. albicans is directly involved in the development of dental caries. 
Although this hypothesis awaits further clarification, it is intriguing in the light of the 
present study which indicates an apparent predilection of C. dubliniensis in dental 
hard tissues. The salivary flow and the composition of saliva in the present study were 
not investigated, thus it is not possible to conclude that salivary change does truly 
influence oral yeast carriage. But certainly the results of the past and the present study 
do suggest a causal link.
Previous studies have shown that there is a great variability in the number of 
patients whose mouths are colonized by Candida species and this may be due to, at 
least in part, sampling methods being employed. However, most of the previous 
researches have shown that patients wearing either partial or complete dentures are 
more often colonized by Candida, in some studies as twice as often, than non-denture 
wearers (Abo-Elteen and Abo-Alteen, 1998; Maza et al., 2002). Furthermore, the 
presence of yeast on dentures was reported to be significantly associated with denture 
related stomatitis (Barbeau et al., 2003; Cross et al., 2004). These previous findings 
have not been confirmed in the present study. The reason of that can be explained in 
part as no examined patients had evidence of oral candidosis. Patients with clinical
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evidence of oral candidosis were excluded from the present study, a factor that may 
not have been considered in previous studies. Furthermore, the patients who were 
colonized and who had complete or partial dentures did not have a higher amount (cfu 
/ ml > 100) of Candida in their oral cavity than those without dentures.
In the present study, subjects with removable or complete dentures showed 
significantly greater colonization by non-albicans species (other than C. dubliniensis) 
than the dentate subjects (p = 0.04). This result is thus in agreement with recent study 
that has shown frequent isolation of non-albicans species from denture wearers with 
denture stomatitis (Cross et al., 2004). Interestingly, C. dubliniensis was not present 
in the mouth of these subjects. This confirms present observations that oral C. 
dubliniensis is associated with the presence of some teeth. However, treatment of 
denture stomatitis by itraconazole may have contributed to the increased colonization 
by non-albicans species (Cross et al., 2004). Certainly, in the present study, patients 
may have had denture stomatitis previously and been frequently exposed to antifungal 
therapy.
In addition, the increased carriage of Candida in dentures or oral removable 
orthodontic appliances may arise in part from the initiation of the carrier state by the 
prosthesis (Arendorf and Addy, 1985). Although a greater density of Candida has 
been reported on the fitting than on other surfaces of a dental prosthesis, this was not 
examined in the present study due to the use of an oral rinse sampling method 
(Arendorf and Addy, 1985). The prevalence of Candida carriage during the wearing 
of removable orthodontic appliances was reported to be significantly higher than the 
prevalence before or after orthodontic treatment (Arendorf and Addy, 1985).
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However, in the present study there was no significant difference in Candida carriage 
between orthodontic appliance wearers and subjects attending other dental settings. 
This result is thus similar to a previous study (Addy et al., 1982) that demonstrated 
there was no significant difference in candidal carriage between patients who were 
wearing either removable or fixed orthodontic appliances and non-appliance wearers 
(Addy et al., 1982). However, the load of Candida in the previous study was 
significantly higher in orthodontic wearers than in non-prosthesis wearers (Addy et 
al., 1982). Lack of difference in Candida carriage or load of Candida (cfu / ml > 100) 
between orthodontic and other subjects from different dental settings in the present 
study may reflect an increased awareness of the benefits of maintaining excellent oral 
hygiene, regular dental attendance and use of antimicrobial mouthwashes during 
orthodontic therapy; however these factors were not investigated in the present study. 
Patients who were wearing either removable or fixed orthodontic appliances were 
younger than those from the other groups but this does not seem to have influenced 
overall Candida carriage. It can thus be concluded that patients are just as likely to be 
colonized with Candida species and have similar amounts of yeast present, 
irrespective of denture status. However, when either a previously non-colonized 
patient becomes colonized, or in a colonized patient, the amounts of oral yeast present 
increases and clinical oral candidosis ensues. Although this would appear to be 
imminently logical, it may not necessarily be true.
It has been reported that there may be an association between oral leukoplakia 
and lichen planus and oral Candida carriage (Krogh et al., 1987). Yeast carriage was 
reported in 82% and 47% of patients with oral leukoplakia and lichen planus 
respectively (Krogh et al., 1987). However, in the present study, there was no
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difference in the oral Candida carriage of patients with leukoplakia (50%) or oral 
lichen planus (59.5 %) and subjects from other dental settings (44.2%) but 
interestingly, isolation of C. dubliniensis from this group was increased. This was not 
previously possible because all positive germ tube species were identified as C. 
albicans.
Candida albicans was the most frequently isolated species in the previous and 
present study. However, other species were also isolated from the present group of 
patients with mucosal abnormalities, and of note 85.7% of the non-albicans species 
isolated from the patients with oral mucosal lesions were C. dubliniensis. In addition, 
the oral carriage of C. dubliniensis from the mouth of patients with special needs was 
significantly greater than that of the other patient groups. These latter patients were 
either physically or mentally disabled and therefore their oral hygiene habits may 
have been significantly impaired. Overall, 5.8% (15/257) of all examined patients had 
C. dubliniensis isolated from their oral cavity and none of these patients was known to 
be immunocompromised. This is an interesting result as many previous studies have 
concentrated upon the increased frequency of C. dubliniensis from the oral cavity of 
HIV-infected individuals (Sullivan et al., 1995; Sullivan and Coleman, 1997; 
McCullough et al., 1999a, b). Moreover, none of the present patients, who carried C. 
dubliniensis, was edentulous, as all had at least some teeth present in their oral cavity. 
It may well be that C. dubliniensis has an enhanced predilection for the co­
colonization, with specific oral microorganisms, of biofilms present on tooth surfaces. 
Recent evidence (Jebra-Rizk et al., 2000) indicates that this may be true as all 15 
isolates of C. dubliniensis examined in this previous study showed high levels of in- 
vitro co-aggregation with Fusobacterium nucleatum, a common oral micro-organism,
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whereas the ATCC C. albicans isolate studied showed no comparable co-aggregation 
(Jebra-Rizk et al., 2000). Further research is required to elucidate the comparative co­
colonization capacity of C. dubliniensis and C. albicans on oral biofilms. This is the 
first study to indicate that local, rather than systemic, factors may play a role in the 
colonization of the oral cavity by C. dubliniensis.
The strong statistical association found in the present study between patients 
of 40 and 50 years of age and the oral isolation of C. dubliniensis may be as a result of 
the acquisition of oral mucosal diseases in this age group being more common. This 
would indicate that the spread o f C. dubliniensis might well be horizontal, rather than 
vertical. It has long been thought that human acquisition, at least initially, of oral 
yeast flora occurs at birth via the birth canal. However, the only species that has thus 
far been assessed is C. albicans (Odds, 1988). Assessment of the similarities of 
species and strains of yeast isolated within family groups may help to clarify the mode 
of transfer of this newly described species.
The genotypic distribution of the C. albicans isolates was very similar for all 
patient groups studied. A notable exception to this is the significant increase in the C. 
albicans genotype B strains isolated from orthodontic patients, particularly those with 
fixed orthodontic appliances. Previous studies (McCullough et al., 1999a) have shown 
that there is significant global genotypic variability of C. albicans. In particular, this 
previous study showed that isolates from the USA and UK were genotypically distinct 
from those isolated from such globally diverse areas as Spain, France, Zimbabwe, 
Colombia, Australia, Singapore, Japan and Israel (McCullough et al., 1999a). 
However, no information regarding local oral conditions (denture status, mucosal
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disease, presence of orthodontic appliances) was available in this previous 
investigation. Comparison of the genotypic distribution of C. albicans found in the 
well-characterized patients from the present study, with the global distribution of C. 
albicans genotypes from the previous study (McCullough et al., 1999a) revealed 
intriguing results. Overall, the isolates in the present study are more similar to the 
USA/UK isolates from the previous study ip = 0.74) and are significantly different 
from the previously reported global isolates ip < 0.001). However, interestingly, the 
C. albicans from patients in the present study who had an intra-oral orthodontic 
appliance (17 patients with genotype A and 9 with non-A genotype) would appear to 
be more similar to the previously reported global isolates (126 genotype A and 80 
with non-A genotype) ip = 0.68) and tend towards being statistically significantly 
different from the similar distribution of C. albicans genotypes previously reported on 
USA/UK isolates (156 genotype A and 35 with non-A genotype) ip = 0.053) 
(McCullough et al., 1999a). The reason why patients with intra-oral orthodontic 
appliances have such genotypically distinct oral C. albicans when compared to others 
in their local community is unclear. It is unlikely that this is related to simple oral 
hygiene practices as a similar genotypic profile should have occurred in other groups 
in this study, in particular in patients with special needs (physically and mentally). 
Perhaps this may be age-related, as most of orthodontic patients were in the younger 
age groups. However, when age alone was assessed no statistically significant 
differences were found in any particular age group or combination of age groups.
The present study is the first to assess the genotypic distribution of C. albicans 
isolates, utilizing the described molecular methodology, from patients whose oral 
cavity have been thoroughly characterized. Previous research, utilizing a variety of
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molecular methods, had indicated that strains of C. albicans tend to be more 
genetically similar to each other if  they are isolated from similar patient cohorts (i.e. 
HIV infected patients versus non-HIV infected patients) (Xu et al., 1999b), 
geographical locality (Kleinegger et a l , 1996), and body site (oral, vaginal or 
systemic) (Soil et a l , 1991; Schmid et a l, 1993; Xu et a l, 1999a). The results of the 
present study suggest that there may be particular, genotypically definable, subgroups 
of C. albicans that have a predilection for specific oral environments or patient 
cohorts.
Tobacco smoking was reported to be associated with increase yeast carriage 
and colonization in complete or partial denture wearers (Alkumru and Beydemir, 
1992; Barbeau et a l,  2003). In contrast to denture wearers, candidal carrier rate was 
notably less in dentate smokers (Alkumru and Beydemir, 1992). This observation was 
not the case in denture wearers o f the present study as only 2 of the 5 smokers 
colonized with oral Candida were similar to the dentate subjects from the private 
dental clinic (2 of the 7 smokers had oral Candida) (Table 3.7).
It has been previously reported that although oral lesions were found to be 
statistically higher (97.9%) in betel quid chewing (BQC) subjects in comparison with 
non-betel quid chewing (30.8%) but oral lesions leasions in BQC subjects (Reichart et 
a l, 2002) or in tobacco smokers (Reichart et a l, 2002) were not associated with oral 
candidal carriage or Candida species diversity (Silverman and Bahl, 1997; Reichart et 
a l, 2002). However, in the present study, tobacco smokers from patients with 
mucosal abnormalities or those with special needs had oral Candida significantly 
greater than that of the healthy subjects ip = 0.003) although Candida diversity was
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not different between the 2 groups (p > 0.05). The reason of that is unclear but may be 
associated with increased in the dental plaque, poor oral hygiene and low salivary pH 
(Moalic et al., 2001) amongst tobacco smokers in patients with special needs. 
Therefore, the result o f the present study would suggest a correlation between the 
presence of local or systemic factor rather than the wearing of prosthesis in candidal 
colonization among tobacco smokers.
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4.1.2. Molecular characterization of oral Candida species in bone marrow 
transplant recipients
The present study examined, in detail, the carriage, colonization, species and 
C. albicans genotypes of fungi of the mouths of bone marrow transplant (BMT) 
recipients from the UK, and compared these factors with those in an appropriate 
group of control subjects from the UK (subjects from the oral medicine clinic with 
non-mucosal disease and subjects from the private dental clinic who had no local or 
systemic conditions that may influence oral candidal carriage or diversity of Candida 
species) and from BMT recipients resident in Greece, Italy and Brazil.
It has been reported that oral candidal carriage may be increased with 
intensive antineoplastic therapy (Tollemar et al., 1999; Salonen et al., 2000; Paterson 
et al., 2001) neutropenia and low salivary flow (Momin and Chandrasekar, 1995; 
Tollemar et al., 1999; Epstein et al., 2003). Mucosal damage caused by total body 
irradiation (together with chemotherapy) may enhance the mucosal adhesiveness of 
Candida species resulting in overgrowth and ultimately cause disease (Verfaillie et 
al., 1991). However, in the present study, recipients of BMT were not at greater risk 
of candidal carriage (50%) than healthy subjects (41.7%). The lower rate of carriage 
of Candida observed in the present study may reflect the influence of a number of 
variables such as patient immune status (Kook et al., 1997), degree of xerostomia and 
history of recent antifungal therapy prophylaxis (Salonen et al., 2000), as most of the 
previous similar investigations examined patients who had only recently completed 
BMT, whereas in the present study samples were collected several weeks to years 
after BMT (Table 2.9). Approximately 48% of BMT recipients from four diverse
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regions had had bone marrow transplantation more than a year before mouth swill 
collection, while most of the remaining patients (52%) were not neutropenic at the 
time of oral examination and thus could possibly account for the relatively low 
candidal carriage in BMT recipients. In the present study 49% of all patients who had 
undergone BMT from the four examined countries carried Candida in their mouths. 
This carriage rate was not different from that of healthy control subjects (41.7%). 
Furthermore, Candida load (cfu / ml > 100) in the BMT recipients did not differ in the 
four groups of patients of different geographic locales nor in the control subjects, 
suggesting that the carriage rate obtained in this study is consistent within different 
groups of BMT recipients. The present data accords with that of the previous similar 
studies as shown in Table 1.2 (Verfaillie et a., 1991; Marr et al., 2000), but contrasts 
with that of patients who had had oral cancer treated with high doses of radiation to 
the head and neck regions which showed significantly high levels of oral Candida 
colonization as a consequence of direct exposure to the radiation beams that may 
result in complete destruction of salaivary glands (Jobbins et al., 1992, Leung et al., 
2000).
The reported frequency of oral carriage of fungi may be falling (Tollemar et 
al., 1999, Marr et al., 2000) as colonization by Candida species in BMT recipients 
and in those undergoing cytotoxic therapy was higher in earlier studies 
(Samaranayake et al., 1984; Tollemar et al., 1993). This may reflect changes in 
conditioning regimens, the increased used of effective systemic antifungal regimes 
(Tollemar et al., 1999; Laverdiere et al., 2000) or as a consequence of performing 
peripheral blood stem cells (PBSC) transfer (as opposed to BMT) where the blood
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count returns to normal more rapidly than with other more established methods 
(Flowers et al., 2002).
The low level of the presently observed oral fungal infection does not reflect 
differences in sampling methods, as the oral rinse technique has been used in several 
similar previous studies (Table 1.2). However, although different cytotoxic 
conditioning regimens can influence oral colonization (Salonen et al., 2000) there is 
no consistent pattern in the effect of autologous versus allogenous transplantation in 
the frequency of candidal carriage in the mouth. For example, while oral yeast 
colonization may be higher in paediatric patients who have undergone autologous 
BMT as opposite to allogenic BMT (Hoppe et al., 1997), the oral fungal colonization 
of adults is higher in those who have had allogenous rather than autologous BMT 
(Epstein et al., 2003). This suggests that the type of transplantation or conditioning 
regimes may not affect Candida colonization. While patients from the UK (96.4%) 
and Brazil (100%) received allogenous BMT, the majority of the Greek patients had 
undergone autologous BMT (77.3%) and, therefore, the type of transplant did not 
seem to influence the oral carriage of Candida as the Candida loads were similar in 
all units irrespective of the percentage of allogenic or autologous transplants 
undertaken.
To date C. albicans has always been identified as the predominant fungal 
isolate of the mouth in healthy persons (Cannon et al., 1995; Al-Karaawi et al., 2002) 
and BMT recipients (Tollemar et al., 1999; Paterson et al., 2001) although a wide 
range of non-albicans species such as C. tropicalis, C. glabrata, C. parapsilosis, C.
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krusei (Anaissie et al. 1998; Muller et al., 1999; Karthaus et al., 1999; Tollemar et al., 
1999; Marr et al., 2000; Paterson et al., 2001) and C. dubliniensis (Moran et al., 
1997; Sullivan and Coleman 1997, Sullivan et al., 1997; Meis et al., 1999; Jabra-Rizk 
et al., 2000; Salonen et al., 2000) have been increasingly isolated from the mouth of 
the immunocompromised patients in the past two decades. In the present study, non- 
albicans Candida species were more commonly isolated from the mouths of BMT 
recipients (26.7%) than the control subjects (4%). Previous similar studies have 
likewise reported higher oral carriage of non-albicans species in BMT recipients 
(Verfaillie et al., 1991; Marr et al., 2000). C. tropicalis and C. glabrata were the most 
common non-albicans isolates to be observed in the present group of BMT recipients 
in agreement with several of previous studies (Table 1.2). However, within different 
BMT groups, a wide range o f non-albicans carriage was found (11.1% in Italy versus 
26.7% in UK). The oral carriage of non-albicans species is clinically significant, 
particularly in immunocompromised patients. The mortality rate in hospitalized 
patients with haematological malignancy or who have undergone BMT can be higher 
with non-albicans Candida such as C. glabrata and C. krusei (46.7-100%) than C. 
albicans (20.8 - 53.8%) (Safdar and Armstrong, 2002). In a retrospective study, it has 
been reported that administration of fluconazole significantly reduced colonization by 
C. albicans (Paterson et al., 2001; Epestin et al., 2004) and candidal infection (Moran 
et al. 1997; Gilfillan et al, 1998; Marr et al., 2000; Epestin et al., 2004) and did not 
increase colonization with non- albicans species in neutropaenic patients and BMT 
recipients (Paterson et al., 2001). However, prolonged azole therapy can predispose to 
the emergence of resistant Candida species such as C. krusei, and C. glabrata or other 
Candida species initially, susceptible to fluconazole (C. albicans and C. dubliniensis) 
may gradually develop resistance (Paterson et al., 2001). C. dubliniensis was only
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isolated once from the mouths of the UK BMT recipients or healthy control subjects 
although shift from C. albicans to C. dubliniensis was observed from consequent 
sampling. C. dubliniensis has previously been isolated from both healthy and HIV 
disease (Moran et al., 1997; Meis et al., 1999; Al-Karaawi et al., 2002; Manfredi et 
al., 2002; Sullivan et al., 2004). The prevalence of the oral carriage of C. dubliniensis 
ranges from 3.5 to 5.8% in immunocompetent individuals (Ponton et al., 2000; Al- 
Karaawi et al., 2002) and from 26 to 32% in HIV infected patients (Ponton et al., 
2000). There have been few studies reported the isolation of C. dubliniensis in BMT 
recipients (Meis et al., 1999), patients with malignancy or who have undergone solid 
tumour transplantation (Brandt et al., 2000, Gottlieb et al., 2001; Sebti et al., 2001). 
C. dubliniensis shares many of the phenotypic features of C. albicans but rarely 
causes systemic infection (Sullivan et al., 2004) although it was responsible for 
candidaemia in three BMT recipients (Meis et al., 1999).
The reason why C. dubliniensis was not present in BMT recipients from Italy, 
Greece and Brazil is not clear but certainly it has been observed in healthy and 
immunocompromised groups from around the world (Sullivan et al., 1997; 
McCullough et al., 1999a).
The results of the present study confirm the findings of previous studies of 
BMT recipients (van Belkum et al., 1994) and patients with nasopharyngeal 
carcinoma (Leung et al., 2000) that the majority of individuals carry one species of 
Candida (Marr et al., 2000; Salonen et al., 2000) or C. albicans genotype (Lasker et 
al., 2001) in their mouths. However, during and after BMT, oral Candida isolates can
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shift from one species to another. The single shift from one strain to another in 
immunocompromised patients may be as a result of immune host defects and / or 
frequent or prolonged antifungal treatment (Salonen et al., 2000). In the present study, 
while there were no changes in the frequency of oral candidal carriage, few of the 
examined patients had changes in the oral Candida species with time. In two of the 20 
UK BMT recipients (10%), C. albicans shifted to C. glabrata and in the other 2 
patients, the shift was from C. albicans to C. dubliniensis (10%) while in the 2 Greek 
patients, the shift was from C. albicans to C. tropicalis and vice versa but the small 
number of the examined Greek patients was not sufficient to conclude the effect of 
time upon changing in the oral carriage of Candida species. Indeed the present 
findings of shifts from C. albicans to C. glabrata would support the notion that this 
shift can be as a result of inherent increased resistance to antifungal agents, especially 
to azoles (Fidel et al. 1999). The presently observed shifts from C. albicans to C. 
dubliniensis in the UK BMT recipients have also been observed in group of HIV- 
infected patients (Martinez et al., 2002) although in the later study, patients had been 
receiving fluconazole during the study period. Likewise, in the present observation, 
fluconazole therapy can be responsible for the shifts from C. albicans to C. 
dubliniensis.
Furthermore, in the present study, changes in the genotypes of C. albicans in 
BMT recipients did not occur with time. It would thus seem that individuals usually 
carry the same genotype as a commensal or during infection as previously reported in 
patients with HIV disease (Lasker et al., 2001). Nevertheless, the mycological shifts 
from C. albicans to non-albicans Candida species is more likely to occur than the 
shift from C. albicans genotype A to non-A and vice versa. To date, no studies
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examined the shift of C. albicans genotypes (according to the presence or absence of 
the intron) in BMT recipients. Further studies are necessary to elucidate the potential 
shift in C. albicans genotypes.
Candida albicans was the predominant Candida species in the present groups 
of BMT recipients and control subjects, and thus it is in agreement with the findings 
of previous similar studies (Table 1.2). The genotypes of oral C. albicans isolates 
from the present study reveal that there was significant diversity in the genotypic 
subgroups of C. albicans isolated from BMT recipients from Italy compared with 
BMT recipients from different geographic areas in the UK, Greece and Brazil. These 
results would support the notion that genotypic distributions are related to locality 
rather than the disease. Genotypic variation of C. albicans can be influenced not just 
by geography (McCullough et al., 1999a), but by dental settings (among healthy 
subjects) (Al-Karaawi et al., 2002) and antifungal therapy as the present patient 
groups were generally uniform other than with respect to their place of residence. It 
would seem that geography is a real influence upon the genotypes of C. albicans 
isolates from the mouth.
In the present study, although the number of tobacco smokers was similar in 
the UK BMT recipients (17.9%), Greek BMT recipients (18.2%) and healthy subjects 
(16.7%), oral candidal carriage among these groups of patients was notably different 
(Table 3.17). However, lack of yeast growing in the mouths of tobacco smokers in 
Greece may be explained in part by the small number of the examined patients. It was 
reported in one study that smoking represented a risk factor for oral colonization by 
Candida during radiotherapy (p = 0.045) (Epstein et al., 1993). Nevertheless, in a
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different study, it has been concluded that smoking and denture wearing were not risk 
factors for increased candidal colonization ip > 0.05) in patients who received 
radiation therapy to the head and neck regions for oral / pharyngeal squamous cell 
carcinoma (Ramirez-Amador et al., 1997). Despite the conflicting data, it would seem 
clinically sensible to reduce any potential factor that predisposes to oral candidal 
infection particularly in immunocompromised patients such as BMT recipients (Abu- 
Elteen and Abu-Alteen, 1998).
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4.1.3. Analysis of the strain relatedness of C. albicans isolates utilizing 
multiple PCR fingerprints
The present study utilized PCR fingerprinting with repetitive DNA sequences 
method that encompassed many genomic loci by combining the results of 5 separate 
oligonucleotide primers (Xu et al., 2000). This method is rapid and useful in 
epidemiological study of strain relatedness from different body sites, different time 
intervals of the same patient, diverse patient cohorts or diverse locales. It has been 
demonstrated that the isolates collected in different time from the same patients in the 
intensive care units, immunosuprresive status or who had undergone BMT were 
similar (Marco et al., 1999; Xu et al., 2000) or identical (Vazquez et al., 1998). In an 
earlier study by Odds and colleagues (1992), utilizing PCR fingerprinting, it was 
reported that strains from different body sites can be identical, unrelated or similar but 
non-identical (Odds et al., 1992). From the 11 cases of C. albicans that were isolated 
from the mouth and vulvovaginal region, seven of the cases were not related and four 
were similar but none of them were identical genetically (Odds et al., 1992). It was 
reported that, similar isolates from different sites of the body grew from a single strain 
and this strain may be adapted to a different body site and then diverge genetically 
(Odds et al., 1992). The results of the present study are consistent with the previous 
study (Odds et al., 1992), that the majority of the patients (10 of the 11) with 
subsequent strains isolated from the UK BMT recipients revealed that these strains 
were similar but not identical (91%) when collected from the mouths of the same 
patients at different times during the course of the study. This raises three 
possibilities: firstly, changes in the oral cavity of the BMT recipients resulted in the 
colonization by a second strain better adapted to these changes: i.e. as the 
immunosuppression status of the BMT recipients changed; or the nature of
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medication (particularly antifungal therapy) changed (either increased or decreased 
susceptibility to antifungal agent) (Xu et al., 2000) a strain with either enhanced or 
diminished attributes was able to colonize. No clinical evidence could be found that 
might support this contention. Secondly, this result may be entirely due to sampling 
error and in these 10 patients there may have always been more than one strain 
present in these patients’ mouths. Previous studies would indicate that it is extremely 
unlikely that this is the case. Finally, this result may indicate that the PCR 
fingerprinting method is too sensitive and recognizes minor genetic mutations within 
the same strain. If this last scenario is true then it would be expected that no two 
isolates of this cloned, a sexual organism would have identical PCR fingerprints using 
this method. As can be seen from the results presented in Table 3.23, many diverse 
strains shared identical PCR fingerprinting patterns; therefore this last possibility can 
be rejected.
It must therefore be concluded that the change in strain that occurred in these 
patients is not related to either sampling or methodological error and is related to that 
individual patient and his / her oral environment. It is interesting to speculate what 
changes might have occurred with these patients that allowed for the colonization of a 
different strain of C. albicans in their oral cavity, changes that may indeed be so 
individual that they are unique to each patient and perhaps related to their individual 
contacts. One possible reason may influence the difference in Candida strain from the 
same patient is the storage condition (e.g. temperature) however, all strains in this 
study were stored in the same conditions (e.g. storage medium and temperature (- 
20°C)). If this possibility is true, it therefore suggests the limitation of phylogenitic
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analysis. Further studies are recommended to investigate in detail candidal growth and 
storage conditions in strains obtained from the same individuals.
The combination of both the statistical and phylogenetic analyses reveals some 
interesting observations. While the strains from BMT recipients in the UK were the 
most genetically diverse group (Table 3.22), there was a large group of these patients 
whose C. albicans isolates were very similar and were all within the same genotypic 
group E (Figure 3.3 and Table 3.23). This cluster of 17 genotypically very similar 
strains within the UK BMT recipients may be caused by environmental factors unique 
in these patients allowing for the colonization of genetically similar or distinct strains. 
The phylogenetic analysis utilizing PCR fingerprinting reveals interesting results; 
although 90% o f genetic similarity was found in all sub-groups (A1-A3, B1-B8, Cl- 
C2, D, E, F1-F3 and G1-G2) but they were only 100% identical in a small number of 
strains as shown in Table 3.18 (3 pairs identical), Table 3.19 (2 pairs identical), and 
Table 3.20 (3 pairs identical).
The observed variation in genotypic diversity of C. albicans strains in the present 
study may represent the distinct ecological niches of the studied patients. The 
diversity of C. albicans strains was most from strains obtained from BMT recipients 
in the UK (mean of diversity = 5.06). This diversity was statistically higher from the 
strains of the UK control subjects or strains from BMT recipients from other diverse 
regions (mean diversity was 4.91 and 4.58 respectively).
A study by Schmid and co-workers (1999), to access genetic relatedness of C. 
albicans strain from 12 geographical diverse regions based upon genetic distances
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generated by Ca3 fingerprinting found that only 37% of all isolates formed a single 
genetically homogeneous cluster. It has been reported that isolates from the same 
region can be genetically more similar to each other than to isolates from other 
regions (Schmid et al., 1993; 1999). In one study, PCR fingerprinting results of C. 
albicans strains collected from blood stream of HIV infected individuals and healthy 
subjects from North America, South Africa, Europe, South America, Turkey and 
Israel utilizing Southern blot hybridization with Ca3 probe revealed that strains from 
different geographical regions are diverse while strains from different regions in 
North America were the least diverse (Pujol et al., 2002). This study suggested the 
geographical attributes of strain relatedness. The present result supports this notion 
that strains from the UK BMT recipients and the UK controls were genotypically 
different than those from other geographical locale.
The diversity of Candida strains in the UK may be related to the different 
ethnicity o f people living in London in comparison with the other study groups which 
suggests the contribution of geographical location (subjects’ background) upon 
Candida strain diversity. However, ethnicity was not investigated in the present study. 
It will be interested to undertake similar study in subjects from different geographical 
background living in the same region to analyse ethnicity as a possible reason for 
genotypic diversity of C. albicans strains.
Furthermore, strain diversity from the UK BMT recipients may reflect either the 
type of antifungal therapy received by those patients or increased resistance of these 
strains to fluconazole (Section 3.5) in comparison to the strains isolated from patients 
living elsewhere in the world.
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Genotypic subgroups of C. albicans strains (A, B and C) are designed according 
to the presence or absence of a transposable intron in the 25S rDNA region (Mercure, 
et al., 1993). The analysis of the genotypic diversity in the present study showed that 
C. albicans genotype A, was less genotypically cohesive than genotypes B and C. 
Presence of the intron in the 25S rDNA region may reflect the cohesiveness of 
genotype B and C strains. In a previous study, it was shown that the presence of intron 
in C. albicans strains exhibited a high degree of susceptibility to a base analogs 
antifungal agent (5-fluorocytosine), while strains lacking the intron (genotype A) 
differed widely in their susceptibility (Mercure et al., 1993). Therefore, as indicated 
above there must be other reasons for the genotypic diversity observed in the strains 
of the UK BMT recipients.
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4.1.4. Analysis of virulence attributes of Candida species from BMT recipients 
from different geographical areas
To date there has been no published studies of the virulence of oral Candida 
isolates of recipients of bone marrow transplantation (BMT). In the present study, the 
in-vitro adherence of oral Candida isolates was not increased in UK BMT recipients 
when compared to the control subjects, and likewise there were no significant 
differences in the adherence of isolates from BMT recipients in different countries. 
Indeed isolates from the UK BMT recipients had reduced adherence when compared 
to those of the control subjects (p = 0.07) although the difference was not significant. 
Reassuringly perhaps, these isolates with increased adherence were associated with 
increased oral colonization, thus indicating that adherence does influence colonization 
and therefore the present observations are clinically relevant (Table 3.30).
In a previous study, two strains of C. albicans (one of which was susceptible 
to fluconazole while the other was resistant to fluconazole) were isolated from 
patients receiving antineoplastic agents such as methotrexate and etoposide. The 
results of this study showed that receiving antineoplastic therapies significantly 
inhibited the growth and the in-vitro adhesion of C. albicans to the buccal epithelium 
or to the acrylic surfaces. However, the inhibition of Candida growth and adhesion 
were less in the strain known to be resistant to fluconazole than that known to be 
susceptible to fluconazole (Fekete-Forgacs et al., 1999). This result is in agreement 
with other studies that fluconazole is able to inhibit colonization and adherence to the 
buccal epithelial cells (Ellepola and Samaranayake 1998; Willis et al., 2001). 
However, the results of Fekete-Forgacs and colleagues (1999) were limited by only 
two strains of C. albicans being examined. It was thus difficult to prove or disprove
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the effects on these agents upon C. albicans pathogenicity. However, the results of the 
present study may support the notion that relevant chemotherapeutic regimes (34%; 
19/56 of the UK BMT recipients were receiving ciclosporin and methotrexate as 
prophylaxis for GvHD) do influence Candida adherence.
Immunosuppresion may also have some effects upon Candida proteinase 
activity, but the data is not consistent. A recent study by de Brito Costa and his 
colleagues (2003) revealed that proteolytic enzyme activity of oral C. albicans 
isolates from HIV infected patients was not different to that of the control subjects (de 
Brito Costa et al., 2003). This study however, contradicted earlier investigations
which observed that oral Candida isolates from HIV-infected patients did produce
/
more aspartyl proteinase than those of healthy individuals (De Bemardis et al., 1992; 
Wu et al., 1996). It is not known why HIV infection may increase proteinase activity, 
although it may be as the result of phenotyping switching of C. albicans (Wu et al.,
2000). In the present study, the production of secreted aspartyl proteinase by isolates 
of BMT recipients and control subjects did not differ and was not influenced by the 
presence or absence of increased adhesion or fluconazole resistance. However, 
production of proteinase from Candida isolates of the Brazilian BMT recipients was 
particularly low. The reason for the lower levels of extracellular proteinase produced 
by oral Candida isolated from the mouth of the Brazilian BMT recipients is not clear 
but may reflect the low quantity of saliva (61.5 % of the patients had xerostomia) or 
probably the constituent of their saliva that may inhibit proteinase activity. It would 
be very interesting to undertake further study to examine the virulence attributes of 
Candida species from BMT recipients from Brazil. The present data, together with the 
knowledge that the oral carriage of Candida is not notably increased by BMT
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recipients, suggests that the majority of patients are not at risk of severe 
mucocutaneous or invasive candidal infection some weeks to months after such 
therapy.
Successful colonisation and infection of host tissues by pathogenic Candida 
species require adherence of the invading microbe to the host surface (Ellepola and 
Samaranayake, 1998; Tsang and Samaranayake, 1999). In general, more pathogenic 
Candida species such as C. albicans (Rotrosen et al., 1986; McCullough et al., 1996; 
al-Rawi and Kavanagh, 1999, Biasoli et al., 2002) and C. tropicalis (al-Rawi and 
Kavanagh, 1999, Biasoli et al., 2002) adhere to the host cells to a greater extent than 
the less pathogenic species such as C. krusei, C. guilliermondii (Rotrosen et al., 1986; 
McCullough et al., 1996, Biasoli et al., 2002), C. lucitaniae and C. glabrata (al-Rawi 
and Kavanagh, 1999). However, there are inconsistencies; for example, in-vitro 
adhesion of C. albicans to buccal epithelial cells may be increased (Sweet et al., 
1995), unchanged (Tsang and Samaranyake 1999) or decreased (Pereiro et al., 1997) 
in HIV disease. Such differences might suggest that adherence, may not be the most 
important factor in determining the virulence of infectious disease. The present study 
did not show any difference in the in-vitro adhesion nor proteinase activity between 
C. albicans and non-albicans Candida (all non-albicans Candida were combined as 
one group due to the small number of these species). Lack of substantial change in the 
adherence of Candida isolates could thus reflect differences in the method of assay. 
The present study employed fibronectin-coated beads, and thus it may be that the use 
of epithelial cells would yield different results. Although C. albicans is considered to 
be one of the most adherent Candida species, it seems unlikely that the observed low 
proportion of non-albicans Candida greatly influenced the adherence of Candida
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isolated from the mouths of BMT recipients. Likewise, it would seem that non- 
albicans Candida species (including C. dubliniensis) do not differ significantly from 
C. albicans in the production of proteinase. However, the study by Biasoli and co­
workers (2002) demonstrated significant differences between the adherence of 
different Candida species, C. albicans adhering the most, whereas C. krusei and C. 
glabrata adhered to the least extent to epithelial cells (Biasoli et al., 2002). In a 
different study, it has been demonstrated that, C. glabrata adhered strongly to the 
human epithelial cells (Cormack et al., 1999) and was responsible for about 15% of 
mucosal and systemic candidosis (Cormack et al., 1999).
The presence of an antimycotic agent can affect the adhesion of Candida 
species. The in-vitro adherence of the Candida species (C. albicans, C. tropicalis, C. 
glabrata, C. krusei and C. guilliermondii) to epithelial cells (Ellepola et al., 1999) and 
to denture acrylic (Egusa et al., 2000) in the presence of polyenes can be decreased. 
However, the reduced ability to adhere was variable. For example, the adherence of 
C. albicans was the least of the examined strains affected by polyenes in one study 
(Ellepola et al., 1999) while in another study (Egusa et al., 2000); C. glabrata was the 
least affected Candida species.
It has been found that acidity (low pH) is important for proteinase expression 
in Candida species (Wu and Samaranayake, 1999). This was explained in part by 
higher proteinase activity produced by C. albicans because of its acidogenicity (Wu 
and Samaranayake, 1999). However, in the present study, there was no correlation 
between Candida species diversity (C. albicans versus non-albicans Candida) and
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proteinase activity, nor enhanced in-vitro adhesion in BMT recipients from different 
regions of the world, or from BMT recipients versus control subjects from the UK. 
Although that the proteinase activity produced by C. albicans did show geographical 
variations (isolates from Brazilian BMT recipients had low proteinase activity).
Candida dubliniensis did not seem to be of relevance to the adhesion or 
proteinase activity of isolates from BMT recipients. In the present study, the secretion 
of aspartyl proteinase or in-vitro adhesion was not different from that of other non- 
albicans species or C. albicans. In one study, C. albicans isolates adhered better than 
C. dubliniensis (Borg-von Zepelin et al., 2002). However, in the presence of 
fluconazole, C. dubliniensis from the mouths of HIV patients showed enhanced in- 
vitro adhesion (Borg-von Zepelin et al., 2002) while C. albicans decreased its 
adherence in the presence of fluconazole (Borg-von Zepelin et al., 2002). An earlier 
study also reported that C. dubliniensis adheres to a greater extent to the buccal 
epithelium than that of C. albicans (McCullogh et al., 1995). In the present study, C. 
dubliniensis was isolated once from the initial sampling of BMT recipients from the 
UK and was absent from the mouth of BMT recipients from Brazil, Italy and Greece. 
It was thus not possible to undertake any analysis on this species from isolates of 
BMT recipients.
It has been demonstrated that the genetically distinct subgroup of C. albicans 
strains determined by PCR fingerprinting was significantly correlated with 
extracellular proteinase activity and in-vitro adhesion (McCullough et al., 1995) while 
in a different study, it was found that there were no correlations between C. albicans
265
genotypes and virulence attributes {in-vitro adhesion and proteinase activity) of C. 
albicans (Macura et al., 1998). In the present study, there were no differences 
observed in the adherence nor proteinase production of C. albicans of different 
genotypes. A study carried out by Sugita and colleagues in Japan (Sugita et al., 2002) 
on different genotypes of C. albicans according to the presence of the intron in the 
26S rRNA gene (B), absence o f the intron (A) or partial presence of the intron (C) and 
their influence in pathoginicity of C. albicans. They revealed that there was a 
significant relationship of the three genotypes and yeast pathogenesis. The authors of 
this study found that extracellular proteinase and phospholipase activity of C. albicans 
genotype B strains were significantly greater than those produced by genotypes A and 
C. This suggests the influence of intron presence and the virulence of these strains 
(Sugita et al., 2002). However, the present study disagrees with the study by Sugita 
and co-workers (2002), as it has been shown that there were no correlations between 
virulence attributes and genotypic variations of C. albicans. In addition, the virulence 
attributes of C. albicans serotypes A and B, have been investigated in last century by 
Hasenclever and Mitchell (1961). The results of this study revealed that there were no 
correlation between the two serotypes of C. albicans and their virulence in mice 
models (Hasenclever and Mitchell, 1961).
Isolates from BMT recipients with a high load of yeast (cfu / ml more than 100) 
adhered better in-vitro (p = 0.069) than isolates from the control subjects. The assay 
used in the present study to assess the in-vitro adherence directly measured the ability 
of yeast to adhere to fibronectin. Therefore, it can be postulated that the more yeast is 
present in the oral cavity; the more likely interaction will be between the yeast and the 
host cells. This supports the notion of increasing the importance of these organisms
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(Sullivan and Coleman, 1997). However, the results of the present study showed that 
bone marrow transplantation does not greatly affect adherence (and resultant 
infections).
Candida albicans strains with a low ability to adhere, had reduced ability to 
cause infection in the animal model (Calderone and Braun 1991) and those strains that 
had high adhesive properties were associated with high mortality in similar animal 
models (Ghannoum and Abu Elteen 1986). In the present study, no good associations 
were found between the virulence attributes of adhesion and proteolytic enzyme 
activity of Candida isolates from the mouth of BMT recipients. However, only a 
small number of samples showed proteolytic enzyme activity, and adhesion, to a 
lesser degree, was found to increase with time. Nevertheless, the small sample size 
does not support the hypothesis that oral strains from the BMT recipients gradually 
become more virulent. If this were true, it must be expected that some patients with 
BMT would develop clinical disease, which does not seem to be the case.
The results of the present study do not suggest that the oral candidal isolates of 
BMT recipients in the UK and other regions of the world exhibit relatively different 
in-vitro adherence or proteinase production. In addition, bone marrow transplantation 
does not seem to change the virulence of oral candidal isolates and that any 
differences observed between isolates of healthy patients and BMT recipients (or 
geographic regions) cannot be attributed to variations in the degree nor diversity of 
oral candidal carriage. The present results would thus support the notion detailed
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previously, that patient undergoing bone marrow transplantation are not at increased 
risk of local (or systemic) candidal infection following engraftment.
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4.1.5. Fluconazole resistance in oral Candida isolates from bone marrow
transplant recipients
The results of the present study indicate that the susceptibility of Candida 
species to fluconazole in-vitro from BMT recipients was variable. The isolates from 
the UK BMT recipients had significantly enhanced resistant to fluconazole than the 
isolates from healthy subjects or isolates from BMT recipients from different parts of 
the world. This study supports the results of previous study that fluconazole resistance 
is more common in candidal isolates of immunosuppressed patients (such as those 
with HIV disease) than healthy subjects (Vargas et al., 2000). Prolonged and / or 
frequent intake of antifungal agents as therapy or prophylaxis received by BMT 
recipients from the UK (39%) may have contributed to the development of enhanced 
in-vitro resistance to fluconazole particularly to C. albicans that was known to be 
susceptible to such agent. Furthermore, different conditioning and 
immunosuppressive regimens between haematological centers and geographical 
regions may interact with antifungal therapy and susceptibility to these agents 
(Fekete-Forgacs et al., 1999). In addition, the time interval between BMT and oral 
sampling from the UK, Italy, Greece and Brazil (Table 2.9) may play a part as a result 
of increased intake of systemic antifungal agents throughout the neutropenic period. 
However, this was not the case in Greek patients (73% of the patients had mouth 
swills collected in less than a year from BMT). Although that 50% of the Greek 
patients were receiving antifungal therapy, only 12.5% (1/8) showed enhanced 
resistant to fluconazole. This is an interesting result that may support the influence of 
immunosuppressive therapy (Fekete-Forgacs et al., 1999) rather than antifungal 
therapy upon the fluconazole resistance of Candida species.
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Distinct genotypic subgroups of Candida albicans from diverse geographical 
regions may be important in determining antifungal susceptibility of candidal 
infection (McCullough et al., 1999a). Of interest, susceptibility to fluconazole of C. 
albicans genotype A was not significantly different in the isolates from BMT 
recipients from four different countries or isolates from the control subjects. 
Furthermore, all isolates of genotypes B and C (had the intron) were sensitive in-vitro 
to fluconazole from isolates of the Italian, Greek and Brazilian BMT recipients and 
isolates from the control subjects, although it is not clear why 50% of C. albicans 
genotypes B and C from the UK BMT recipients showed enhanced resistant to 
fluconazole. It has been reported previously that there was a direct correlation 
between the presence of a self-splicing intron in the 25S rDNA region of C. albicans 
and susceptibility to 5-fluorocytosine (Mercure et al., 1993). But to the best of my 
knowledge, no studies examined the correlation between the presence of intron and 
strain susceptibility to fluconazole. Further studies utilizing more strains are necessary 
to clarify the relation between the presence of intron and susceptibility to fluconazole. 
However, antifungal regimen in the UK may influence the increased resistance of 
such therapy to C. albicans genotypes B and C.
The present study supports the previous studies that non-albicans Candida are 
more resistant to fluconazole than C. albicans, regardless of the medical status of the 
patients. However, the susceptibility of C. dubliniensis to fluconazole was not 
different to that of C. albicans, in contrast to a recent report that showed C. 
dubliniensis develops resistance to fluconazole rapidly (Sullivan et al., 2004).
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In the present study, there were no significant associations observed between 
the receipt of antifungal therapy and oral Candida colonization, nor in-vitro 
susceptibility to fluconazole. This observation agrees with a previous report that 
fluconazole prophylaxis did not influence oral Candida colonization in patients with 
haematological malignancies (Salonen et al., 2000; Garrelts et al., 2004). But this is in 
contrast to other studies which have reported that fluconazole prophylaxis in BMT 
recipients reduced Candida colonization in these patients (Epstein et al., 1996; 2004). 
Although fluconazole prophylaxis has been given to neutropenic patients and severely 
ill patients in many centers, consideration should be given for its role in reducing 
fungal colonization and infection (Garrelts et al., 2004)
The presence or absence of fluconazole resistance did not seem to be 
associated with any alteration in extracellular proteinase activity nor in-vitro 
adhesion. It may thus be considered that other virulence attributes may be associated 
with enhanced resistance to fluconazole. Certainly virulence of Candida can be 
associated with fluconazole resistance as previously reported by Graybill and co­
workers (Graybill et al., 1998). In one study, fluconazole resistant strain of C. 
albicans adhered to a greater extent than a strain known to be susceptible to 
fluconazole (Fekete-Forgacs et al., 2000) (Section 4.1.4) while other studies reported 
that extracellular proteinase activity increased in C. albicans isolates from HIV- 
infected individuals that were known to be resistant to fluconazole and decreased in 
the isolates that were known to be susceptible to this drug (Ollert et al., 1995, Wu et 
al., 2000). However, the present data showed that in-vitro resistance to fluconazole 
may not be associated with extracellular proteinase production nor with adherence. 
This was confirmed by the lack of any association between changing fluconazole
271
resistance and the two virulence factors of isolates obtained from patients who were 
sampled on more than one occasion. No striking pattern of changing fluconazole 
susceptibility was observed in serial isolates and no associate was noted between 
previous fluconazole therapy and resistance to this agent. This lack of increasing 
resistance has been previously observed in isolates from BMT recipients (Marr et al., 
1998), and may suggest that, unlike other immunocompromised studies such as HIV 
disease, fluconazole resistance is not a consistent or likely problem in the 
management of BMT recipients.
Increased resistance to fluconazole might reflect changes in the Candida 
species with time. In the present study, changes in susceptibility (or resistance) to 
fluconazole with time were not associated with notable changes in Candida species. 
Most of the strains that showed enhanced resistance to fluconazole from subsequent 
sampling, had the same Candida species or C. albicans genotypes from succeeding 
sampling. Such observations would support the notion that the same strain of Candida 
gradually develops resistance to fluconazole as a consequence of frequent exposure to 
this agent or as a result of insufficient or intermittent doses of fluconazole (Marr et 
al., 1997). Nevertheless, fluconazole resistance can be also reversible (transient) as 
previously described in chapter 1 (Sanglard and Odds, 2002; White et al., 2002) or 
can be as a result of cross-resistant. For example, in a study of isolates that were 
known to be susceptible to fluconazole and resistant to flucytosine, half became 
flucytosine-fluconazole cross resistant when both antifungal agents were used 
concurrently (Noel et al., 2003).
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It is thus concluded that oral candidal isolates of patients who have received 
bone marrow transplantation may become resistant to fluconazole. However, the exact 
cause of such resistance and its influence upon the virulence of Candida remains 
unclear. The present evidence suggests that while candidal resistance to fluconazole 
can occur, it does not give rise to significant clinical disease in patients who have 
received bone marrow transplantation.
273
4.1.6. Application of RT-PCR to study the differential expression of agglutinin 
like-sequence (ALS) and secreted aspartyl proteinase (SAP) genes in 
different growing media
The results of the present study indicate that previously employed in-vitro 
methods used to assess the virulence attributes of C. albicans isolates did not measure 
the activity of whole gene families. Rather, they would appear to measure the ability 
of an isolate to respond to its local environment by differentially expressing specific 
genes. Utilizing RT-PCR directed cDNA from RNA to analyze differential gene 
expression (ALS and SAP genes) in-vitro may provide the only methodological 
approach to analyze gene expression where the amount of biological tissue is severely 
restricted (McPherson et al., 1993; Malhotra et al., 1998).
Previously, the elongation factor 1 such as EFB1 was used to prove the 
absence of contaminating genomic DNA and to estimate the level of gene expression 
(Felk et al., 2002; Kretschmar et al., 2002) and therefore primers specific for the 
intron-containing housekeeping gene encoding elongation factor 1 were used for this 
purpose (Schaller et al., 1999; Felk et al., 2002; Kretschmar et al., 2002). However, in 
the present study, EFB1 and 18S rDNA genes were assessed to measure the accuracy 
of these genes as house-keeping utilizing RT-PCR. The results showed significant 
variations between EFB1 and 18S rDNA genes (the standard error for the mean of the 
EFB1 was 1/4 comparing with 1/16 for the 18S rDNA genes) that advocate the 18S 
rDNA as an internal control is more reliable and reproducible than the EFB1. To the 
best of my knowledge, this is the first study which has investigated the expression of 
EFB1 in comparison with the internal 18S rDNA. Further studies of the effectiveness
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of 18S rDNA as house-keeping are necessary to access the accuracy of this gene as a 
house-keeping control.
It has been suggested that as a consequence of the differential expression of 
individual SAP genes at various stages of infection, it would be expected that the 
individual Sap isoenzymes would vary according to their biochemical properties, 
allowing the fungus to use the proteinase that is best adapted to a certain environment 
and for a specific function (Staib et al., 2000). It has been reported that SAP2 is 
responsible for proteolytic activity in-vitro and may have the dominant role in 
virulence (Hube et al., 1997, Sanglard et al., 1997, Monod et al., 1998, Staib et al., 
2000; Bektic et al., 2001). SAP2 mRNA is always present when C. albicans is grown 
in a medium containing protein as a source of nutrient (Hube et al., 1997; Sanglard et 
al., 1997; Staib et al., 2000; Hube and Naglik, 2001; Naglik et al., 2003). The present 
study is thus in agreement with previous studies that showed expression of SAP2 in- 
vitro when grew in a medium containing protein such as BSA. However, all of the 
other SAP or ALS genes investigated in this study were either down-regulated or did 
not show any difference with the addition of protein to the growing media. 
Nevertheless, SAP1 and SAP3 were described as phase-specific genes in C. albicans 
strain and may express only in the opaque phase but not in the white phase (Hube et 
al., 1997; Staib et al., 2000).
SAP genes were reported to be associated with adhesion (Hube et al., 1997). 
Increase carbohydrate intake was suggested to reduce the pH of the host and stimulate 
SAP expression and adhesion to the epithelial cells (Wu and Samaranayake, 1999). In
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the present study the adhesion of SAP genes in a medium containing protein were 
variables. It was down-regulated in SAP1 while it showing up-regulation with SAP2. 
Other SAP (SAP3, SAP6 and SAPS) genes did not show any difference in a medium 
containing protein. Enhanced adhesion of SAP2 suggested its role in virulence and 
infection. In one study, it has been demonstrated that the expression of SAP 1-3 genes 
enhanced the adherence to the epithelium (Borg-von Zepelin et al., 1999) while in a 
different study; it has been revealed that SAP4-6 significantly increased the adherence 
to the epithelial tissues (Watts et al., 1998). Although proteinase production has been 
observed during experimental infection, the in-vivo regulation and the role of 
pathogenicity of each individual SAP gene remains unclear (Staib et al., 2000). 
Certainly, the present study would suggest that at least SAP2 gene in particular has a 
major role in causing infection.
It has been demonstrated that the addition of protein inhibitor pepstatin A to 
the SAP genes, showed reduction in adhesion to human mucosal cells (Borg-von 
Zepelin et al., 1998; 1999). HIV proteinase inhibitors were also reported to be 
effective in reducing adherence of SAP gene activity (Korting et al., 1999, Bektic et 
al., 2001). Interestingly, the disruption of SAP2 can reduce the expression of the other 
member of SAP gene family (Hube et al., 1997). In addition, salivary antibodies may 
affect the growth of organisms and prevent their adherence and colonization to the 
mucosal epithelium and therefore reduce the risk of infection (Epstein, 1990).
The fact that the presence of a SAP gene family was unique to only the most 
pathogenic Candida species such as C. albicans, C, dubliniensis, C. tropicalis and C.
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parapsilosis and absent in the non-pathogenic yeast such as S. cerevisiae supported 
the fact that these genes are associated with the virulence (Hube and Naglik, 2001; 
Naglik et al., 2003) however; in the present study, SAP genes of C. albicans were the 
only species investigated as the number of isolates of non-albicans species was small 
but further study to support the hypothesis of the role of SAP genes in other 
pathogenic fungi is recommended.
SAP8 is usually enhanced at 25°C (Hube et al., 1997, Monod et al., 1998; 
Naglic et al., 2003). It has been reported that the optimum level of SAP8 mRNA was 
observed when grew at 25°C which elucidate that this gene is temperature dependent 
(Monod et al., 1998, Naglic et al., 2003). However, in the present study, when SAP8 
was grown at room temperature (more or less than 20°C), SAP8 showed expression 
with C. albicans genotypes only. C. albicans genotype A in SAP8, SAPS and ALS3, 
were significantly down-regulated in a medium contains protein. There were no 
detailed studies examined the direct effect of both SAP and ALS gene families on the 
different genotypes of C. albicans and this study would suggest the role of SAP8 in 
the virulence and pathogenicity of C. albicans genotype B.
ALS genes allow Candida to adhere to a variety of host surfaces (Hoyer et al., 
2001) and can express differentially under a variety of conditions that include 
morphological form, growth medium composition, growth phase and strain of C. 
albicans (Hoyer et al., 1998; 2001; Zhao et al., 2003; Sheppard et al., 2004). 
Interestingly, the examined ALS genes in the present study were down-regulated 
(.ALS2, ALS3, and ALS7) or did not regulate at all (ALS1 and ALS9) in the presence of
277
protein (fibronectin coated to beads) in the growing medium. The reason for this 
could be as a result of one or more factors mentioned above that are directly 
associated with the expression of these genes. Most previous studies examined the 
role of growing medium in SAP genes pathogenicity but there are no detailed studies 
about the role o f growing medium in ALS genes. Of interest, there was no association 
of ALS gene expression in the presence of protein in both adhesion and Candida 
colonization (Table 3.53) while proteinase activity of ALS9 was notably enhanced in a 
medium contains protein.
Furthermore, in the present study, SAP and ALS genes did not regulate in strains 
known to be colonized at high extent (cfu / ml > 100) or in strains that are known to 
be susceptible or enhanced resistance to fluconazole in-vitro. However, it has 
previously been reported that the expression of SAP genes was significantly reduced 
when grown in a medium containing fluconazole of isolates which were known to be 
susceptible to fluconazole and increased in isolates that were resistant to fluconazole 
(Wu et al., 2000).
The measurements o f normality on variables using the Kolmogorov-Smirnov test 
showed that all factors, other than age, were non-parametric and thus cannot easily be 
accounted in a multivariate analysis. Therefore, the analyses have been undertaken 
using simple, repetitive analyses with Chi square and Fisher Exact tests (except for 
the analyses of strain relatedness and the expression of SAP and ALS genes utilizing 
RT- PCR) and these results interpreted with the caution that these variants came from 
different patient populations.
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4.2. Conclusions
The present study assessed in particular the characteristics of the molecular 
epidemiology, virulence, diversity and anti-fungal resistance of candidal isolates from 
the mouth of individuals from different parts of the world who have undergone, and 
survived, bone marrow transplantation. The results of the present investigations 
indicate that there are no striking differences in oral candidal carriage, load and 
number of different Candida species from the recipients of bone marrow 
transplantation. However, there is some geographic diversity in genotypic diversity of 
C. albicans. The variation observed in genotypic attributes in oral Candida isolates 
did not appear to be a consistent phenotypic or genotypic marker that exists between 
all of these geographically diverse BMT recipients. This finding would support the 
hypothesis that oral Candida infections in immunocompromised patients are caused 
by the resident oral flora that act as opportunistic pathogens and these results may 
help in future epidemiological study that discriminate Candida species from different 
groups of subjects particularly in immunosuppressive patients such as BMT 
recipients.
By using PCR fingerprinting it has been found that C. albicans strains from 
recipients of BMT do not greatly change with time. However with respect to the 
strains obtained from the UK BMT recipients, these strains are genetically dissimilar 
to the C. albicans strains from the control subjects. Some differences do occur 
between strains from patients in different geographical locales but these are not as 
great as those observed between UK BMT recipients and control UK persons. Thus 
local and systemic factors would seem to exert a greater influence upon the character
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of candidal carriage in the mouths of recipients of BMT than the geographic location 
of residence of the patients receiving such therapy.
Virulence factors of oral candidal isolates, such as adhesion and extracellular 
proteinase activity, do not seem to be influenced by bone marrow transplantation. 
Perhaps this explains why there are no striking differences in the carriage of Candida 
species in the mouth following bone marrow transplantation. The results of the 
present study designated that oral candidal isolates, particularly non-albicans species 
or C. albicans genotypes B and C of the recipients of bone marrow graft from the UK 
may have enhanced in-vitro resistance to fluconazole when compared with isolates 
from healthy subjects or BMT recipients from non-UK geographical regions. The 
differences in fluconazole resistance may be due to the consequences of different anti- 
fungal regimes employed in various countries of the world.
The expression of the 18S rRNA gene is more reliable as an internal control 
for semi-quantitative RT-PCR than the elongation factor (EFBI) gene. Specific genes 
within a gene family (SAP and ALS genes) are generally down-regulated during in- 
vitro assays of virulence associated phenotypes. Thus these assays do not fully 
represent the in-vivo environment and may mis-represent the virulence potential of C. 
albicans strains. Hence there is a need to establish assays that more closely represent 
the in-vivo situation when undertaking studies of the virulence of oral Candida 
isolates of healthy and unhealthy patient groups.
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In conclusion, while the geography of patient residence, previous or current 
antifungal therapy and local factors can influence oral candidal carriage of patients 
who have survived bone marrow transplantation, the load, diversity and virulence 
characteristics of the fungal isolates from such patients are not greatly different from 
those in healthy persons.
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